{
  "id": 104,
  "title": "Impact of Resistance Training on Recovery and Functional Status in Older Adults Undergoing Transcatheter Aortic Valve Replacement (TAVR)",
  "authors": "Murillo Y",
  "year": 2021,
  "doi": "NR",
  "journal": null,
  "rating": 4.0,
  "tags": [
    "obesity",
    "older_adults",
    "concurrent_training",
    "sprint_interval",
    "RT"
  ],
  "population": {
    "training_status": "thesis_RCT"
  },
  "sections": {
    "abstract": ".................................................................................................................................... x CHAPTER 1:",
    "introduction": ".................................................................................................... 1 Purpose of the Study ........................................................................................................................ 4 Specific Aims and Research Hypotheses ........................................................................................ 4 Assumptions .................................................................................................................................... 5 Delimitations ................................................................................................................................... 6 Limitations ....................................................................................................................................... 6 Definition of Terms ......................................................................................................................... 7 CHAPTER 2: REVIEW OF LITERATURE ............................................................................... 10 Aortic Stenosis and the Transcatheter Aortic Valve Replacement ................................................ 10 Etiology of Aortic Stenosis ........................................................................................................ 10 Severity Classification of Aortic Stenosis (AS) ........................................................................ 11 Symptoms of Aortic Stenosis .................................................................................................... 12 The Transcatheter Aortic Valve Replacement (TAVR) ............................................................ 13 Effects of TAVR on Patients of Varying Risk Levels ............................................................... 15 Trends for Mortality Post-TAVR .............................................................................................. 17 Clinical Diagnosis of Sarcopenia .................................................................................................. 17 Sarcopenia Diagnosis in Healthy Older Adults ......................................................................... 17 Sarcopenia Diagnosis in TAVR Patients ................................................................................... 19 Age-Related Mechanisms of Muscle Atrophy and Strength Loss ................................................ 20 Muscle Protein Balance ............................................................................................................. 20 Anabolic Resistance ................................................................................................................... 22 Inflammation, Oxidative Stress and Myostatin ......................................................................... 26 Fat Mass and Intramuscular Adipose Tissue ............................................................................. 28 Neuromuscular Modifications ................................................................................................... 32 Anorexia of Aging ..................................................................................................................... 33 Mechanisms of Muscle Atrophy in Aortic Stenosis ...................................................................... 34 Differences in Measurement of Muscle Mass ........................................................................... 34 \n\n v \nAortic Stenosis and Inflammation ............................................................................................. 36 Myostatin ................................................................................................................................... 36 Physical Activity Intolerance ..................................................................................................... 37 Effects of Body Composition, Strength, and Physical Function on TAVR Outcomes ................. 38 Muscle Mass and Mortality ....................................................................................................... 38 Muscle Mass and Quality of Life .............................................................................................. 38 Muscle Strength and Mortality .................................................................................................. 39 Muscle Strength and Quality of Life ......................................................................................... 39 Physical Function and Mortality ................................................................................................ 40 Physical Function and Quality of Life ....................................................................................... 41 Intramuscular Adipose Tissue and TAVR Outcomes ................................................................ 41 Rehabilitative Protocols in TAVR Patients ................................................................................... 42 Effects of Resistance Training in Healthy Older Adults ............................................................... 45 Muscle Mass, Strength, and Physical Function ......................................................................... 45 Resistance Training and Intramuscular Adipose Tissue ............................................................ 47 Resistance Training Variables Influencing Gains in Strength and Muscle Mass ...................... 47 Effects of Resistance Training in TAVR Patients ..................................................................... 49 Effects of Resistance Training on Inflammation ........................................................................... 50 Tumor Necrosis Factor-Alpha ................................................................................................... 50 C-Reactive Protein ..................................................................................................................... 51 Effects of Protein Supplementation in Healthy Older Adults .................................................... 52 Effects of Resistance Training and Protein Supplementation in Healthy Older Adults ............ 54 Concluding Remarks ..................................................................................................................... 56 CHAPTER 3: RESEARCH METHODOLOGY ........................................................................... 58 Experimental Design ..................................................................................................................... 58 Participants ................................................................................................................................. 59 Participant Recruitment ............................................................................................................. 60 Researcher On-site ..................................................................................................................... 60 Researcher Off-Site .................................................................................................................... 60 Pre and Post Testing ...................................................................................................................... 61 Anthropometrics ........................................................................................................................ 61 \n\n vi \nBody Composition ..................................................................................................................... 62 Blood Collection ........................................................................................................................ 63 Muscular Strength Testing ......................................................................................................... 64 Food and Activity Logs ............................................................................................................. 65 Physical Function Testing .......................................................................................................... 65 Protein Intervention ................................................................................................................... 68 Resistance Training (RT) Intervention ...................................................................................... 69 Statistical Analysis ........................................................................................................................ 71 Sample Size Estimation ............................................................................................................. 71 Data Analyses ............................................................................................................................ 71 CHAPTER 4:",
    "results": ".............................................................................................................. 73 Participants .................................................................................................................................... 73 Baseline Characteristics ................................................................................................................. 74 Post-Intervention Measures ........................................................................................................... 80 CHAPTER 5:",
    "discussion": "........................................................................................................ 87 Body Composition ......................................................................................................................... 87 Blood Biomarkers .......................................................................................................................... 91 Muscular Strength and Physical Function ..................................................................................... 94 Quality of Life ............................................................................................................................... 97 Activity Levels and Dietary Intake ................................................................................................ 99 Protein Intake ............................................................................................................................. 99 Activity Levels ......................................................................................................................... 101 Correlations of Baseline Measures .............................................................................................. 102 Limitations and Future Directions ............................................................................................... 103",
    "conclusions": "................................................................................................................................. 105 APPENDICES ............................................................................................................................. 106 A. IRB APPROVAL LETTER .................................................................................................... 106 B. INFORMED CONSENT FORM ............................................................................................ 109 C. PHYSICIAN CONSENT FORM ........................................................................................... 119 D. INFORMATIONAL PAMPHLET ......................................................................................... 120 E. TMH HIPAA AUTHORIZATION ......................................................................................... 122 \n\n vii \nF. AUTHORIZATION FORM .................................................................................................... 126 G. RECRUITMENT LETTER .................................................................................................... 127 H. QUALITY OF LIFE QUESTIONNAIRES ........................................................................... 128 I. DIAGRAM OF EXERCISES .................................................................................................. 139 J. MEDICAL HISTORY QUESTIONAIRRE ............................................................................ 151 REFERENCES ............................................................................................................................ 155 BIOGRAPHICAL SKETCH ....................................................................................................... 185 \n\n viii \n LIST OF FIGURES Figure 1: Revised Diagnostic Criteria for Sarcopenia in Healthy Older Adults According to the European Working Group on Sarcopenia in Older People (EWGSOP2) ..................................... 19 Figure 2: Regulators of Muscle Protein Synthesis and Muscle Atrophy. ..................................... 28 Figure 3: Quantification of Body Composition Using a CT-Scan at L3. ...................................... 35 Figure 4: Participant Flow Through the Study .............................................................................. 73 \n\n ix \nLIST OF TABLES Table 1: Baseline Anthropometrics & Body Composition (N=22) ............................................... 75 Table 2: Baseline Clinical & Echocardiographic Characteristics (N=22) ..................................... 76 Table 3: Baseline Muscular Strength Measurements (N=22) ....................................................... 77 Table 4: Baseline Physical Function Measurements (N=22) ........................................................ 78 Table 5: Baseline Quality of Life Assessment (N=22) ................................................................. 79 Table 6: Training Volume of Participants Across the 12 Weeks (N=22) ..................................... 80 Table 7: Body Composition (N=22) .............................................................................................. 81 Table 8: Clinical Measures (N=22) ............................................................................................... 82 Table 9: Muscular Strength Measurements (N=22) ...................................................................... 83 Table 10: Physical Function Measurements (N=22) ..................................................................... 84 Table 11: Quality of Life Assessment (N=22) .............................................................................. 85 Table 12: Dietary Intake and Activity Levels (N=22) ................................................................... 86 \n\n x \nABSTRACT BACKGROUND: Approximately 5-6% of older individuals ≥75 years of age will develop aortic stenosis and require aortic valve replacement via transcatheter aortic valve replacement (TAVR). Due to most patients not surviving ≥5 years post-TAVR the reduction of morality risk and maximization of quality of life (QoL) in the post-procedural setting are crucial. As high as 70% of TAVR patients may develop low muscle mass which will remain post-TAVR and can increase mortality risk and reduce QoL. The combination of resistance training (RT) with protein supplementation is an effective modality for maintaining and gaining muscle mass. However, their effectiveness is unexplored in TAVR patients. PURPOSE: To determine the effects of a 12-week home-based digitally supervised progressive RT program combined with protein supplementation (RT+PRO) vs. protein supplementation only (PRO) on body composition, inflammation, strength, physical function, and QoL measures in post-operative TAVR patients.",
    "methods": "Twenty-two TAVR patients participated in study (75.7±6.5 years). Measurements included anthropometrics, body composition via hand-foot bioelectrical impedance analysis, blood draws to measure serum levels of tumor necrosis factor alpha (TNF-α) and C-reactive protein (CRP), muscular strength assessments via handgrip dynamometer, leg dynamometer, 30-second chair stand, and 5-repetition chair stand, and physical function via short physical performance battery (SPPB), 8-foot Up-and-Go, 2-minute step test, and 30-second arm curl, and subjective QoL. After completion of testing participants were stratified by gender and arm curl performance into one of two groups: digitally supervised home-based RT+PRO (n=11) or PRO (n=11) for 12 weeks. Participants in RT+PRO completed a whole-body RT program of 12 exercises, 2x/week of 8 to 15 repetitions for up to 3 sets and both groups consumed an additional 75g (37.5 g twice a day) of whey protein per day. All baseline tests were immediately repeated at \n\n xi \nthe",
    "conclusion": "of 12 weeks. A two-way repeated measures analysis of variance (ANOVA) was used to evaluate differences in variables between groups. In the case of significance, a post hoc one-way ANOVA was used to identify significant differences. Significance was accepted at p≤0.05. RESULTS: Participants in PRO (Height: 1.69±0.13 m, Weight: 92.2±21.6 kg, 74±6 years of age) had significantly lower diastolic blood pressure at baseline compared to RT+PRO (Height: 1.70±0.09 m, Weight: 86.4±15.4 kg, 77±7 years of age; 68±6 vs. 73±7 mmHg). No other significant differences were observed at baseline. All participants in RT+PRO completed all RT sessions (24 session per participant) and adherence to PRO consumption was 91% for RT+PRO and 95% for PRO. Compared to PRO, participants in RT+PRO experienced a significantly greater improvements in 30-second chair stand repetitions (RT+PRO Pre: 11±3 vs. Post: 13±3; PRO Pre: 12±2 vs. Post: 12±3 repetitions;), time to complete 5 sit-to-stands in a chair (RT+PRO Pre: 12.3±3.8 vs. Post: 9.6±2.7; PRO Pre: 11.2±2.4 vs Post: 10.9±2.9 seconds), SarQoL score (RT+PRO Pre: 63.7±12.9 vs. Post: 74.0±14.6; PRO Pre: 69.7±13.6 vs. Post: 69.2±16.1 points), and serum levels of CRP (RT+PRO Pre: 3.1±2.1 vs. Post: 2.0±1.5; PRO: Pre: 2.5±2.1 vs. Post: 2.2±2.0 mg/L). RT+PRO (9.5±2.3 vs. 9.5±2.0 kg/m2) and PRO (9.3±2.3 vs. 9.1±2.3 kg/m2) maintained SMI from baseline to follow-up. CONCLUSION: Digitally supervised home-based RT+PRO significantly improved measures of strength, inflammation, and QoL in TAVR patients over 12 weeks. The convenient nature of home-based RT should be pursued as a method for cardiac rehabilitation to increase both patient participation and benefits from exercise. Protein supplementation should be taken in unison with RT to ensure retention of muscle mass. High protein consumption for periods of >6 months may elicit a benefit for the retention of muscle mass. \n\n 1 \nCHAPTER 1 INTRODUCTION As of 2020, the population of individuals in the United States ≥65 years of age is expected to reach 55 million and increase to 72 million by 2030 (1). Subsequently, the portion of the population effected by age-related diseases such as valvular-heart disease will be higher than ever before. It is estimated that 4-6 million individuals in the United States suffer from some form of valvular heart disease (2). Of the known valvular heart diseases, aortic stenosis (AS) has become one of the most common with estimates being as high as 5-6% in individuals ≥75 years of age (2, 3). Aortic stenosis is caused by the progressive calcification of the aortic valvular trileaflet and typically presents symptoms in the 7th to 9th decade of life (4). However, once AS becomes symptomatic the average survival rate is only 2-3 years with a 25% yearly mortality rate (5). If left untreated, the progression of AS will lead to the development of congestive heart failure (CHF) (6). Since medications do not exist to alleviate the symptoms of AS, the only treatment option is aortic valve replacement (AVR). Prior to 2011, the only existing form of AVR was surgical AVR (SAVR) (7, 8). While effective at treating AS, SAVR was only considered a viable option for patients classified as having low or intermediate surgical risk (4, 9, 10, 11). In 2011, the Federal Drug Administration (FDA) approved a new minimally invasive form of AVR known as transcatheter AVR (TAVR) which allowed for previously inoperable patients to receive AVR (12) that was less invasive. Since its approval in 2011, TAVR has been effective at reducing long-term mortality (1- 4 years) and improving quality of life (QoL) in patients of all risk levels (13, 14, 15, 16). Despite these outcomes most AS patients, do not survive ≥5 years after TAVR (17, 18). In addition, the survival rate of patients prior to 5 years post-TAVR are still lower than that of the general \n\n 2 \npopulation (18). With most patients not surviving ≥5 years, the importance of maximizing post-procedural QoL and minimizing risk of mortality is crucial. While TAVR can correct AS, it is unable to correct other existing comorbidities that may negatively affect QoL and mortality risk in the post-procedural setting. Thus, cardiac rehabilitation should identify and aim to improve comorbidities that could negatively affect these measures. One of the comorbidities of recent interest in TAVR patients is muscle wasting or sarcopenia. Sarcopenia is classified as a progressive skeletal muscle disease associated with increased risk of falls, fractures, physical disability, and mortality (19, 20). This increased risk stems from the age-related declines of muscle mass and strength that are characteristic of sarcopenia (21, 22). Due to the average age of most TAVR patients being 80 years it is expected that low muscle mass may be an issue (4). Evidence suggests that low muscle mass can be as high as 50% in healthy octogenarians however this percentage jumps to as high as 70% in TAVR patients (23, 24, 25, 26). This difference is hypothesized to relate to chronic elevations in the inflammatory cytokines, increased expression of myostatin, and impaired tolerance to physical activity (27, 28, 29, 30, 31). TAVR patients with low muscle mass are reported to have both increased length of hospital stays, and long-term mortality rates compared to those without low muscle mass (23, 32, 33). Other age-related changes associated with sarcopenia are lower levels of muscle strength and physical function, which can also affect QoL and mortality risk in TAVR patients (34, 35, 36). Both measures have shown inverse associations with mortality rates and QoL in TAVR patients (34, 37). Preliminary unpublished data from our laboratory suggest that muscle mass, strength, and physical function do not change ~6 months after TAVR Thus, there is a need in the rehabilitative setting to focus on improving these in TAVR patients. \n\n 3 \n A common modality for improving measures of muscle mass, strength and physical function is participation in resistance training (RT) programs. RT is well established in its ability to improve these measures in older adults (38, 39). However, the majority of research relating to exercise in TAVR patients focuses on aerobic training with little emphasis placed on RT (40). Of the few studies that have evaluated the effects of RT on TAVR patients (41, 42) Pressler et al., (43) is the only one to assess changes in a sarcopenia-related measure. In their study 7 weeks of RT increased muscular strength and resulted in no adverse events. However, this study did not evaluate muscle mass or physical function. Thus, it remains uncertain if RT positively affects these measures in TAVR patients. The elevation of dietary protein intake via protein supplementation may also help to attenuate age-related and AS-related reduction of muscle mass (44). Evidence suggests the current recommended dietary allowance (RDA) of protein (0.8 grams/kilogram/day (g/kg/d)) is inadequate for preventing the loss of muscle mass in older adults (≥65 years of age) (45). Recommendations ranging from 1.0-2.0 g/kg/d distributed in doses of 0.4 g/kg have been proposed as optimal for the maintenance of muscle mass (46, 47, 48, 49). However, the supplementation of dietary protein intake has yet to be explored in TAVR patients. Preliminary unpublished findings from our laboratory demonstrated that our sample of TAVR patients consumed below the RDA for protein (0.73±0.38 g/kg/d; N=19) suggesting protein supplementation could be an effective strategy in this population. When protein supplementation is added to a RT protocol it may help to induce greater gains in muscle mass compared to RT alone (50, 51, 52). In particular, protein supplementation that increases habitual protein intake to ~1.3 g/kg/d in combination with RT has elicited significantly greater gains in muscle mass compared to RT alone (50). With the prevalence of \n\n 4 \nlow muscle mass in TAVR patients it is plausible that combining RT with protein supplementation could be beneficial. \nPurpose of the Study The purpose of this study was to examine the effects of a 12-week home-based digitally supervised progressive RT program combined with protein supplementation (RT+PRO) compared to protein supplementation only (PRO) on body composition, inflammation, strength, physical function, and QoL measures in post-operative TAVR patients. \nSpecific Aims and Research Hypotheses The following specific aims were designed to test our hypotheses: Specific Aim 1: To determine the extent to which a 12-week home-based RT program and protein supplementation (RT+PRO) would affect body composition (lean mass, skeletal muscle index (SMI), and fat mass) compared to protein supplementation only (PRO) in post-operative TAVR patients. To test this aim, body composition was measured using hand-foot bioelectrical impedance (BIA) before and after 12 weeks of RT+PRO or PRO. Hypothesis 1: RT+PRO will have greater improvements in measures of body composition (increased lean mass, SMI, and decreased fat mass) compared to PRO after the 12-week intervention. Specific Aim 2: To determine the extent to which 12 weeks of RT+PRO would improve blood biomarkers related to inflammation compared to PRO in post-operative TAVR patients. To test this aim, we analyzed serum samples of tumor necrosis factor alpha (TNF-a) and C-reactive protein (CRP) using an enzyme-linked immunosorbent assay (ELISA) before and after 12 weeks of RT+PRO and PRO. \n\n 5 \nHypothesis 2: RT+PRO will have lower levels of inflammation (reduced levels of TNF-a and CRP) compared to PRO after the 12-week intervention. Specific Aim 3: To determine the extent to which 12 weeks of RT+PRO would improve strength, physical function, and both general health and disease specific QoL compared to PRO in post-operative TAVR patients. To test this aim, we assessed strength with maximal isometric handgrip and leg extension strength, physical function with the short physical performance battery (SPPB) and the Senior Fitness Test, general health QoL with the Medical Outcomes Study 12-Item Short Form Health Survey (SF-12), and disease-specific QoL using the Sarcopenia Quality of Life Questionnaire (SarQoL) and Kansas City Cardiomyopathy Questionnaire Short Form (KCCQ-12) Hypothesis 3: RT+PRO will have greater strength, physical function, and QoL (SF-12, KCCQ-12, and SarQoL) measures to PRO after the 12-week intervention. There may be some improvements in QoL for PRO, but increases will be less than that of RT+PRO. Assumptions The following assumptions for this study included: 1. All participants accurately reported their age, medical history (diagnosis and treatment), current exercise status, and current dietary intake. 2. All participants followed the instructions given to them regarding protein supplementation and honestly and accurately reported their adherence to the protein when prompted to do so. 3. All participants followed instructions given to them regarding maintenance of current lifestyle (e.g., diet and daily physical activity) outside of the prescribed program. \n\n 6 \n4. All laboratory equipment accurately recorded measurements over the course of repeated testing. Delimitations 1. Participants with physical disabilities that made regular exercise impossible, unstable cardiac conditions, diabetes, thyroid problems, kidney dysfunction, milk allergies, severe chronic obstructive pulmonary disease, signs of valve prothesis were not eligible to participate in the study. 2. Participants who consumed pharmacological doses of Vitamin D (6000 IU/day or 50,000IU/week), or participated in a regular exercise program (RT >1 day/week or aerobic training >2 days/week) were not eligible to participate in the study. 3. Participants received their TAVR procedure before enrollment in the study. 4. Participants were educated on how to record dietary intakes using food logs prior to the beginning of data collection. 5. During the study, participants were asked not to change their diets or exercise habits outside of the laboratory. 6. Participants in either the RT+PRO or PRO consumed two daily doses of whey protein (37.5 g), which will total 75 g/day. The first serving was consumed within 30 minutes of completing exercise on training days and in the morning with breakfast on non-training days. Participants consumed the second serving with lunch on all days of the week Limitations The major limiting factors in this study were the following: \n\n 7 \n1. Only TAVR patients were recruited for participation. Therefore, results may not be generalized to other forms of heart disease. 2. Participants were recruited from the city of Tallahassee, FL and surrounding areas. Therefore, results obtained may not be representative of TAVR patients in other regions of the country. 3. The participants in this study were volunteers and may have been healthier and more motivated to get nutritional and body composition benefits. Therefore, they may not be representative of the entire population. 4. Bias will exist in this sample due to geographical location since all participants were from the Tallahassee, FL area. Responses of these participants to protein consumption and exercise may have been different than that of another TAVR patient randomly selected from the population. 5. Diet, sleep, and exercise outside of the laboratory were not controlled. However, participants were asked to follow a similar diet and to not be physically active outside of study-based exercise. Definition of Terms • Anabolic Resistance: The reduced capacity of skeletal muscle to generate a robust increase in muscle protein synthesis in response to nutrition or physical activity (53, 54). • Aortic Stenosis (AS): Calcification of the aortic valvular trileaflet resulting in the narrowing of the aortic valve opening and restriction of blood flow from the left ventricle to the aorta (55). • Appendicular Skeletal Muscle Index (ASMI): The mass of skeletal muscle in the arms and legs (kilogram) indexed by the squared height (meter) of an individual. The gender \n\n 8 \nspecific cutoff points for low muscle mass in older adults using dual energy X-ray absorptiometry (DXA) are <7.0 kg/m2 for men and <5.5 kg/m2 for women (56) • Computed Tomography (CT): A computerized x-ray imaging procedure in which a narrow beam of x-rays is aimed at a patient and quickly rotated around the body, producing signals that are processed by the machine’s computer to generate cross-sectional images—or “slices”—of the body (57). The gender specific cutoff points for low muscle mass in older adults using CT is 55 cm2/m2 for males and 39 cm2/m2 for females (58). • Dual energy x-ray absorptiometry (DXA): A method for measuring body composition in adults, correlating highly with methods such as underwater weighing, deuterium dilution, and total body potassium. It provides a three-compartment model of body composition: fat, lean tissue mass, and bone mineral content (59). • Frailty: A geriatric syndrome in which a decline in physiologic reserve increases the risk of adverse health and physical outcomes, including physical dependence, falls, fractures, and mortality (60). • Mammalian Target of Rapamycin Complex 1 (mTORC1): A kinase that integrates signals from growth factors, energy, oxygen and amino acids to regulate downstream pathways that stimulate mRNA translation of proteins (61). • Sarcopenia: A progressive skeletal muscle disease characterized by an age-related decline in muscle mass, strength, and physical function resulting in increased risk of falls, fractures, physical disability, and mortality (19, 56). \n\n 9 \n• Skeletal Muscle Index (SMI): The CT-derived skeletal muscle cross-sectional area (cm2) at the level of the 3rd lumbar vertebra (L3) indexed to the square of the participant's height (m2) (SMI; cm2/m2) (23). • Short Physical Performance Battery (SPPB): A valid measure of lower extremity performance that is predictive of adverse health outcomes like morbidity, institutionalization, and mortality. The score comprises assessment of timed test of 5 chair rise repetitions, standing balance, and time to walk 4 meters. Scoring ranges from 0 (low performance) to 12 points (high performance) (62). • Transcatheter Aortic Valve Replacement (TAVR): A minimally invasive surgical procedure which utilizes a catheter to wedge a replacement aortic valve into a defective aortic valve's place (63). • Quality of Life (QoL): A patient’s general well-being, including mental status, stress level, sexual function, and perceived health status (medicaldictionary.thefreedictionary.com) \n\n 10 \nCHAPTER 2 REVIEW OF LITERATURE Aortic Stenosis and the Transcatheter Aortic Valve Replacement Etiology of Aortic Stenosis Aortic stenosis (AS) is one of the most common and severe forms of valvular heart disease and is caused by the progressive calcification of the aortic valvular trileaflet (2, 3, 4). The calcification observed in AS has both genetic and non-genetic causes. Genetically, congenital aortic bicuspid valve disease (ABVD), the presence of two valvular leaflets as opposed to three, is largely responsible for AS prior to 70 years of age (64). As a percentage, ABVD is estimated to be present in 30-50% of those with AS (65). Non-genetically, the progression to AS begins with the development of its precursor, aortic sclerosis. Like AS, aortic sclerosis is spurred by calcification of the valvular leaflets, however, in this case, the calcification has a benign effect on cardiovascular function (66). Development of aortic sclerosis is caused by many of the same risk factors that cause atherosclerosis including advancing age, male gender, smoking, hypertension, high low density lipoprotein (LDL) cholesterol, and diabetes (67). Male gender carries a 32% increased risk for the development of aortic sclerosis while hypertension, diabetes, and hyperlipidemia have been shown to account for 30% of severe AS incidence (68, 69). While the presence of ABVD and/or aortic sclerosis do not guarantee development of AS, evidence suggests that 9% of individuals ≥65 years of age with aortic sclerosis develop AS after ~5-year follow-up while ~24% of those with ABVD (~32 years of age) develop AS after 20-year follow-up (68, 70). For those who do develop AS, its progression in severity is inevitable. \n\n 11 \nSeverity Classification of Aortic Stenosis (AS) According to the American Heart Association, the progression of AS is stratified into seven stages (A, B, C1-2, D1-3) once present. The increase in classification of severity of AS increases from stages B to D and is based on three factors: peak aortic jet velocity (m/s), transaortic pressure gradient (mmHg), and aortic valve area (cm2) (71). The presence or absence of left ventricular ejection fraction (LVEF) <50% is also considered. The severity criteria are defined as follows: peak aortic jet velocity is the pressure placed on the stenotic aortic valve during systole; transaortic pressure gradient is the pressure difference between the left ventricle and aorta during systole, and aortic valve area is the area of aortic valve orifice during systole (72). On average, the annual progression of AS increases peak aortic jet velocity and transaortic pressure gradient by 0.15 m/s and 3 mmHg, respectively, and decreases aortic valve area by 0.3 cm2 (72). The seven stages of AS are grouped into four levels of severity: at risk (Stage A), mild to moderate (Stage B), severe asymptomatic (Stages C1-2), and severe symptomatic (Stages D1-3). Of most importance are stages C1-D3 as it is within these stages that AS has progressed to the level of “severe”. Severe AS is defined as the combination of peak aortic jet velocity <4 m/s, transaortic pressure gradient ≥40 mmHg, and aortic valve area ≤1.0 cm2 (71). In addition, with the except of Stage C1, LVEF of <50% is also present in each of these stages. Upon reaching severe status, the implementation of AVR will hinge upon the absence or presence of symptoms, thus those receiving AVR typically fall into stages D1-3 (71). The attainment of AVR shortly after presentation of symptoms is crucial as the average survival rate is only 2-3 years with an annual mortality rate of 25% if AS is left untreated (5). \n\n 12 \nSymptoms of Aortic Stenosis The hallmark symptoms of severe AS include syncope, exertional dyspnea, exercise-induced angina, and congestive heart failure (CHF) (6). The mechanism for the development of each symptom stems from the reduction in aortic valve area. Reduction in aortic valve area results in a significant rise in resting aortic afterload. This rise in afterload will lead to a reduction in stroke volume and ultimately resting cardiac output due to the slowed speed of myocardial contraction (6). Subsequently, there will be an increase in end-systolic volume which will remain and increase end diastolic volume when added to incoming venous return. In a healthy individual, an increase in end diastolic volume would result in greater preload and activate the Frank-Starling mechanism to compensate for a reduction in stroke volume (6). However, the presence of AS, especially if allowed to progress, will further reduce stroke volume via end systolic volume continually exceeding that of end diastolic volume. Declines in stroke volume and cardiac output can result in feeling “out of breath” during physical activity, also known as exertional dyspnea (6). Exertional dyspnea is a biproduct of insufficient tissue oxygenation which is typically corrected by the chemoreceptor reflex triggering increased rate and depth of breathing in healthy individuals. However, the limitations placed on stroke volume and cardiac output by AS can limit these compensations and result in syncope due to reduced cerebral perfusion of oxygen (6). In another attempt to compensate for reduced stroke volume, the myocardium of the left ventricle will experience hypertrophy, pathologically referred to as left ventricular hypertrophy (LVH). In this case, LVH will not be due to a gain in myocardial myofibrils, but to fibrosis. Since connective tissue lacks contractile units, the contractility of the myocardium will progressively decline (6). An increase in oxygen demand by the enlarged myocardium, and \n\n 13 \nsubsequent inability to meet that demand, can result in exercise-induced angina. As the myocardium continues to enlarge, the contractile ability of the heart will continue to decline by virtue of an increased ratio of connective to myocardial tissue. If left untreated, AS will cause the contractile ability of the myocardium to decline to a point where it can no longer pump adequate stroke volume to the systemic tissues, resulting in CHF (6). Thickening of the myocardium, which reduces stroke volume and ultimately cardiac output will also contribute to syncope and dyspnea in these patients. Thickened myocardium results in a reduction of chamber size within the left ventricle and a reduction of myocardial elasticity (6). Both modifications will limit compensatory increases in end diastolic volume and cause a significant elevation in end-diastolic pressure within the left ventricle. Elevated ventricular pressure during diastole will be reflected in the left atria, veins, and ultimately the alveolar capillaries of the lungs (6). Increased pressure within the alveolar capillaries increases hydrostatic pressure and causes excessive plasma to be expelled through the capillary walls (6). Because the resting pressure of the capillaries is now higher, there will be less of a pressure gradient for plasma reabsorption on the venular end of the capillary. Ultimately, excessive fluid will remain in the alveoli of the lungs resulting in pulmonary edema that will interfere with the ability of the lungs to re-oxygenate blood (6). The Transcatheter Aortic Valve Replacement (TAVR) Because there is no known therapeutic treatment, and due to the dire nature of severe symptomatic AS, the only solution is surgical intervention via aortic valve replacement (AVR). AVR is divided into two types of procedures, surgical AVR (SAVR) and transcatheter AVR (TAVR). The primary difference between the two procedures is the invasiveness required to replace the defective aortic valve. In the case of SAVR, the chest is opened in order to access the \n\n 14 \nheart and the aortic valve is then removed and replaced by an artificial valve that is sewn onto the aortic annulus (73). TAVR does not require the chest to be opened and utilizes a catheter to transport an artificial aortic valve to the heart, typically via the femoral artery (73). Initially, a balloon catheter is inserted into the femoral artery and guided into the center of the aortic valve (73). The balloon is then expanded in order to increase AVA via compression of the calcified valvular trileaflet (73). A catheter will then be equipped with an artificial aortic valve, inserted into the femoral artery, and guided into the center of the aortic valve (73). The artificial valve will then be expanded into place over top of the previously compressed calcified valvular trileaflet, completing the TAVR procedure (73). Until recently, the selection of SAVR or TAVR was individualized based on the risk and the degree of classification of the patient. Risk assessment of AS patients is based on four criteria: Society of Thoracic Surgeons Predicted Risk of Mortality score (STS-PROM), number of frailty indices, number of compromised major organ systems that will not improve after AVR, and the possibility of procedure-specific impediment (9). Based on these criteria, prospective AVR patients are stratified into the categories of low, intermediate, high, and prohibitive risk. Traditionally, SAVR was recommended in those that were classified as low (<4% STS-PROM and presence of no other criteria) and intermediate risk (4-8% STS-PROM or presence of either 1 frailty index, 1 compromised organ system, or possible procedure specific impediment) (4, 9). TAVR can be a reasonable alternative to SAVR in those classified as intermediate risk but is most common in those with high (STS-PROM >8% or presence of either ≥2 frailty indices, 2 compromised organ systems, or possible procedure-specific impediment) or prohibitive risk (predictive risk with surgery of death or major morbidity >50% at 1-year or presence of either ≥3 compromised organ systems or severe procedure-specific impediment) (4, 74). \n\n 15 \nEffects of TAVR on Patients of Varying Risk Levels Prior to the Food and Drug Administration (FDA) approval of TAVR in 2011, numerous patients, specifically those who classified as having high and prohibitive surgical risk, did not have a viable option for AVR (7, 8, 12). In these cases, balloon valvuloplasty was considered the standard treatment although its application did not slow AS progression and carried risk of severe vascular complications (75, 76, 77). With TAVR, AS patients that were previously deemed inoperable acquired a surgical option for AS treatment. The implementation of TAVR in the prohibitive risk population has produced significant benefit. In those who received TAVR vs standard treatment (balloon valvuloplasty) the mortality rate at 1-year post-operation was shown to be 20% lower (p<0.001) while the cardiovascular-cause mortality was 24% lower (p<0.001) 16). In addition, mortality risk was 22% lower in TAVR patients at 5 years post-operation (p<0.0001) (78). Outcomes with TAVR have also been compared to SAVR across patients of lesser risk classification. Some evidence suggests all-cause mortality at 1 and 2 years post-procedure is no different in high-risk patients undergoing TAVR or SAVR (10, 11). However, these findings could be related to the type of artificial valve that was used as evidence suggested a self-expandable valve, as opposed to a balloon-expandable valve, produced significantly lower all-cause mortality at 1 and 3 years, respectively (14% vs 19%; p=0.04; 13% vs 22%; p=0.03) (79, 80). However, this improvement disappears at 5 years post-operation as no significant difference in all-cause mortality was found between TAVR and SAVR at this time point (81). TAVR has been recommended as a viable option for those classified as intermediate risk since 2016 (74). All cause-mortality at 1 and 2 years post-operation (7.4% vs 13.0%; p<0.0001; 16.3% vs 20.0%; p=0.04) and cardiovascular-cause mortality at 1 year post-operation (4.5% vs \n\n 16 \n8.1%; p<0.0001) (15, 82) has been shown to be superior with TAVR as opposed to SAVR in several studies. However, other evidence suggests no difference at 1 and 2 years post-operation (83, 84). Opposing findings may again be related to differences in valve selection as those who were showing benefit had balloon-expandable valves and those who did not had self-expandable valves. Prior to 2015, the effects of TAVR on all-cause mortality in low-risk patients was seemingly unexplored. Thyregod et al., (85) found no difference between the effects of TAVR and SAVR on all-cause and cardiovascular cause mortality at 1-year post-operation. Later evidence by Popma et al., (86) reported that TAVR using a self-expanding valve produced similar all-cause mortality at 2 years post-operation when compared to SAVR. On the other hand, Mack et al., (13) reported TAVR with a balloon-expandable valve resulted in significantly lower all-cause mortality compared to SAVR at 1-year post-operation (8.5% vs 15.1%; p<0.001). This finding may explain the lack of difference found by Thyregod et al., (85) and Popma et al., (86) as a self-expanding valve was also utilized. Overall, TAVR is a viable option for those suffering from severe AS and may be preferable across patients of all risk levels. In other countries, such as Germany, TAVR has already surpassed SAVR as the preferred procedure for the correction of AS (87). Independent from mortality, TAVR provides multiple benefits that SAVR does not. In particular, TAVR results in a significantly shorter length of hospital stay compared to SAVR due to its minimal invasiveness and use of local anesthesia (88, 89). Shortened length of stay can also result in a reduction in hospital costs leading to a lower financial burden on the patient and taxpayer (90, 91). \n\n 17 \nTrends for Mortality Post-TAVR While TAVR reduces morality risk and rate, it is important to note that mortality rate remains high at ≥5 years post-operation. Consistently, the survival rate at 5 years post-TAVR is below 50% (17, 18, 92, 93). In the few cases that investigated beyond 5 years (7 and 8 years) the survival rate was below 30% (18, 92). In addition, Chakos et al., (18) stratified risk in accordance with long-term outcomes and found higher survival rates (~40% vs ~20%) in intermediate and low risk patients compared to prohibitive and high-risk patients ≥5 years after TAVR. Those who receive TAVR are also at a disadvantage compared to the general population. Based on actuary tables, Chakos et al., (18) found the survival rates of TAVR patients were lower than that of the age-matched general population on a yearly basis for up to 7 years. Overall, this underscores the importance of minimizing the effects of comorbidities that may increase mortality risk post-TAVR and reduce QoL. One of the comorbidities of recent interest in TAVR patients is sarcopenia. Clinical Diagnosis of Sarcopenia Sarcopenia Diagnosis in Healthy Older Adults As of 2016, sarcopenia was formally classified as a disease and is defined as a progressive skeletal muscle disorder that is associated with increased risk of falls, fractures, physical disability, and mortality (19, 20). Specifically, sarcopenia raises the risk for negative health outcomes by causing an age-related decline in both muscle mass and strength (21, 22). As of 2019, low muscle strength became the primary criterion for the diagnosis of sarcopenia while low physical function became indicative of severe sarcopenia (56). Thus, the current diagnostic criteria for sarcopenia determines its presence to be probable if low muscle strength is detected and the diagnosis is confirmed after low muscle mass is then detected (56). Sarcopenia is \n\n 18 \nconsidered to be severe if low physical function is also present (56). Strength, muscle mass, and physical function have cutoff values used to confirm the impairment (see Figure 1.0) (56). Low muscle mass is defined as an appendicular skeletal muscle index (ASMI; appendicular skeletal muscle mass (kg)/height (m2)) two standard deviations (SD) below the mean SMI for young adults of each gender (94). If assessing SMI via dual energy x-ray absorptiometry (DXA) this translates to an SMI <7.0 kg/m2 for males and <5.5 kg/m2 for females (56). Muscle mass is commonly indexed to height based on its greater ability to predict adverse health outcomes and mortality when compared to weight and body mass index (BMI) (95). Low muscle strength is diagnosed via grip strength or chair stand performance. Low grip strength is defined as a grip 2.5 standard deviations (SD) below the mean for young adults of each gender. If using a grip of 2 SD below the mean, the presence of low grip strength in octogenarians is nearly 50% for both genders (96). This prevalence declines to 23% in men and ~27% in women when using 2.5 SD below the mean (96). Thus, the use of 2.5 SD provides for a more conservative diagnosis. Overall, this translates to a grip of <27 kg for men and <16 kg for women (56). Grip strength is assessed via handgrip dynamometer and shares moderate correlation with strength in other body regions (97). To diagnose low muscle strength using a chair stand test for both men and women the time must take >15 seconds to complete 5 rises from a chair (56). Physical function assesses the functional capacity of the body in relation to locomotion (19). For this reason, multiple methods are used for measuring physical function including gait speed, the short physical performance battery (SPPB), the timed up and go test (TUG), and the 400 m walk test. Low physical function is defined as gait speed ≤0.8 m/s, SPPB score ≤8 points, \n\n 19 \n≥20-second completion time for TUG, or non-completion or ≥6-minute completion time for the 400 m walk test (98, 99, 100, 101, 102). \n Figure 1: Revised Diagnostic Criteria for Sarcopenia in Healthy Older Adults According to the European Working Group on Sarcopenia in Older People (EWGSOP2) ASM=Appendicular Skeletal Muscle Mass; SPPB=Short Physical Performance Battery; TUG= Timed Up and Go (56). Sarcopenia Diagnosis in TAVR Patients In TAVR patients, sarcopenia is diagnosed by the presence or absence of low muscle mass alone, which is defined as a SMI (skeletal muscle cross-sectional area (cm2)/m2) two SD below the mean SMI for each gender (23, 26, 94, 103). When assessing SMI via a single-slice computed tomography (CT) scan at the level of the L3 vertebrae this translates to an SMI <55 cm2/m2 for men and <39 cm2/m2 for women (58). While muscle mass is the only factor used to diagnose sarcopenia in TAVR patients the other parameters used in healthy older adults should not be overlooked. Thus, it is necessary to discuss age-related mechanisms contributing to muscle atrophy and strength loss in addition to mechanisms of muscle atrophy in AS. \n\n\n 20 \nAge-Related Mechanisms of Muscle Atrophy and Strength Loss Muscle Protein Balance Before discussing age-related changes that may induce muscle atrophy and strength loss it is important to review the pathways responsible for maintaining muscle protein balance. Net protein balance refers to the difference between muscle protein synthesis (MPS) and muscle protein breakdown (MPB) (104). If MPS exceeds MPB it will result in muscle protein accretion and a positive net protein balance while the opposite (MPB exceeds MPS) results in MPB and a negative net protein balance (104). Chronic occurrence of MPS or MPB will result in muscle hypertrophy or atrophy, respectively (105, 106). The Insulin/Insulin-like growth factor 1 (IGF1) -insulin receptor substrate 1 (IRS1) - phosphatidylinositol 3-kinase (PI3K) -protein kinase B (AKT) -mammalian target of rapamycin complex 1 (mTORC1) pathway is considered to be the master pathway for the regulation of muscle growth (see Figure 2.0) (107, 108, 109). In particular, mTORC1 is responsible for the unification of signals from growth factors, energy, mechanical loading, and amino acids which are used to regulate downstream pathways responsible for mRNA translation to proteins (110). The binding of IGFI to IRS1 generates PI3K which recruits AKT to the plasma membrane where it is phosphorylated and activated by phosphoinositide-dependent kinase-1 (PDK1) (111, 112). Once active, AKT can phosphorylate the tuberous sclerosis 2 within the TSC1/2 protein complex on TSC2 causing inactivation of its nucleotide guanosine triphosphate hydrolysis (GTPase) -activating protein (GAP) activity towards Ras homolog enriched in brain protein (Rheb) (112, 113). With GTP intact, Rheb will then activate one of mTOR’s two known protein complexes known as mTOR complex 1(mTORC1) (112). Active mTORC1 can then phosphorylate and subsequently activate ribosomal protein S6 kinase beta-1 (p70S6K) and eukaryotic initiation \n\n 21 \nfactor 4E binding protein 1 (4E-BP1) (112, 113). Phosphorylation of p70S6K and 4E-BP1 allow for the assembly and activation of the ribosomal pre initiation complex responsible for initiation of mRNA translation, specifically those with the 5’ terminal oligopyrimidine motif (112, 114). Muscle atrophy is regulated by the imbalance of MPS and MPB. One of the mechanisms contributing to MPB is the ubiquitin proteasome system (UPS). The UPS functions to remove sarcomeric proteins in response to changes in muscle activity (113). The UPS consists of ubiquitin (Ub), ubiquitin-activating enzyme (El), ubiquitin-conjugating enzyme (E2), ubiquitin-protein ligase (E3), and a 26S proteasome (115). Sarcomeric proteins must be ubiquitinated prior to degradation by the 26S proteasome. El and Ub combine to form the Ub-El complex (115). The Ub-El complex then interacts with E2, which replaces El to form the Ub-E2 complex (115). Finally, ubiquitin is transferred to E3 which will transfer the ubiquitin molecule to the protein targeted for degradation (115). This process is repeated again until the target protein is connected with four to five ubiquitin molecules and then degraded in the 26S proteasome (115). The rate-limiting step of the UPS, which affects proteasome-dependent degradation, is catalyzed by E3 (115). Thus, the upregulation of E3’s such as Muscle RING-finger protein-1 (MuRF1) and muscle atrophy F-box (Atrogin-1) result in the degradation of sarcomeric proteins (115). The upregulation of MuRF1 and Atrogin-1 is largely under the control of Forkhead box O transcription factors (FOXO) (113). The phosphorylation of FOXO by active AKT renders FOXO incapable of nuclear translocation and thus upregulation MuRF1 and Atrogin-1 (113). In the presence of reduced AKT activity, unphosphorylated FOXO will upregulate MuRF1 and Atrogin-1 leading to muscle protein breakdown (113). FOXO can also be activated directly by the cellular energy sensor adenosine monophosphate-activated protein kinase (AMPK). AMPK is responsible for detecting changes in the ratio of adenosine monophosphate (AMP) to \n\n 22 \nadenosine triphosphate (ATP) (116). Increases in the ratio of AMP to ATP results in activation of AMPK and phosphorylation of FOXO on multiple AKT-independent sites causing nuclear translocation (117). In addition, AMPK may simultaneously inhibit protein synthesis by activating TSC2 and reducing mTORC1 activity (118, 119). Anabolic Resistance Prior evidence suggested that reductions in basal rates of MPS (120, 121, 122) or increases in basal MPB (123) in older adults were the driving factor(s) behind muscle atrophy. However, more recent evidence has failed to find these differences and has cast doubt on their validity (124, 125, 126). This has caused investigators to hypothesize that the age-related inability of MPS to respond to anabolic stimuli may be a driving force behind muscle atrophy. The term “anabolic resistance” is used to describe the age-related decline in MPS response to exercise and/or nutrient intake (127). Kumar et al., (128) reported MPS (4-hour measurement) to be significantly higher at 1-2 hours post exercise in young (24±6 years of age; n=25) vs older males (70±5 years of age; n=25) in response to volume equated knee extensions at 20-90% of one-repetition maximum (1-RM). While evidence from Moore et al., (129) suggest a significantly higher dose of protein (~0.40 g/kg vs 0.24 g/kg) is required to maximally stimulate MPS in older (71±1 years of age; n=43) vs younger adults (22±4 years of age; n=65). Anabolic resistance is multicausal with age-related changes in mTOR signaling, insulin sensitivity, and muscular disuse being frequently hypothesized causes. Declines in mTOR signaling appear to be related to modifications in the activity of mTORC1, p70S6K, and 4E-BP1. Kumar et al., (128) reported significant reductions in p70S6K and 4E-BP1 phosphorylation in older compared to young adults 1 hour after volume equated knee extensions at 60-90% 1-RM (p<0.05). In addition, a positive correlation was reported between increased MPS at 1-2 hours \n\n 23 \npost exercise and p70S6K phosphorylation at 1 hour post exercise in young but not older adults (p=0.049 vs p=0.7). Evidence by Cuthbertson et al., (126) found this pattern to hold over a 3-hour postprandial period after consuming essential amino acids (EAA) alone. mTORC1 and P70S6K phosphorylation increased by 5.2-fold and 8.1-fold in young males, respectively, after consuming 10 grams of EAA’s. However, mTORC1 and P70S6K phosphorylation increased only 2.7-fold and 3.5-fold, respectively, in older men (p<0.05). While the activation of mTORC1 plays a role in the upregulation of MPS, it is important to note that its degree of activation does not guarantee an elevation in MPS will follow (130). Insulin is a stimulator of MPS via its ability to phosphorylate 4E-BP1 and P70S6K and may aid in suppressing MPB via AKT phosphorylation (131, 132). In addition, the higher doses of protein required to stimulate MPS in older adults are trivial unless the EAA’s can be transported into the muscle cell. Insulin aids in this process by inducing vasodilation from production of nitric oxide (NO), which can simultaneously inhibit vasoconstriction (133, 134, 135). In particular, the phosphorylation of AKT by insulin increases NO synthase (eNOS) leading to production of NO (134, 135). At the same time, NO production can reduce vasoconstriction by diminishing its antagonist endothelin-1 (EN-1) (136, 137). In older adults, evidence suggests the presence of an age-related insulin resistance of MPS. Fujita et al., (138) reported that in older adults (~71 years of age; N=14) supraphysiological levels of insulin (0.30 mU min-1 100 ml-1) were able to significantly increase mixed muscle protein fractional synthetic rate (FSR) compared to basal levels (p<0.01) whereas normal postprandial levels (0.15 mU min-1 100 ml-1) did not. Accordingly, p70S6K phosphorylation was greater under supraphysiological conditions (p<0.05) while AKT phosphorylation tended to be greater but was not significantly different (p<0.07). In addition, leg \n\n 24 \nblood flow only increased significantly in response to supraphysiological levels of insulin (p<0.01). Rasmussen et al., (136) found similar results when evaluating the effects of hyperinsulinemia (0.15 mU min-1 100 ml-1) on muscle protein metabolism in young (25±2 years of age; n=7) compared to older adults (68±1 years of age; n=6). Blood flow across the leg was significantly lower in older compared to young adults under both basal and hyperinsulinemia conditions (Basal: 2.6±0.2 vs 4.0±0.4 ml·min−1·100 ml of leg−1; Hyperinsulinemia: 2.7±0.2 vs 6.7±1.3 ml·min−1·100 ml of leg−1; p<0.01). MPS showed significant positive correlations with insulin-induced changes in amino acid delivery (r=0.89, p=0.0001) and intracellular amino acid concentration (r=0.94, p<0.0001). Of note, EN-1 was significantly higher in older adults under both basal and hyperinsulinemia conditions (Basal: 3.53±0.72 vs 1.54±0.52 pg/ml; Hyperinsulinemia: 2.46±0.39 vs 0.71±0.28 pg/ml; p<0.01) providing a potential explanation for the observed insulin resistance of MPS. It is important to note that, while insulin can stimulate key mediators of MPS, insulin signaling must occur in unison with heightened amino acid availability in order for MPS to increase. When older adults (70±2 years of age; N=7) were exposed to hyperinsulinemia a subsequent increase in the phosphorylation of AKT, 4E-BP1, and P70S6K was observed (p<0.05) in the absence of increased MPS (FSR: Basal: 0.063±0.007 vs Insulin: 0.062±0.005 % per hour; p>0.05) (139). However, under the conditions of hyperinsulinemia and hyperaminoacidemia older (72±2 years of age; n=8) and young adults (25±1 years of age; n=6) increased MPS but a lesser increase was observed in older adults (FSR: 0.084±0.005 vs 0.119±0.006 % per hour; p<0.05). This was paired with a significant increase in the phosphorylation of AKT, mTORC1 and 4E-BP1(p<0.05) however P70S6K phosphorylation was not stimulated in older adults (140). Overall, insulin appears to play a vital role in stimulating \n\n 25 \nMPS however insulin insensitivity may not entirely explain the occurrence of anabolic resistance. Multiple comorbidities are common in TAVR patients and thus it could be hypothesized that periods of muscular disuse occur during their lifetime (23, 141). Disuse atrophy describes the loss of skeletal muscle mass in response to long-term (10-42 days) or short-term (≤10 days) muscular disuse as is observed in limb immobilization, limb unloading/suspension, and bed rest (114). Kortebein et al., (142) found a 0.6%/day loss of muscle mass in addition to a 30% decline in MPS following short-term bed rest (10 days) in older adults (67±5 years of age; N=12). Ferrando et al., (143) also reported a 0.2%/ day reduction in muscle mass and a 30% decline in MPS following long-term bed rest (28 days; 68±5 years of age; N=12). The decline in MPS may be related to changes in mTORC1 signaling while reductions in muscle mass may be related to elevated expression of E3’s. Significant increases in Atrogin-1 and MuRF1 gene expression have been reported after just 4 days of limb immobilization (144). While decreased mTORC1 phosphorylation in response to EAA’s has been reported after just 7 days of bed rest (145). Interestingly, changes in E3 gene expression are not commonly reported in long-term disuse atrophy (143, 146, 147, 148). This has led investigators to hypothesize that long-term disuse atrophy is likely caused by reductions in basal and postprandial MPS while short-term disuse atrophy likely results from a transient increase in MPB (141). It is also important to note that disuse atrophy can result from less drastic behavioral changes than bed best. Evidence suggests that changes in daily step counts can lead to significant reductions in muscle mass, insulin sensitivity, MPS, and fat mass. Breen et al., (149) reported a 26% decline in postprandial MPS, a 12% increase in postabsorptive insulin resistance, and a 43% reduction in postprandial insulin sensitivity after reducing step counts (5962±695 vs 1413±110 \n\n 26 \nsteps/day; ~76% reduction) for 14 days in older adults (72.3±1.0 years of age; N=10). These metabolic changes were accompanied by a 3.9% decline in leg lean mass, a 7.4% increase in total body fat% (p=0.053), and a 2.6% increase in trunk fat mass (p=0.024). Later evidence by Devries et al., (150) reported a similar effect on leg lean mass (1.4% reduction; p=0.003) using nearly the same step reduction (7714±809 vs 1288±62 steps/day; ~80% reduction; p<0.001) in older men for 14 days (70±1 years of age; N=30). While modifications to exercise and nutrition may negate anabolic resistance their implementation is low in the general population. Older adults are documented to consume less protein than younger individuals and from low-protein sources such as bread and cereal (151, 152). In particular, evidence suggests protein intakes at breakfast (10±10 g) and lunch (19±9 g) fall well below the recommended 0.4 g/kg in community dwelling older adults (151). In addition, physical activity declines with age resulting in nearly a third of adults over 50 years of age being classified as sedentary (153, 154, 155). In cases where physical activity does occur it is typically of low intensity (156). Thus, the conditions under which anabolic resistance is reported may be highly representative of the olderpopulation. Inflammation, Oxidative Stress and Myostatin Aging is associated with an increase in serum levels of inflammatory cytokines resulting in a state of chronic low-grade inflammation known as “inflammaging.” It is hypothesized that increased levels of inflammatory cytokines can result in a chronic activation of the UPS with subsequent muscle atrophy. Elevated inflammatory cytokines also stimulate greater release of C-reactive protein (CRP), an acute phase protein produced by the liver in response to local or systemic infection, tumor growth, or tissue injury (157). Of the inflammatory cytokines involved, tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) may have roles in the potentiation \n\n 27 \nof muscle atrophy (158, 159). TNF-α can activate the transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) which can lead to the synthesis of MuRF1 (113). TNF-α may also contribute to anabolic resistance through the inhibition of the anabolic effects of IGF-1. TNF-α can activate C-Jun N-terminal kinase (JNK) which can phosphorylate and inhibit IRS1 and negate the downstream anabolic effects of IGF-1 (160). Like TNF-a, IL-6 may contribute to muscle atrophy but through a different mechanism. In this case, chronic elevations in IL-6 are associated with proteolysis of IGF-1 binding protein 3 (IGFBP3) which transports IGF-1 in circulation (161). Destruction of IGFBP3 is posited to cause a negative effect on the half-life of IGF-1 and may explain the reduction of IGF-1 that has been observed in unison with elevated IL-6 levels (161). Paired with inflammaging is the presence of chronic oxidative stress. Skeletal muscles consume large quantities of oxygen that result in the production of reactive oxygen species (ROS) (162). The production of ROS can typically be offset via antioxidant systems (superoxide dismutase, catalase, glutathione peroxidase) however aging can disrupt this balance (162). An age-related rise in mitochondrial dysfunction and the impaired ability to remove dysfunctional mitochondria both contribute to elevated ROS production (163). Excessive ROS can intensify the effects of inflammation by aiding in the activation of inflammatory cytokines. For example, ROS can directly activate NF-kB, which can lead to the upregulation of the UPS (164). Like TNF-α, ROS also possess the ability to impair the anabolic effects of IGF-1. Upregulation of FOXO by ROS can lead to subsequent activation of 4E-BP1 which can then prevent the cap-dependent binding of mRNA to the 43S pre-initiation complex, negating the anabolic effects of mTORC1 (165). \n\n 28 \nThe myostatin protein is a negative regulator of skeletal muscle growth that resides in the extracellular matrix of all myocytes (166). When activated, myostatin can stimulate the nuclear translocation of the transcription factors SMAD family member 2 and SMAD family member 3 (SMAD 2/3) (166). Myostatin-Smad 2/3 signaling is noted to have an inhibitory effect on the IRS1-PI3K-AKT-mTORC1 pathway. In particular, the downregulation of AKT results in the increased expression of FOXO and thus upregulation of MuRF1 and Atrogin-1 (113). In addition to the upregulation of protein degradation, myostatin can also inhibit genes that can induce differentiation such as myogenin and myoblast determination protein 1 (myoD), suggesting that myostatin may regulate muscle differentiation by modulating programs of differentiation and atrophy (114). \n Figure 2: Regulators of Muscle Protein Synthesis and Muscle Atrophy (167). Fat Mass and Intramuscular Adipose Tissue Separate from declines in muscle mass, the aging process is associated with other changes to body composition such as increased adiposity and ectopic fat deposition (168, 169, \n\n\n 29 \n170). Each of these changes may contribute to muscle atrophy via increased release of inflammatory cytokines. The inflammatory effects of adipose tissue may relate to the phenotype of macrophages found in adipocytes. Under non-obese conditions the M2 macrophage phenotype is dominant in adipose tissue and produces anti-inflammatory cytokines such as interleukin-10 (IL-10) and interleukin-1 (IL-1) receptor antagonist (171, 172). On the other hand, under conditions of weight gain macrophages switch to a pro-inflammatory M1 phenotype producing inflammatory cytokines such as TNF-a and (IL-6) (173). Evidence from Weisberg et al., (174) estimates that macrophages may account for up to 40% of all cell types contained in the adipose tissue of obese individuals compared to an estimated 10% in lean/non-obese individuals (174). Age-related gains in fat mass have a higher propensity to be stored as visceral adipose tissue (VAT) (175). Compared to subcutaneous adipose tissue (SAT), VAT may produce higher levels of IL-6 and TNF-a. Schlecht et al., (176) reported moderate positive associations between VAT, IL-6 (β =0.29; p=0.046), and TNF-a (β=0.30; p=0.049) in overweight middle-aged men and women (53±12 years of age; N=97). While Park et al., (177) found VAT to significantly correlate with IL-6 (β=0.012; p=0.042) in obese middle-aged men and women (36±11 years of age; N=46). In middle-aged men and women (38±3 years of age; N=10), Fried et al., (178) found IL-6 release to be significantly higher in samples of VAT compared to SAT (642±476 vs 17±2 ng/g.day; p<0.015). Increases in fat mass may also result in increased concentrations of intramuscular adipose tissue (IMAT) (168, 169, 170). In order to avoid excess fatty acid and/or lipid storage in non-adipocyte cells, SAT must expand by either hypertrophy or hyperplasia of existing adipocytes (179, 180). The adipose tissue expandability hypothesis suggests that the capacity for adipocytes to undergo hypertrophy or hyperplasia is limited and determines the tendency for fatty acid \n\n 30 \nand/or lipid deposition in non-adipocyte tissues (181). Thus, exceeding the storage threshold for SAT results in ectopic fat deposition in tissues such as skeletal muscle (179). It is important to note that while obesity can cause ectopic fat deposition it is not required for it to occur. Advancing age alone has been shown to increase the presence of ectopic fat deposition and may be related to an age-related decline in mitochondrial function (182, 183). In either circumstance the build-up of IMAT is problematic for the maintenance of muscle mass and strength in older adults. Accumulation of IMAT is associated with accumulation of intramyocellular lipids (IMCL) resulting in a phenomenon known as liptoxicity (180, 184). Lipotoxicity has been hypothesized to contribute to the development of anabolic resistance by inducing insulin insensitivity and may contribute to muscle atrophy via upregulation of E3’s and FOXO (185, 186, 187, 188, 189, 190, 191). IMCL’s are predominately stored in lipid droplets as triacylglycerols which when metabolized can produce lipid intermediates such as diacylglycerols and ceramides (192). It is the accumulation of these lipid intermediates that may be responsible for insulin insensitivity and E3 upregulation. Ceramides and diacylglycerols can induce upregulation of protein kinase C and subsequent serine kinase cascades involving inhibitor of nuclear factor kB kinase (IKK) and c-Jun N-terminal kinase-1 (JNK) (185, 186, 187). Both IKK and JNK can phosphorylate the serine residues of IRS1 and inhibit the activity of PI3K (188). This results in, not only the impairment of glucose uptake but, the inability to phosphorylate AKT and thus increase NO synthase production and suppress nuclear translocation of FOXO (189, 190). Rivas et al., (191) reported a significant reduction in insulin mediated mTOR signaling (27% vs 120%; p<0.05) in accordance with a twofold increase in intramuscular ceramide storage (p<0.05) in older non-obese old mice compared to young non-obese mice (21 vs 3 months of \n\n 31 \nage, N=46). In vitro evidence suggests a role for ceramides in the upregulation of Atrogin-1 and FOXO. When De Larichaudy et al., (190) treated L6 myotubes with TNF-a, a potent stimulator of ceramide synthesis, subsequent elevations in Atrogin-1 (p=0.01) and dephosphorylation (activation) of FOXO (p<0.02) were observed. However, when myotubes were treated with both TNF-a and an inhibitor of ceramide synthesis the negative effects were significantly reduced (p<0.001). These results were extrapolated to a mouse model bearing C26 tumors, known to cause muscle wasting, treated with a ceramide synthesis inhibitor. Treatment with the inhibitor resulted in an 11% increase in weight of the tibialis muscles (p=0.05) and significantly increased the cross-sectional area (CSA) of the gastrocnemius (p=0.0002) and tibialis muscles (p=0.005) compared to untreated mice with C26 tumors. This coincided with a significant decline in the expression of both FOXO and Atrogin-1 (p<0.05). The accumulation of IMAT and IMCLs may also contribute to the age-related decline of strength. Goodpaster et al., (193) found thigh muscle attenuation, a measure of muscular fat infiltration (194, 195), to positively correlate with greater leg extension torque (p=0.001) and specific torque (force per unit area (CSA); N/cm2; p=0.001) in older adults (74±3 years of age; N=2,627). Later evidence by Choi et al., (196) reported significantly higher numbers of lipid droplets in type I (167±6.6 vs 293±12 droplets; p<0.05) and type IIa muscle fibers (69±4.0 vs 101±4.2 droplets; p<0.01) in older obese compared to older non-obese adults (69±2 years of age; n=21 vs 70±2 years of age; n=13). This corresponded with a negative correlation between single fiber contraction velocity (r=-0.71; p<0.05), maximal velocity (r=-0.73; p<0.05), and specific power (r=-0.69; p<0.05), which was not found in the non-obese. \n\n 32 \nNeuromuscular Modifications Age-related modifications to the neuromuscular system have been implicated in muscular strength reduction and muscle atrophy. Compared to young adults, older adults ranging from 70-80 years of age are shown to have 20-40% weaker isometric and concentric leg extension strength (197). This percentage increases to 50% once past the eight decade of life (197). Strength reductions are accompanied by a ~40% reduction in total muscle CSA from the 2nd to 8th decade of life (198). These changes may relate to shifts in muscle fiber type via altered motor unit function. Age-related remodeling of motor units is defined by denervation of type II muscle fibers resulting in a decline in the number of fast motor units (199, 200, 201). This is combined with subsequent reinnervation of type II fibers by slow motor units resulting in shift of type II fibers to type I fibers (198, 199). At the point when denervation exceeds reinnervation muscle atrophy will occur primarily from the loss of denervated type II fibers (202, 203). The effects of reinnervation are highlighted by histochemical evidence showing a random distribution of fiber types in the vastus lateralis of young adults compared to a homogenous “grouping” of fiber types in older adults (204). In addition, older adults have shown significantly higher proportions of type I fibers (66% of total muscle) compared to young adults (39% of total muscle) (205). Reduced muscle strength may also be attributed to deficits in voluntary activation. In the case of Harridge et al., (206) older adults (85-97 years of age; N=11) elicited incomplete voluntary activation during maximal isometric leg extensions (81±7%; range: 69-93%). Other consequences of aging such as declines in motor unit discharge rate and synchronization could also contribute to loss of strength in older adults (207, 208, 209). \n\n 33 \nAnorexia of Aging Evidence supports that the aging process is accompanied by a decline in daily caloric intake causing older adults to consume significantly fewer kilocalories than that of young adults (210, 211, 212, 213). Evidence from Briefel et al., (214) suggests a mean caloric reduction from 20 to 80 years of age of 1,300 kcal/day for men and 600 kcal/day for women. Reduction in caloric consumption, in addition to reduced protein consumption, is associated with reductions in muscle mass, strength, and physical function (215, 216). This age-related decline in caloric intake is referred to as the anorexia of aging (210). Anorexia of aging is multicausal stemming from changes to gustation, gastrointestinal motility, and inflammation. Gustation in older adults has a higher threshold for sweet, bitter, salty, and acid and may cause reduced desire for food consumption (217, 218). Modifications to gastrointestinal motility manifest as delayed gastric emptying resulting in prolonged elevations in satiety and potential caloric restriction. In response to an 800 kcal mixed meal, older adults (77±3 years of age; n=10) had significantly longer gastric emptying time (448±104 minutes, p<0.002) compared to young adults (306±57 minutes; 32±8 years of age; n=9) (219). As a result, postprandial satiety sensation remained elevated 4 hours after meal consumption compared to returning to fasting values in young adults (219). Older adults were also found to have higher levels of the anorexigenic peptides cholecystokinin (p<0.05) and peptide YY (p<0.01) at 4 hours although these variables did not correlate with satiety. The presence of inflammaging may also contribute to anorexia of aging through elevations in TNF-a and IL-1. Pilot data from Zumbach et al., (220) found increased secretion of leptin (3.1±0.28 vs 5.2±0.6 ng/mL; p<0.001), an anorexigenic hormone, 12 hours after TNF-a infusion in middle-aged men (range: 51-65 years of age; N=6). In addition, \n\n 34 \nrodent data have found the administration of an IL-1 receptor antagonist to prevent lipopolysaccharide induced increase in leptin levels (221). Many of the medications prescribed for those with cardiovascular complications are accompanied by side effects that may accelerate anorexia of aging. Evidence from Arunkumar et al., (222) found oral symptoms (xerostomia, dysgeusia, or a burning sensation) as a result of cardiovascular drugs occurred in ~63% of cardiovascular patients (55±2 years of age; N=603). Specifically, combinations of drugs such as b-blockers and calcium channel blockers caused xerostomia in up to ~22% of patients and dysgeusia in up to ~16% of patients. Each of these conditions can result in an altered or reduced food intake that may result in malnutrition and/or weight loss (223, 224). In addition, intestinal bowl wall edema associated with CHF may disrupt the absorptive mucosa of the intestinal tract which can impair nutrient absorption (225). Mechanisms of Muscle Atrophy in Aortic Stenosis Differences in Measurement of Muscle Mass The occurrence of low muscle mass in healthy octogenarians can be as high as 50% (25, 94). However, this percentage is significantly higher in those with AS at up to 70% (23, 24). A non-physiological explanation for this difference could relate to variance in the methodology of muscle mass assessment used in the research setting. Much of the literature on muscle mass in TAVR patients is unique in that muscle mass is quantified via CT-scan. In particular, it is common for muscle mass to be assessed from a single-slice abdominal cross-sectional image at the level of third lumbar vertebrae (L3; see Figure 3.0) (23, 24, 33). At this level, the CSA (cm2) of all abdominal skeletal muscles (psoas and paraspinal muscles, erector spinae, quadratus lumborum, transversus abdominus, external and internal oblique abdominals, and the rectus abdominus) are measured and then indexed to the square of the patient’s height and reported as \n\n 35 \nthe SMI (cm2/m2) (23). This is in contrast with the use of DXA, which quantifies muscle mass by directly measuring ASM (kg) and indexing it to the square of the participant’s height (ASMI: ASM/m2) (56, 94). While the L3 CT method does not directly measure muscle mass in the appendages as does DXA, it is highly associated with both DXA and full-body magnetic resonance imaging (MRI), which is the gold standard for assessment of muscle mass (226). Evidence from Shen et al., (227) reported a correlation of r=0.924 between CSA of muscle at 5 cm above the L4-L5 vertebrae and full-body MRI measurement of muscle mass in middle-aged adults (Men: 41.6±15.8 vs Women: 47.8±18.7 years of age; N=358). Mourtzakis et al., (58) reported a significant correlation between whole body fat free mass (kg) as measured by DXA and CSA of skeletal muscle measured at L3 (r=0.94, p<0.001) in middle-aged adults with cancer (63±10 years of age; N=51). In addition, ASMI as measured by DXA significantly correlated with SMI as measured by CT at L3 (r=0.89; p<0.001). Overall, differences in measurement modality appear unlikely as an explanation for higher incidence of low muscle mass in TAVR patients. \n Figure 3: Quantification of Body Composition Using a CT-Scan at L3. Skeletal muscle (RED), visceral adipose tissue (YELLOW), subcutaneous adipose tissue (BLUE), intramuscular adipose tissue (GREEN). A: An 83-year-old male sarcopenic TAVR patient with a BMI of 30 kg/m2 and an SMI of 33 cm2/m2. B: A 77-year-old male non-sarcopenic TAVR patient with a BMI of 31 kg/m2 and an SMI of 65 cm2/m2 (23). \n\n\n 36 \nAortic Stenosis and Inflammation The increased presence of low muscle mass in TAVR patients may be attributed to the effects of AS on TNF-a production. Separate from AS, TNF-a levels are well established to be elevated in patients with CHF compared to age-matched healthy controls (30, 228, 229). Kapadia et al., (30) reported patients with AS-induced pressure and volume overload (71±12 years of age; n=21)) had significantly higher levels of serum TNF-a (0.7±0.2 vs 2.1±1.6 pg/mL; p<0.05), TNF receptor 1 (841±361 vs 1,614±884 pg/mL; p<0.05), and TNF receptor 2 (2,694±884 vs 4,559±2,389 pg/mL; p<0.05) compared to healthy controls, respectively (55±8 years of age; n=28). Interestingly, TNF-a (1.3±0.7 vs 2.1±1.6 pg/mL; p<0.05), TNF receptor 1 (1,060±270 vs 1,614±884 pg/mL; p<0.004), TNF receptor 2 (3,201±838 vs 4,559±2,389 pg/mL; p<0.01) were also significantly higher in AS patients when compared to a group of patients with mitral valve regurgitation, respectively. It is posited that these elevations in TNF-a may relate to the endotoxin hypothesis. The endotoxin hypothesis suggests that bowel wall edema, a common occurrence during CHF, can alter gut permeability to the inflammatory stimulator endotoxin-like lipopolysaccharide (LPS) 230, 231). Genth-Zotz et al., (232) reported LPS levels to be 4.3 times higher in patients with CHF (65±8 years of age; n=15) compared to healthy controls (59±11 years of age; n=7). Whole blood from the same CHF patients had 3.6 times higher TNF-a release in response to LPS treatment (232). Myostatin While limited, evidence has reported elevated levels of serum myostatin in patients with AS (157±12 vs 100±0.1 ng/dL; p<0.001) (233). In patients with CHF, myostatin levels appear to undergo similar changes. Gielen et al., (234) found ~54% higher expression of myostatin mRNA in the vastus lateralis of CHF patients compared to age-matched healthy controls (50±6 vs 29±3 \n\n 37 \narbitrary units; p=0.03). While findings by Gruson et al., (235) showed significant elevations in plasma myostatin (63±6 vs 43±6 ng/dL; p<0.001). In addition, elevations in myocardial myostatin observed in CHF may have a detrimental effect on systemic muscle mass (236). Cardiomyocyte specific overexpression of myostatin in mice resulted in a significant reduction in the weight of the quadriceps, gastrocnemius, and soleus muscles compared to control mice (p<0.01) (237). Thus, increased myocardial expression of myostatin during CHF may influence whole-body muscle mass. Physical Activity Intolerance Behavioral modifications such as step count reduction have been shown to be detrimental to MPS and the maintenance of muscle mass (149, 150). This highlights the importance of the maintenance of physical activity throughout life. However, the frequency and intensity of physical activity are also found to decline with age (153, 156). CHF can accelerate inactivity levels by impairing systolic or diastolic function resulting in exercise intolerance due to fatigue and/or shortness of breath (27). In the case of those with AS, intolerance stems from increased afterload caused by the reduction of AVA and reduction in the contractile ability of the myocardium (6). Both changes impair the ability of the heart to meet the metabolic demands of the working tissues by reducing stroke volume and cardiac output. Myocardial modifications are commonly accompanied by changes in muscle morphology that can further reduce exercise tolerance. Drexler et al., (238) reported significant reductions in both volume density and surface density of skeletal muscle mitochondria (volume density: 5.99±1.3 vs 4.94±1.2 volume%; p<0.005; surface density: 1.01±0.2 vs 0.84±0.25 volume%; p<0.05) in CHF patients (58±8 years of age; n=57) compared to healthy controls, respectively (49±7 years of age; n=13). Importantly, volume density of the mitochondria was found to \n\n 38 \nsignificantly correlate with peak exercise oxygen consumption (r=0.59, p<0.001). In addition to mitochondrial modifications, the capillary length density (654±141 vs 524 ±156 mm/mm3; p<0.05) and percentage of type I muscle fibers were significantly reduced in CHF patients, respectively (54.5±14 vs 40.5±12%; p<0.05). Effects of Body Composition, Strength, and Physical Function on TAVR Outcomes Muscle Mass and Mortality Low muscle mass appears to correlate with increased long-term mortality in TAVR patients. Heidari et al., (24) reported higher long-term mortality rates at 4 years post-operation (~94% vs ~89%; p=0.02) in TAVR patients with low muscle mass (82±8 years of age; n=374) as opposed to those without (80±10 years or age; n=228). In a multivariate analysis for the entire cohort low muscle mass remained a significant predictor of mortality (p=0.03). A meta-analysis of 8 studies by Soud et al., (33) found an inverse relationship (OR 0.49, 95% CI: 0.28–0.83, p=0.049) between CT-derived muscle CSA or SMI and the risk of long-term mortality (1-2 years) in TAVR patients. Of note, these relationships were found despite variance in vertebrae (L3, L4, or L1-L4) and muscle measurement (CSA alone or SMI) among different studies. In addition to mortality, low muscle mass has been associated with other poor outcomes such as longer length of stay in hospitals (23, 103) Muscle Mass and Quality of Life Data on muscle mass and QoL are lacking in TAVR patients. However, correlations between QoL and muscle mass have been established in CHF patients, older individuals, and cancer patients. Based on the European Quality of Life–5 Dimensions (EQ-5D) questionnaire, ASM (kg) of the legs showed positive correlation with QoL in CHF patients (left leg: r=+0.5, p= 0.001, right leg: r=+0.38, p=0.01; 70±9 years of age; N=117) (239). In both healthy (74±4 years \n\n 39 \nof age; n=26) and mobility-limited older adults (77±4 years of age; n=22), lower CSA of the thigh muscles was associated with reduced scores on the physical component score of the 36-Item Short Form Health Survey (SF-36; p<0.046) (240). Of most interest is the correlation of QoL and muscle mass from patients with non-small cell lung cancer (65±9 years of age; N=734) (241). In this case, SMI showed a positive correlation with the global QoL component of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (QLQ)-Core 30 questionnaire (p=0.004). However, this correlation was in men only and may be explained by the influence of factors other than SMI on global QoL (241). Muscle Strength and Mortality Muscle strength as assessed by handgrip strength appears to correlate with early (30-day) mortality and long-term (1 year) mortality in TAVR patients. Evidence from Afilalo et al., (242) showed that pre-procedural grip strength in those who had died before reaching 1-year post-TAVR was significantly lower compared to those who were still living (20 kg vs 26 kg; p<0.001). This finding was corroborated by Kagase et al., (37) who found higher mortality rates (Men: 5% vs 2.7%; p=0.009; n=281 Women: 18% vs 5.6%; p<0.001; n=646) in TAVR patients with low peak grip strength (Men: ≤26 kg; Women: ≤12 kg) vs high peak grip strength (Men: >26 kg; Women: >12 kg). Finally, Forcillo et al., (243) found poor grip strength (Men: <25 kg; Women: <15 kg; N=351) to be associated with the probability of long-term mortality (p=0.04). Additionally, Forcillo et al., (243) reported that the odds of dying before 1 year were found to decrease by 3% with every 1 kg increase in grip strength. Muscle Strength and Quality of Life While not studied in TAVR patients, grip strength has been shown to correlate with QoL in older adults, COPD patients, and middle-aged adults. Using the World Health Organization \n\n 40 \nQuality of Life-BREF (WHO-BREF) questionnaire, Musalek and Kirchengast (34) found that grip strength correlated with the physical domain of the WHO-BREF in older adults (73±7 years of age; N=63; p<0.001). In addition, grip strength of older adults with COPD (64±9 years of age; N=88) positively correlated with QoL as determined by the St. George Respiratory Questionnaire (SGRQ; p=0.026) (244). In middle-aged adults (55±1 years of age; N=1152), Kang et al., (245) reported low grip strength (Men: ~31 kg; Women: ~19 kg) resulted in significantly higher odds for poor QoL on the mobility, self-care, usual activities, and pain/discomfort dimensions of the EQ-5D compared to high grip strength (Men: ~45 kg; Women: ~27 kg; p<0.001). Physical Function and Mortality Physical function as determined by gait speed (m/s) may predict both 30-day and 1-year mortality in TAVR patients. In the case of short-term mortality, Alfredsson et al., (36) stratified TAVR patients (65 years and older; N=8039) by gait speed (slowest (n=2,272): <0.5 m/s, slow (n=3,828): 0.6-0.5m/s, and normal (n=1,939): ≥0.6m/s) and found a decrease in 30-day all-cause mortality rate in accordance with gait speed (slowest: 8%; slow: 6%; normal: 5%; p<0.001). Additionally, for every 0.2 m/s decline in gait speed there was an 11% increase in 30-day mortality risk. Kano et al., (246) found similar results for 1-year mortality rate (80-90 years of age; N=1256) but used slightly different cutoff values (unable to walk (n=59); slowest (n=205): <0.5 m/s; slow (n=429): 0.5 - 0.83 m/s, and normal (n=563): >0.83 m/s). One-year mortality rate showed significant differences between gait speed groups (unable to walk: 41%; slowest: 18%; slow: 7%; normal: 8%; p<0.001). \n\n 41 \nPhysical Function and Quality of Life Data on physical function and QoL in TAVR patient is yet to be explored as well. However, gait speed and the SPPB are shown to correlate with QoL in older adults and other special populations. Bjerk et al., (247) found gait-speed to positively correlate with the physical function (r=0.537, p<0.001), role physical (r=0.275, p<0.001), general health (r=0.168, p<0.05), and vitality dimensions (r=0.175, p<0.05) of the SF-36 in older adults (83±7 years of age; N=155). In COPD patients (range: 63-67 years of age; N=511), gait speed showed a positive correlation with all dimensions of the SF-36 (p<0.001) (248). In addition, gait speeds <0.8 m/s showed significantly lower QoL scores compared to gait speeds ≥0.8m/s on the St. George’s Respiratory Questionnaire compared to gait speeds ≥0.8m/s (49.6 (38.7 - 61.1) vs 63.1 (48.9 - 71.6) points; p<0.001) (249). Other measures of physical function, such as the SPPB, have shown correlations with QoL. While relationships are lacking in TAVR patients, the SPPB has shown an association with QoL as determined by the Kansas City Cardiomyopathy Questionnaire (KCCQ) in transthyretin amyloid cardiomyopathy patients (75±8 years of age; N=75). When modeled with age, New York Heart Association class (an indicator of CHF’s impact on physical activity), Mayo and National Amyloidosis Centrestaging (NAC) systems (indicators of transthyretin amyloid cardiomyopathy severity), ejection fraction, wall thickness, and BMI the SPPB remained an independent predictor of QoL (p<0.01) (250). Intramuscular Adipose Tissue and TAVR Outcomes In addition to muscle mass, IMAT is another measure of body composition that is associated with aging and sarcopenia (56). Although seemingly unexplored in relation to QoL and mortality in TAVR patients, Tzeng et al., (35) recently provided insight on IMAT by determining its influence on hospital length of stay. IMAT measured from the psoas muscle at \n\n 42 \nthe L3 vertebra was an independent predictor of prolonged length of stay (>14 days) in multivariate analysis when compared to psoas muscles area and index (p<0.0001). In liver transplant patients, high IMAT (Males: <-0.375 HU; Females <-0.216 Houndsfeld Units (HU)) measured from the psoas muscles at the L3 vertebra has been reported as an independent risk factor for death 1 year post transplant (p<0.001) (251). While Okumura et al., (252) reported high IMAT (Males <-0.343 HU; Females:<-0.256 HU; p<0.001) in pancreatic cancer patients undergoing resection resulted in lower survival time compared to low IMAT (22 vs 57 months; p<0.001). Rehabilitative Protocols in TAVR Patients If present, low muscle mass, strength, or physical function may have a significant impact on post-procedural QoL and mortality risk in TAVR patients. It is important to establish interventions to minimize or attenuate the effects of low muscle mass, strength and physical function. Before discussing these measures, a discussion on the effects of interventions in cardiac rehabilitation on TAVR patients is presented below. Cardiac rehabilitation (Phase 2) takes place in the outpatient setting consisting of 36 medically supervised sessions provided over a period of up to 36 weeks (253). Phase 2 cardiac rehabilitation typically incorporates exercise training (aerobic, resistance, balance, stretching) and education on heart-healthy living (253). In the case of TAVR patients, the primary issue with cardiac rehabilitation is the patient participation rate. In a cohort of over 12,000 TAVR patients, Holmes et al., (254) reported only 32% of patients were transferred to an acute rehabilitation or translational care facility. The low participation rates relate to the percentage of patients referred for cardiac rehabilitation. Compared to the 41% referral rate for TAVR patients found by Imran et al., (41) those who presented with acute myocardial infarction, percutaneous coronary \n\n 43 \nintervention, coronary artery bypass grafting, or cardiac surgery had higher referral rates at 60–66% (255, 256). For those who do receive referral, other barriers such as lack of insurance coverage and cost of services may further reduce participation (253, 257). It should be noted that there are currently no existing guidelines for the delivery of exercise in heart valve replacement patients of any kind (71, 258). Because of this, guidelines for patients with cardiovascular disease given by the American College of Cardiology (ACC) and European Society of Cardiology (ESC) are the point of reference. The ACC recommends supervised aerobic exercise for 20-60 minutes at 40-60% of heart rate reserve on ≥3 days/week and moderate intensity RT on 2-3 nonconsecutive days each week (259). While the ESC recommends ≥150 minutes/week of aerobic exercise starting at 50% of maximal workload and increasing up to 70% of maximal workload (260). In addition, the inclusion of full body RT should be completed 2x/week (260). The existing data on the effect of cardiac rehabilitation in TAVR patients consistently shows that cardiac rehabilitation is safe and beneficial (41, 42, 261, 262, 263, 264). On 6 days/week for 2 weeks Russo et al., (262) had patients complete morning aerobic training on a cycle ergometer or arm ergometer (83±4 years of age; N=78). Thirty minutes of calisthenics were then conducted in the afternoon. Aerobic training sessions began at 10 minutes and were progressively increased in 5-minute increments until reaching 30 minutes. Exercise intensity was performed at a constant work rate at ≤70% of age predicted maximal heart rate. Significant improvements were found in the 6-minute walk test (6MWT) (241±95 vs 273±108 meters; p<0.001) and in Barthel Index score, an indicator of independence in activities of daily living (81±24 vs 90±17 points; p<0.01). \n\n 44 \n In the study by Genta et al., (261), patients underwent a 3-week protocol involving 2 daily 30-minute aerobic training sessions on a treadmill or cycle ergometer (82±6 years of age; N=65). Aerobic training occurred 6 days/week with intensity beginning at a minimum workload (0 watts for cycle ergometer and 1 kilometer/hour for treadmill) and progressed up to a subjective intensity of 14 on the Borg Scale. Significant improvements were found in the 6MWT (162±87 vs 240±92 meters; p<0.001) and in Barthel Index score (67±24 vs 85±17 points; p=0.001). In addition, reduction in Morse Fall Scale (MFS) score, an indicator of risk of falls, was found (36±22 vs 30±20 points; p<0.05). Genta et al., (265) repeated the same training protocol (83±5 years of age; N=95) and then followed patients for 3 years after completion to determine factors that may affect mortality. At the 3-year follow-up, those who were still living were found to have significantly higher scores on the MFS (24.3±14.1 vs 35.6±24 points; p=0.0056) and Barthel Index (89±15 vs 74±27 points; p=0.007) at discharge. Finally, Imran et al., (41) enrolled patients in a 12-week protocol involving aerobic training 3 days/week (80±2 years of age; N=24). Exercise was conducted on either an arm ergometer or a recumbent bike with intensity beginning at 70-85% maximal heart rate or an ratings of perceived exertion (RPE) scale of 4-6/10 on the modified Borg scale. Intensity was increased once a patient was able to maintain an intensity of 2-3/10 on the modified Borg scale. Average duration of exercise significantly increased from the first sessions to week 12 (20.1±6.5 minutes vs 34.1±5.5 minutes; p<0.01). In addition, exercise intensity significantly increased from the first session to week 12 (2.6±0.9 vs 3.6±1.3 METs; p<0.01). Interestingly, although functional capacity increased, this was not reflected on the physical capacity score on the SF-36 (36±11 points vs 38±11 points; p=0.32). However, mental capacity score did improve (49±9 vs 58±5 points; p<0.01). \n\n 45 \nOverall, cardiac rehabilitation appears to be safe and able to improve cardiorespiratory function, QoL, and risk of falls. However, the emphasis placed on aerobic training in cardiac rehabilitation also means that little or no emphasis is placed on RT. Few studies report the implementation of RT and those that do, do not assess body composition, strength, or physical function (41, 42). Thus, it remains to be determined if RT can modulate these measures in TAVR patients. However, RT is established as an effective method to improve these measures in healthy older adults and other patient populations and thus its effects will likely extend to TAVR patients. Effects of Resistance Training in Healthy Older Adults RT is well documented to produce positive effects on muscle mass, strength, and physical function. RT is a potent mechanical stimulator of MPS via upregulation IGF-1-IRS1-PI3K-AKT-mTORC1 pathway and can help to maintain or even improve muscle mass (266, 267). In addition, RT may help to negate muscle atrophy through reductions in the activity of TNF-a and IL-6 (268, 269). RT has been shown to produce increases in motor unit discharge rate (270) in addition to increases in isometric and dynamic quadriceps muscles (agonist) activation with simultaneous decreases in biceps femoris (antagonist) coactivation (271). These modifications result in increased muscle strength, which manifests as improvements in physical function (272, 273, 274). Muscle Mass, Strength, and Physical Function One of the earliest studies in older adults by Frontera et al., (275) had participants complete leg extensions and leg curls 3x/week for 12 weeks at 3 sets of 8 repetitions and 80% of 1-RM (range: 60-72 years of age; N=12). One-RM strength of both knee flexors (8±1 vs 23±2 kg; p<0.05) and extensors (20±2 vs 40±2 kg; p<0.05) increased in addition to midthigh girth \n\n 46 \n(49.3±0.2 vs 51.6±0.7 cm; p<0.05). Fiatarone et al., (276) found similar results after 8 weeks of leg extensions 3x/week for 3 sets of 8 repetitions beginning at 50% 1-RM and progressing to 80% 1-RM (90±1 years of age; N=10). Leg extensor 1-RM increased by 167±28% (8±1 vs 21±2 kg; p<0.001), midthigh muscle area by 9.0±4.7% (p=0.05), and gait speed by 48% (0.14 m/s vs 0.21 m/s; p=0.05). These changes were later confirmed in meta-analysis by Liu and Latham (277) of 121 trials in older adults (≥60 years of age; N=6700). Progressive RT caused moderate to large improvements on measures of physical function such as gait speed (24 trials; mean difference (MD) +0.08 m/s; 95% CI: 0.04 to 0.12 m/s; N=1,179) and ability to rise from a chair (11 trials; MD -0.94 seconds; 95% CI: -1.49 to -0.38 seconds; N=384). In addition, progressive RT caused moderate to large improvements in leg extensor strength (73 trials; MD +0.84 kg, 95% CI: 0.67 to 1.00 kg; N=3,509). A later meta-analysis by Peterson et al., (278) of 49 trials (66±7 years of age; N=1328) found progressive RT caused a mean improvement in lean body mass of 1.1 kg (95% CI: 0.9 to 1.2 kg). Vikberg et al., (38) examined the effect of RT on sarcopenia. Vikberg et al., (38) directly assessed changes in the diagnostic criteria for sarcopenia utilizing the same tests recommend by Cruz-Jentoft et al., (279) for muscle mass, strength, and physical function. Older adults (70.00±0.03 years of age; N=36) diagnosed with pre-sarcopenia (low muscle mass without decrement in strength or physical performance) completed a 10-week whole-body progressive RT protocol at moderate to high intensity as dictated by the modified Borg Scale (RPE 6-7). Training frequency was maintained at 3x/week while sets and repetitions began at 2 sets of 12 repetitions during week 1 and progressed to 4 sets of 10 repetitions at week 10. Resistance was added when RPE was reported to be below 6 during the weekly training sessions. Strength (handgrip strength: 31±10 vs 32±11 kg; p=0.007), muscle mass (ASMI: 6.2±0.9 vs 6.4±0.9; \n\n 47 \np<0.001), and physical function (SPPB composite score: 11.4±1.5 vs 11.7±1.0 points; p=0.048) all improved significantly. Resistance Training and Intramuscular Adipose Tissue In addition to muscle mass, strength, and physical function RT may reduce IMAT in older adults (39, 280). Marcus et al., (39) found a reduction in thigh IMAT (-11%, p< 0.05) following 12 weeks of eccentric leg extensor ergometry (frequency: 3x/week; duration: 5-30 minutes; resistance: perceived exertion of “very light” to “somewhat hard”) in adults of varying ages (range:18-87 years of age; N=30). Mueller et al., (281) found similar results in older adults (-6.9±1.5% thigh IMAT; p=0.03; 81±4 years of age; N=23) using eccentric leg ergometry for 12 weeks (frequency: 2x/week; duration: 20 minutes; resistance: 50 or 30 watts progressively increase by 20% maximum power output). After 5 months of full body RT (3x/week, 3 sets of 10 repetitions, 70% 1-RM), Nicklas et al., (280) reported a 5% reduction in thigh IMAT (-2.2 ± 6.2 m3; p<0.05) in older adults (65-79 years of age; N=126). While Taaffe et al., (282) found significant improvements in both hamstrings and thigh muscle attenuation (51.5±1.3 vs 54.2±1.3 HU; p<0.001; 41.9±1.7 vs 44.2±2.0 HU; p<0.001) after a 12-week full body RT protocol in older adults (2x/week, 2 sets of 8 repetitions, 70% 1-RM, 65-83 years of age; N=13). Resistance Training Variables Influencing Gains in Strength and Muscle Mass Peterson et al., (283) and Peterson et al., (278) found that intensity and volume were the most important factors in improving strength and muscle mass in older adults. In 49 studies reviewed by Peterson et al., (283) (67±6 years of age; N=1079), RT duration lasted from 6-52 weeks (17.6±8.6 weeks) with training occurring 1-3 days/week (2.7±0.5 days/week). Intensity ranged from 40-85% of 1-RM (70.0±12.7% 1-RM) while sets ranged from 1-6 per muscle (2.5±1.0 sets) and repetitions ranged from 2-20 (10±3 repetitions). All of the factors influencing \n\n 48 \nstrength improvement (age, study design, length of training, and training volume) had a significant positive correlation with training intensity. Thus, with each elevation in training intensity (low intensity (<60% 1-RM), low/moderate intensity (60-69% 1-RM), moderate/high intensity (70-79% 1-RM), and high intensity (≥ 80% 1-RM) there was a subsequent 5.5% increase in relative strength. Peterson et al., (278) reviewed 49 studies (69±7 years of age; N=1328) in which RT duration lasted from 10-52 weeks (20.5±9.1 weeks) with training occurring 2-3 days/week (3±0 days/week). Intensity ranged from 50-80% of 1-RM (74.6±6.9% 1-RM) while sets ranged from 7-39 per exercise session (20±7 sets) and repetitions ranged from 2-20 (mean=10 repetitions). Multiple meta-regressions determined a strong linear association between the magnitude of lean body mass change and volume of training (total sets per session) after controlling for confounding variables (age, study duration, type of lean body mass assessment, study design, gender, training intensity, and frequency; p<0.01). Thus, for every 10 additional sets of whole-body exercise performed per exercise session an average 0.5 kg increase in lean body mass was gained. The importance of intensity and volume are well-illustrated in the context of overcoming age-related anabolic resistance. Kumar et al., (284) found that conducting knee extensions at 40% 1-RM (3 sets of 14 repetitions) or 75% 1-RM (3 sets of 8 repetitions) failed to produce significant increases in post exercise MPS (4-hour measurement) in older men (70±5 years of age; N=12). However, when doubling the sets performed at each %1-RM, and thus exercise volume, significant increases in MPS were found (40% 1-RM: Area Under the Curve (AUC) 1× volume: 0.01±0.01% vs AUC 2× volume: 0.13±0.03% protein synthesized in 4 hours; p<0.01; 75% 1-RM: AUC 1× volume: 0.07±0.01 vs AUC 2× volume: 0.14±0.02% protein synthesized in \n\n 49 \n4 hours; p<0.001). Post exercise MPS was significantly greater (p<0.05) at 40% 1-RM in young men compared to older men before doubling sets. However, this difference subsided after sets were doubled. In addition, no differences were detected between young and older men at 75% 1-RM before and after sets were doubled. Sheffield-Moore et al., (285) also found no differences in post exercise MPS when leg extensions were conducted at 80% 1-RM (6 sets of 8 repetitions) however this only persisted 0-1 hours post exercise with MPS being greater at 1-2 hours in younger men. Conversely, Fry et al., (286) reported significantly higher postprandial MPS (p<0.05) at 3, 6, and 24 hours following knee extensions at 70% 1-RM (8 sets of 10 repetitions) in young (27±2 years of age; n=16) compared to older men (70±2 years of age; n=16). Differences in findings could be explained by variance in physical activity levels of the older participants. Effects of Resistance Training in TAVR Patients To date, a pilot study by Pressler et al., (43) is the only published study that has evaluated the effects of RT in TAVR patients. Thirty patients (81±6 years of age) participated in an 8-week combined resistance and endurance exercise protocol compared to standard care (no exercise). Exercise sessions were conducted 2x/week during week 1 of the protocol and increased to 3x/week from weeks 2-8. Endurance training was conducted on a cycle ergometer starting at 20 minutes at 40% of peak oxygen uptake (VO2peak) and progressing to 45 minutes at 70% VO2peak by week 8. Resistance training began in week 2 of the protocol and was conducted after endurance training 2x/week. Resistance exercises were performed on 5 different machines (bench press, rowing, shoulder press, pulldown, and leg press) starting at 30% of 1-RM for 1 set of 10 repetitions and progressing to 50-60% 1-RM for 3 sets of 15 repetitions. Strength significantly improved across all exercises as did VO2peak compared to standard care. 6MWT \n\n 50 \nimproved significantly (366±93 vs 392±100 meters; p<0.05) however it was not significantly different from those receiving standard care (p=0.428). This is to be expected as TAVR alone is shown to improve 6MWT Bagur et al., (287). KCCQ overall (77±16 vs 82±16 points; p<0.05) and clinical summary score (76±16 vs 84±14 points; p<0.05) improved in those who exercised in comparison, to standard care (Overall: p=0.044; Clinical: p=0.009). SF-12 PCS improved (40±10 vs 46±9 points; p<0.05) but was not significantly different from standard care (p=0.90). Most importantly, resistance and endurance training were found to be safe as no patients developed echocardiographic signs of prosthesis dysfunction or developed renal dysfunction. Overall, while the evidence is limited, it appears that RT may be a safe modality to improve QoL and muscular strength in TAVR patients. However, it remains uncertain how RT will impact muscle mass and physical function in TAVR patients. Effects of Resistance Training on Inflammation Tumor Necrosis Factor-Alpha One of the mechanisms by which RT may help to retain or improve muscle mass in TAVR patients could be through reduction in circulating levels of TNF-a. Evidence suggests that TAVR does not reduce circulating levels of TNF-a which could increase the risk of further muscle loss post-procedure (288). Data on the effect of RT on TNF-a in patients with any type of heart condition is limited. In mice with CHF, 8 weeks of RT did not have an effect on TNF-a but did reduce levels of IL-6 and improve levels of the IL-10 (289). While TNF-a was not reduced, IL-10 was noted to antagonize TNF-a and thus higher levels may have led to its reduction (168, 290). In human models, Macêdo Santiago et al., (291) reported significant reductions in serum TNF-a (66.27±10.31 vs 37.85±9.05 pg/mL; p=0.01) and TNF-a gene expression (cDNA: 0.01±0.01 vs 0.0002±0.0001 ng/mL; p=0.007) after 8 weeks of RT (3 sets of \n\n 51 \n8-12-RM, 3x/week) in older women (63±2 years of age; N=19). Of note, reductions in TNF-a were accompanied, by a reduction in fat mass (25.0±1.7 vs 23.5±1.7kg; p<0.02) and an increase in lean mass (38.6±3.6 vs 41.4±4.1 kg, p=0.02). In contrast, Greiwe et al., (269) found 3 months of RT (3 sets of 8-12 repetitions at 85-100% 1-RM, 3x/week) caused a 34% decline in muscle TNF-a protein content (p<0.01) and a 46% decline in TNF-a mRNA (p<0.01) without changes in fat mass and increased lean mass that was approaching significance (p=0.06). In addition, mixed muscle MPS increased by 83% (p<0.01) and was inversely correlated with TNF-a protein concentration (r= -0.53; p<0.04). RT for 12 weeks (3 sets of 8-12-RM, 3x/week) has also been shown to reduce circulating TNF-a levels by 29% (p<0.05) in older obese, postmenopausal women (66±3 years of age; N=23) without changes in fat or lean mass (292). C-Reactive Protein In response to elevations in TNF-a and other inflammatory cytokines the liver will increase secretion of CRP (157). Thus, it follows that CRP is found to be elevated in patients with AS (293, 294). Higher levels of CRP have been shown to correlate with severity of AS, progression of AS, and lower survival rates over ~2 years (295, 296). In addition, elevated CRP levels prior to TAVR have been associated with increased risk of death at 1-year post-procedure (297, 298). CRP appears to be unaltered after TAVR which may be explained by the inability of TAVR to reduce levels of TNF-a and IL-6 (288). In fact, TAVR is shown to cause a 0.5 mg/L increase in CRP at 3 months post-TAVR (288). Elevated CRP levels are associated with adiposity and increased risk of strength loss (299, 300). Therefore, the ability of RT to increase strength and muscle mass or reduce body fat may aid in reducing CRP post-TAVR. In a review of 11 studies by Sardeli et al., (301) older adults (≥65 years of age; N=51) were found to have significant reductions in CRP (MD = −0.61 mg/L; 95% CI = −0.83 - −0.31mg/L; p<0.001) when \n\n 52 \nRT was conducted for >12 weeks. Twelve months of RT (3 sets of 8 repetitions at 80% 1-RM, 3x/week) in older adults with type 2 diabetes (68±6 years of age; N=88) caused reductions of CRP that were significantly associated with increases in muscle mass (p=0.01) and loss of total fat mass (p=0.02) (302). In older women (68±6 years of age; N=30), 8 weeks of RT (3 sets of 8-12-RM, 3x/week) caused a 23% reduction in serum CRP levels with increased strength, muscle mass, and reduced body fat percentage (p<0.05) (303). Twelve weeks of RT in older women (85±5 years of age; N=21) induced reductions in CRP that were significantly correlated with increased muscle thickness (r= -0.61; p<0.01) (304). In older Hispanics with type II diabetes (66±2 years of age; N=62), 16 weeks of RT decreased CRP (3.5±9.1 vs 2.8±2.8 mg/L; p=0.05) while improving whole body lean mass (44.3±1.7 vs 45.5±1.9 kg; p=0.04) (305). Effects of Protein Supplementation in Healthy Older Adults Independent from RT, supplementation of the diet with protein has been proposed as a dietary intervention to combat the age-related loss of muscle mass. It is estimated that 32–41% of women and 22–38% of men older than 50 years consume less than the RDA for protein (0.8 g/kg/d) (306). In addition, very few older adults introduce the highest acceptable macronutrient distribution range (AMDR) for protein at 35% of total energy intake (306). While evidence for protein supplementation in TAVR patients is lacking, preliminary unpublished data from our laboratory show that TAVR patients consume below the RDA for protein (0.73±0.38 g/kg/d; N=19). With this in mind, it is important to discuss the ideal daily intake and dosage of protein that should be consumed to maintain or improve muscle mass. The dietary protein needs of humans are described using the Estimated Average Requirement (EAR) and the RDA. The EAR is estimated to meet the needs of 50% of the population while the RDA is estimated to meet the needs of 97.5% of the population. The current \n\n 53 \nRDA appears inadequate for the preservation of muscle mass let alone its improvement. As early as 2001, Campbell et al., (45) found significant reductions in mid-thigh muscle area (-1.7±0.6 cm2; p=0.019) after older adults consumed 0.8 g/kg/d protein for 14 weeks (66±3 years of age; N=10). Houston et al., (307) later found ~40% greater retention of lean mass and appendicular lean mass in older adults consuming 1.2 g/kg/d of protein compared to those consuming the 0.8 g/kg/d over 3-years (75±3 years of age; N=2066). While Mitchell et al., (308) found that consumption of 1.6 g/kg/d protein for 10 weeks maintained appendicular lean mass (25.0±2.5 vs 25.2±2.5 kg; p=0.56) compared to 0.8g/kg/d (24.4±7.7 vs 23.8 ± 4.4 kg; p=0.005). The apparent inadequacy of the RDA has led to recommendations ranging from 1.0-2.0 g/kg/d for older adults (47, 48, 49). While this range is large, evidence using invasive indicator amino acid oxidation (IAAO) suggests an EAR of ~1.0 g/kg/d and an RDA ~1.2 g/kg/d may be the minimum for maintenance of muscle mass (309, 310). Age-related anabolic resistance to protein ingestion requires the need for greater quantities of protein to maximally stimulate MPS in older adults (48). Evidence from Moore et al., (46) suggests nearly double the amount of protein (0.24 vs 0.40 g/kg) is required for older adults to maximally stimulate MPS compared to young adults. This amount translates to ~35 g per meal for an 80 kg individual (311). The difference in protein requirement may relate to the leucine content of the protein consumed. Of all the EAA leucine is the most potent stimulator of MPS for its ability to directly upregulate mTORC1 (312). Katsanos et al., (313) found that consumption of 6.7 g of EAA’s containing 1.7 grams of leucine (equivalent to 15 grams of whey protein) was unable to stimulate postprandial MPS (3.5-hour measurement) in older (67±2 years of age; n=10) compared to young adults (31±2 years of age; n=8; p<0.05). However, this difference subsided when leucine was increased to 2.8 grams (equivalent to 25 grams of whey \n\n 54 \nprotein; p<0.05). Evidence from Gorissen et al., (314) also supports that leucine amounts of <2.0 grams (20 grams casein protein containing 1.4 grams of leucine) are unable to significantly increase postprandial MPS (2-hour measurement). It is important to note that some evidence suggests that anabolic resistance may be phenomena related to differences in postprandial measurement time for MPS. While Gorissen et al., (314) found evidence of anabolic resistance after 2 hours, there was no significant difference in MPS between young and older adults when assessing MPS over 5 hours. This was also reported by Drummond et al., (315) who found no significant differences in postprandial MPS over 6 hours after consumption of 20 grams of EAAs (7 grams of leucine). In addition, MPS was significantly higher in young men (30±2 years of age; n=7) over 1-3 hours compared to baseline and to older adults (70±2 years of age; n=6; p<0.05). Older adults did not significantly increase MPS compared to baseline during the same time. However, MPS elevation was similar between groups over 3-6 hours and significantly different from baseline (p<0.05). These data imply that age may induce a delay of MPS response to protein consumption as opposed to anabolic resistance. However, this would not explain the greater retention of muscle mass that is observed with higher daily protein intake. Thus, higher doses of protein may be advisable in older adults. Effects of Resistance Training and Protein Supplementation in Healthy Older Adults The combination of RT and protein supplementation is a common recommendation for maintaining and even increasing muscle mass (44). In a fasted state, RT can cause elevation of MPS for ~48 hours however post-exercise net balance will remain negative (316, 317). Availability of EAAs can result in a positive net balance by intensifying the magnitude and duration of post-exercise MPS in addition to lengthening the duration of anabolic sensitivity (318, 319). This may explain the evidence suggesting larger gains in muscle mass when \n\n 55 \ncombining protein supplementation with RT compared to RT alone. A meta-analysis by Hou et al., (320) (18 randomized control trials; N=1039; range: 50-91 years of age) found RT combined with protein (range:12-40 g/day) or EAA (range: 3-6 g/day) supplementation produced larger improvements in fat-free mass (MD: 0.23kg; 95% CI: 0.09, 0.38; p=0.002) and ASM (MD: 0.39 kg; 95% CI: 0.14, 0.64; p=0.003) compared to RT alone. In addition, larger improvements in handgrip (MD: 0.29 kg; 95% CI: 0.08, 0.50; p=0.008), knee extension (MD: 0.27 kg; 95% CI: 0.06, 0.47; p=0.013), and leg press strength (MD: 0.33 kg; 95% CI: 0.01, 0.64; p=0.04) were reported. However, this did not result in greater improvements in physical function as determined by gait speed (p=0.83) or SPPB (p=0.07). On the contrary, Maltais et al., (321) examined the effects of 12 weeks of RT combined with protein supplementation in older men (range: 60-75 years of age; N=26). 12g of protein (7g EAA; 3.5g leucine) was consumed immediately after RT as either a milk or soy supplement and compared to a rice milk control (0.6g protein). Full-body RT occurred 3x/week at 80% of 1-RM for 3 sets of 8 repetitions. Habitual protein intake remained at ~1.2 g/kg/d for those who consumed soy while milk declined from 1.04 g/kg/d to 0.95 g/kg/d. Interestingly, the control group began at 1.32 ± 0.45 g/kg/d and declined to 1.05 ± 0.2 g/kg/d. Results found increases in muscle mass index (MMI; total body muscle mass (kg)/m2) (control: 18.5±1.5 vs 18.9±1.6 kg/m2; soy: 18.9±1.6 vs 19.7±1.7 kg/m2; milk: 18.3±1.6 vs 18.9±1.3 kg/m2; p<0.05). However, there were no significant differences between groups suggesting no additional effect of protein on muscle mass. The lack of difference may relate to sample size as a cohort of 30-35 may be necessary to detect changes in muscle mass when RT is accompanied by protein supplementation (322). \n\n 56 \nChalé et al., (323) tested the effect of RT combined with 40 g supplemental whey protein in mobility-limited older adults for 6 months (78±4 years of age; N=80). Protein was consumed in two separate 20 g servings after breakfast and dinner. On days that RT occurred, one serving of protein was consumed immediately after completion of RT. RT was conducted 3x/week and progressed participants to 80% of their 1-RM. Initially, 2 sets of 10 repetitions were performed on all exercises and then progressed to 3 sets of 12 repetitions. Habitual protein intake increased from 71±17 g/day to 89±22 g/day with the addition of supplemental protein. Total lean mass improved by 1.6% compared to 0.6% for those practicing RT alone (46.7±8.6 to 47.3±8.6 kg vs 46.4±8.4 to 46.7±8.4 kg; 95% CI: 0.26 kg (−0.43,0.95); p=0.01). However, the difference between groups was not statistically significant (p=0.48). While an additional 40 g of protein was provided the average increase in total protein intake was only 18 g due to 72% adherence to supplement consumption. Thus, it is possible that a higher adherence rate may have produced significant differences between groups. \nConcluding Remarks Aortic stenosis (AS) is the most common form of valvular heart disease effecting 5-6% of individuals ≥75 years of age. While TAVR is effective at correcting AS, a majority of patients do not survive for >5 years after their procedures. Thus, it is important to minimize comorbidities that may increase the risk of mortality and reduce QoL in the postprocedural setting. Sarcopenia is an age-related disease that can increase the risk of falls, fractures, physical disability, and mortality due to declines in muscle mass, strength, and physical function. Low muscle mass is present in up to 70% of TAVR patients in addition to decrements in strength and physical function which can increase mortality and reduce QoL. RT is well-documented to improve all of these measures in older adults and other special populations. In addition, dietary modifications \n\n 57 \nsuch as increased protein intake have shown to be effective at preserving muscle mass and may enhance gains in muscle mass when combined with RT. However, the effects of RT alone or in combination with protein supplementation are largely unexplored in TAVR patients. Based on the literature it is likely that a 12-week home-based full body progressive RT intervention will improve muscle mass, strength, and physical function in TAVR patients. In addition, when paired with protein supplementation, it is likely that RT will further promote improvements in muscle mass. \n\n 58 \nCHAPTER 3 RESEARCH METHODOLOGY The purpose of this study was to examine the effects of a digitally supervised 12-week progressive home-based RT program combined with protein supplementation (RT+PRO) on body composition, inflammation, strength, physical function, and QoL measures in post-operative TAVR patients, as compared to12 weeks of protein supplementation only (PRO). This study was approved by the Florida State University Human Subjects Institutional Review Board (Appendix A). Experimental Design Prior to conducting pre-test measures, participants signed the informed consent document (Appendix B) and physician approval for participation was obtained (Appendix C). Baseline visits 1 and 2 were conducted in the participant’s home during which all guidelines laid down by the Centers for Disease Control, National Institute of Health, and the Florida State University Office of Research were observed for social distancing, sterilization of materials, and use of personal protective equipment due to the country’s response to the COVID-19 pandemic in March of 2020. The research team provided masks if participants did not have their own. All research personnel wore masks, no more than two research personnel attended each baseline visit, and a distance of at least 6 feet was observed whenever possible. Visit 1 began at each participant’s home with each participant completing the Sarcopenia Quality of Life Questionnaire (SarQoL), Kansas City Cardiomyopathy Questionnaire (KCCQ), and the Medical Outcomes Study 12-Item Short-Form Health Survey (SF-12). This was followed by measurements of height, weight, waist circumference, blood pressure, and heart rate. Participants had their body composition assessed via hand-foot BIA (Biodynamics Model 310e, \n\n 59 \nSeattle, Washington) followed by blood collection. Visit 1 concluded with strength testing to determine maximal grip strength via Jamar dynamometer (JLW Instruments, Chicago, IL) and isometric leg extension strength via a leg dynamometer (Baseline Instruments, White Plains, NY). After completion of strength testing, all participants were given a 3-day food log and an activity log with a FitbitTM to complete before visit 2. Baseline visit 2 occurred at least one week later and consisted of the measurement of physical function via the Short Physical Performance Battery (SPPB) and the Senior Fitness Test. Based on the results of the baseline testing, participants were stratified by gender and arm curl performance into the RT+PRO group or the PRO group. Participants All participants were diagnosed with symptomatic severe AS (aortic valve area <1.0 cm2) and deemed to be at low, intermediate, high, or prohibitive risk by the Tallahassee Memorial Hospital (TMH) cardiology team. Inclusion criteria were: TAVR prior to enrollment, physically able and clinically stable to perform exercise as determined by their physicians, receiving treatment for cardiac and concomitant diseases, and signed informed consents. Exclusion criteria included any physical disabilities tht made regular exercise impossible, unstable cardiac conditions (decompensated heart failure, New York Heart Association (NYHA) Class IV), uncontrolled hypertension (>160/100 mmHg), diabetes, thyroid problems, kidney dysfunction, milk allergies, or severe COPD (forced expiratory volume in 1 second <50%). Individuals were also excluded if signs of valve prothesis were detected as defined by Valve Academic Research Consortium (valve orifice area of <1.2 cm2 plus a mean transaortic pressure gradient of ≥20 mmHg, a velocity of ≥3 m/s, at least moderate paravalvular regurgitation, signs of ischemia, severe arrhythmias, or hemodynamic deterioration); if they were taking pharmacological doses \n\n 60 \nof Vitamin D (6000 IU/day or 50,000 IU/week); or if they were participating in a regular exercise program (RT >1 day/week or aerobic exercise >2 days/week). Participant Recruitment All participants enrolled in the intervention were recruited from the Department of Interventional Cardiology at the Southern Medical Group or from our previous study with TAVR patients. Recruitment occurred in one of three ways: Researcher On-site 1. The principal investigator was present at Southern Medical Group on the day of the participant’s pre/postoperative appointment. The principal investigator met with the participant and his or her family members to discuss the intervention. During this time the participant and his or her family members received an informational pamphlet (Appendix D) on the intervention and were informed of the intervention benefits and requirements. If interested, and ruled eligible by the TMH cardiology team, the participant signed an informed consent document and a HIPAA Research Authorization Form (Appendix E). The HIPAA Research Authorization Form allowed the principal investigator to gain access to participants’ contact information (name, phone number, address), aortic valve area, ejection fraction, and mean aortic valve gradient measurements from the medical record. Participants were contacted at home < 2 weeks post-discharge to schedule the initial baseline visit. Researcher Off-Site 2. Participants were also recruited via discussions with Southern Medical Group’s cardiology clinicians. If a clinician identified a potential participant during a clinic visit the clinician would discuss the study with the patient and obtain a signed authorization form for \n\n 61 \nrelease of contact information to the principal investigator (Appendix F) as well as the HIPAA Research Authorization form. Recruitment then proceeded in the same manner with consent obtained at each participant’s first visit to the home. 3. Independent from in-clinic recruitment, all participants who underwent TAVR ≤6 months prior to the initiation of the intervention were contacted. Because it was not feasible to obtain consent or HIPAA authorization from these patients a signed letter from one of the cardiologists was sent to each patient who received TAVR ≤6 months prior (Appendix G). The letter was pre-approved by both FSU and TMH IRB’s and included the cardiologist’s signature introducing the patient to the intervention and providing the contact information for the principal investigator. If interested the patient contacted the principal investigator and HIPAA Authorization and informed consent were obtained during the first visit to the participant’s home. Pre and Post Testing Medical history of aortic valve area, ejection fraction, and mean aortic valve gradient was obtained from all participants at the beginning of the study from their electronic medical records. Before all pre-testing, participants were asked to refrain from alcohol consumption or exercise for 24 hours. Participants were asked to remain in a fasted state (>8 hours) prior to the first home visit, for the purposes of drawing blood. The visit began with each participant completing three questionnaires to assess QoL: the KCCQ-12 and the SarQoL to assess disease-specific QoL and the SF-12 to assess general health-related QoL (Appendix H). Anthropometrics After completion of questionnaires, blood pressure and heart rate were assessed in the seated position using an Omron HEM-907XL Professional Blood Pressure Machine (Omron Healthcare, Inc.,Kyoto, Japan). A blood pressure cuff was placed on the left arm at the brachial \n\n 62 \nartery and inflated to 180 mmHg. Blood pressure and heart rate were measured twice and then blood pressure was averaged if within 6 mmHg for systolic blood pressure, 4 mmHg for diastolic blood pressure, and 5 bpm for heart rate. Height and weight were assessed using a tape measure against a wall and a portable digital scale, respectively, (Seca Corporation, Hanover, MD) and body mass index (BMI) was calculated from these measures. Waist circumference was measured using a Gulick fiberglass measuring tape with a tension handle (Creative Health Products, Inc.; Ann Arbor, MI) encircling the smallest area around the torso, above the umbilicus and below the xiphoid process. A minimum of two measurements were taken and then averaged if the measurements were within 5 mm. If the first two measurements were not within 5mm a third measure was taken. Body Composition Body composition was measured using a hand-foot BIA (Biodynamics Model 310e, Seattle, Washington) at a single frequency of 50 kHz. BIA testing was performed while the participant was in a supine position on the floor with socks, shoes, and jewelry removed. Feet were positioned approximately 12-18 inches apart and hands were positioned approximately 6-12 inches from the torso with palms facing down. The skin of the right hand and foot were cleaned with alcohol and adhesive ECG tab electrodes were placed on the wrist and hand, and on the ankle and foot. Wrist electrodes were placed midway between the radius and the ulna, and hand electrodes were placed about one-half inch above the third metacarpophalangeal joint. Ankle electrodes were placed approximately midway between the lateral and medial malleoli, and foot electrodes were placed approximately one inch above the third metatarsal. All electrodes were placed so that the electrode tabs were facing outward and away from the body, and clips attached to the analyzer were then connected to the participant’s ECG tabs. The \n\n 63 \nparticipant was then asked to relax and remain motionless during the test. Measurements included body mass, fat weight, lean weight, and percent body fat. Skeletal muscle mass index was also determined from BIA measurement using the equation derived by Janssen et al., (324) as follows (SM is skeletal mass; Ht is height in centimeters; R is BIA resistance in ohms; for gender, men =1 and women= 0; and age is in years): SM (kg) = [0.401 x (Ht2/R) + (3.825 x gender) - (0.071 x age) + 5.102] After skeletal muscle mass was attained from the above equation it was converted to a skeletal muscle index (SMI) by dividing the measured muscle mass by the participant’s height in meters squared (kg/m2). The presence of low muscle mass was determined by the SMI cutoff values established by Chien et al., (325) of <8.87 kg/m2 and <6.42 kg/m2 for men and women, respectively. Blood Collection The blood biomarkers tumor necrosis factor-alpha (TNF-a) and C-reactive protein (CRP) were measured as markers of inflammation. Fasting blood draws were conducted in the home of each participant. Blood was drawn from the antecubital vein in the amount of 20 milliliters by a trained phlebotomist then blood was stored on ice in a cooler until it could be taken back to the laboratory in the Sandels building for processing and storage. Whole blood was centrifuged (4oC for 15 min @ 3500 RPM) and serum was then separated into individual aliquots and frozen at -80oC. All blood samples were analyzed at the conclusion of the intervention using commercially available ELISA kits (R&D Systems®) that were run in duplicate. Both blood biomarkers were initially run using normal sensitivity assays at Florida State University’s Institute of Sports Sciences and Medicine. The assay range of the normal sensitivity TNF- α ELISA was between \n\n 64 \n15.6-1,000 pg/mL with a sensitivity of 6.23 pg/mL. The assay range of the normal sensitivity CRP ELISA was between 0.8-50 ng/mL with a sensitivity of 0.022 ng/mL TNF- α was re-run using a high sensitity assay with a range of 0.2-10 pg/mL and a sensitivity of 0.049 pg/mL. Intra-assay coeffecients of variability were 6.1% and 3.4% for TNF-α and CRP, respectively. Muscular Strength Testing Grip strength was measured using a Jamar dynamometer (JLW Instruments, Chicago, IL). All participants were screened for arthritis in each hand before measurement but were not excluded from participation if arthritis was found. If more than one participant was found to have arthritis, they were equally stratified between groups. Each participant was seated with shoulders adducted and neutrally rotated and the elbow was flexed at 90° and resting on an arm of the chair with the forearm and wrist were in a neutral position. Grip measurements were taken three times on each arm, alternating between arms, and the highest measure for each arm was recorded. Isometric leg extension strength was measured using a leg dynamometer (Baseline Instruments, White Plains, NY). Participants were again seated in a chair with knees flexed at 90o. The dynamometer was placed on the distal tibia approximately 10 cm above the lateral malleolus. The researcher stood opposite of the leg being tested and held the dynamometer perpendicular to the limb. Each participant was then asked to exert maximal effort against the dynamometer while avoiding explosive movements. Measurements were repeated three times on each leg in alternating between each leg. Strength was determined by the measured “break” point which was the measured peak force that had to be applied to overcome the participant’s isometric contraction, indicated by a slight movement of the participant’s leg in the opposite direction of the voluntary contraction. The highest of the three measurements from each leg was recorded as the peak isometric strength for right and left leg. Lower body strength was also determined using \n\n 65 \nthe 30-second chair stand test. While seated in a chair with knees flexed at 90o the participant was asked to cross his or her arms across the chest and then rise to a standing position. If successful, the participant returned to the seated position and on the signal “go” attempted to complete as many sit-to-stands as he or she could in 30 seconds. RPE was assessed after completion using the Borg Scale. Food and Activity Logs Participant were asked to complete a 3-day food log on two weekdays and one weekend day of their choosing. All food records were analyzed twice by the same researchers using the MyFitnessPal (Under Armour Inc., Baltimore, MD). Step counts were recorded for a week on activity logs using a FitbitTM. Participants were told to wear the activity logs continuously throughout the seven-day period other than during sleep or while showering. If participants removed the FitBitTM for any other instance, they were to report it on their log sheets. Steps per day were averaged across the number of days participants wore the FitBits. Three-day food and activity logs were returned at baseline visit 2. Three-day food logs and activity logs were also completed on week 6 and week 12 of the intervention. Food logs were immediately analyzed at week 6 to ensure participants were not changing their food intake during the intervention. Physical Function Testing Approximately one week after completion of the first visit, the research team returned to participants’ homes for the second visit. Food and activity logs were collected for analyses followed by the assessment of physical function via the SPPB. Each participant first attempted a balance battery that involved standing in three different foot positions for 10 seconds. Participants were required to stand unassisted without the use of a cane or walker. Participants were asked to stand with feet together (side-by-side); in a semi-tandem position with the side \n\n 66 \nheel of one foot touching the big toe of the other foot; and in a tandem stance with heel of one foot in front of and touching the toes of the other foot. Each test was scored as follows: Side-by-side stand: 10 seconds = 1 point, <10 seconds = 0 points; Semi-tandem stand: 10 seconds = 1 point, <10 seconds = 0 points; Tandem Stand: 10 seconds = 2 points, 3-9.99 seconds = 1 point, <3 seconds or not attempted = 0 points. If the side-by-side stand was not completed, the semi-tandem and tandem stands were not attempted, and the participant moved on to gait speed assessment. Gait-speed (m/s) was determined by the time required to walk 4 meters. The distance walked was based on the preference of each participant. Participants could use any sort of walking aid to complete the test. Masking tape was placed on the floor to denote the start and end of the walk. Each participant stood behind the denoted starting line and began walking at a normal walking speed when prompted. The investigator simultaneously began timing upon prompting the participant to begin walking and stopped timing once the participant’s entire body had crossed the finish line. The test was then be repeated in the same manner. For the 4-meter walking distance, scoring was as follows: >8.70 seconds = 1 point, 6.21–8.70 seconds = 2 points, 4.82–6.20 seconds = 3 points, <4.82 seconds = 4 points. For the 3-meter walking distance, scoring was as follows: >6.52 seconds = 1 point, 4.66–6.52 seconds = 2 points, 3.62–4.65 seconds = 3 points, <3.62 seconds = 4 points. The final measure of the SPPB required participants to perform a chair stand test to determine muscle power (peak power, peak velocity, average power, average velocity) via a Tendo Unit (Tendo Sports Machines, London, United Kingdom). The Tendo Unit system was attached to the waistband of each participant’s pants near the hip and the participant’s weight was entered into the system. The participant then sat in an armless, straight-backed chair with \n\n 67 \nthe back against the wall with arms crossed in front of the chest and was asked to rise to a standing position. If successful, the participant returned to the seated position and the Tendo Unit was reset. Upon being prompted, the participant then attempted to complete 5 sit-to-stands as quickly as possible. Upon prompting the participant, the investigator began timing and stopped timing when the participant’s buttocks returned to the chair after completion of the 5th sit-to-stand. Completion times for the chair stand test were scored as follows: Could not complete 5 repetitions or did so in >60 seconds = 0 points, ≤16.70 seconds = 1-point, 13.70-16.69 seconds = 2 points, 11.20-13.69 seconds = 3 points, ≤11.19 seconds = 4 points. RPE was assessed after completion using the Borg Scale. After completion of all measures of the SPPB, participants then completed three exercises included in the Senior Fitness Test: the 30 second arm curl test, the two-minute step test, and the 8-foot Up-and-Go test. The 30-second arm curl test was used to determine upper-body muscular endurance. To complete this test, participants sat in a chair with their back straight and feet flat on the floor with the dominant side of the body close to the edge of the seat with a dumbbell (2.3 kg for women and 3.6 kg for men) held in the dominant hand at their side, perpendicular to the floor. Participants were then instructed on how to properly complete an arm curl from the down position, by bending the elbow and gradually rotating the palm to a facing-up position during flexion of the elbow as the weight was curled upward. The weight was then returned to the down position as the elbow was fully extended down. Participants then attempted to complete as many arm curls as possible in 30 seconds. RPE was assessed after completion using the Borg Scale. Next, participants completed a two-minute step test to determine aerobic endurance. Participants were asked to step in place as many times as possible for two minutes while \n\n 68 \nmaintaining appropriate knee height at a level even with the midway point between the kneecap and the iliac crest. The number of times that the right knee reached the appropriate height during the two-minute period was recorded. RPE was assessed after completion using the Borg Scale. Finally, participants completed the 8-foot Up-and-Go test to assess agility and dynamic balance. A chair was placed against a wall and participants sat in the chair with feet flat on the floor and hands resting on their lap. A cone was placed 8 feet in front of the chair. On the signal “Go” participants rose from the chair, walked to the cone, rounded the cone, and returned to sit in the chair. The time required to leave and subsequently return to the seated position in the chair was recorded. RPE was assessed after completion using the Borg Scale. Protein Intervention Participants in both groups consumed two servings of a whey protein supplement (hydrolyzed whey protein isolate, whey protein isolate, natural and artificial flavor; 110 calories, 0g fat, 1g carbohydrate, 25g protein; ISO-100 hydrolyzed protein powder, leucine Enterprises, LLC, Dallas, TX) each day. Participants in the PRO group consumed 1.5 servings of protein (37.5g protein) in the morning with breakfast and with lunch every day equating to 75g of protein per day. Participants in the RT+PRO consumed the first 37.5g of protein within 30 minutes of completing exercise and in the morning during breakfast on non-training days. The second 37.5g of protein was consumed with lunch on all days of the week. Participants in both groups received two 1.6lb pre-packaged tubs of protein after finishing visit 2 to begin supplement consumption. Participants were given the option of choosing from three different flavors of protein (vanilla, chocolate, strawberry) to help provide variety and prevent flavor intolerance. \n\n 69 \nSupplements were mixed with water at a volume based on personal preference. All participants received a reminder phone call or text message in the morning and evening of all non-training days and in the evening on training days to promote consistent supplement consumption. To calculate supplement compliance, participants were required to display their empty protein tubs to their exercise instructor before receiving more supplement. Adherence sheets were also completed to confirm both servings of supplement were consumed daily. All supplements were delivered to each participant’s home. All participants were asked to maintain their normal dietary habits for the duration of the intervention. To ensure participants were not altering food intake during the intervention. food logs were given at week 6 and analyzed for protein. Protein change, which is the change in habitual protein intake (g/kg/d) of each group was determined according to the calculations of Bosse and Dixon (326) as follows: Protein Change (%) = [(intake during the study – intake at baseline) / intake at baseline)) x 100] Resistance Training (RT) Intervention All participants were asked to maintain their usual activity levels excluding exercise sessions for those in RT+PRO. Resistance training was completed in each participant’s home on two nonconsecutive days each week, under the digital supervision of exercise instructors. Using either a telephone or video conferencing format, an exercise instructor contacted each participant at a specified time and guided them through a series of exercises. All exercises were completed with household materials such as a chair, beverage jugs such as a milk jug, and ankle weights. Water was used to fill the jugs to increase the intensity of the exercises. Each jug was pre-marked to designate how much water would need to be added for a poundage to be achieved. \n\n 70 \nJugs could weigh as little as 0.5 kg or as much as 3.6 kg and were weighed on a calibrated scale. Beverage jugs and 2.3 kg ankle weights were provided for each participant if needed. Upper body exercises included seated lateral raise, biceps curl, shoulder shrugs, triceps extension, one arm row, chest press, and abdominal crunch. Lower body exercises included leg extension, heel raises, hamstrings curl, gluteal extension, and body weight squat. A separate document was provided to each participant with written instructions and pictures on how to complete each exercise (Appendix I). Participants performed exercises in a superset design in which completion of an upper body exercise was immediately followed by completion of a lower body exercise. Three sets of each superset exercise were completed before continuing to the next pairing of upper and lower body exercises. Exercise pairings were as follows: chest press and bodyweight squat, one arm row and legs extension, seated lateral raise and hamstrings curl, shoulder shrugs and gluteal extensions, biceps curl and heel raise, triceps extension and abdominal crunch. Participants rested for 1-2 minutes between each pairing of exercises. Intensity began at a weight that each participant could lift for 8 to 15 repetitions for 1 set on each exercise. When a participant was able to complete 15 repetitions another set was added to the respective exercise. Sets were increased in the same manner until the participant was able to complete 3 sets on each exercise. Weight was progressively increased in the beverage jugs up to 3.6 kg or to the maximum weight (<3.6 kg) a participant could complete for 8 to 15 repetitions. The total training volume for the intervention was calculated by multiplying the weight lifted by the number of repetitions performed for each set for each week (weight lifted x repetitions x sets). The average training volumes for upper body (chest press, seated lateral raise, biceps curl, shoulder shrugs, \n\n 71 \none arm triceps, and one arm row) and lower body (leg extension, heel raises, hamstrings curl, gluteal extension, body weight squat) exercises were calculated for weeks 1–6 and 7–12. Statistical Analysis After all baseline testing, each participant was randomly or stratified by gender and arm curl performance to one of two intervention groups: 1) RT+PRO or 2) PRO. Running means of arm curl performance were kept for each group to ensure nonsignificant differences between groups when enrolling a new participant. In the same way, the number of males and females in each group was monitored to ensure equal gender distribution. Sample Size Estimation In accordance with the specific aims, a priori power analysis (JMP Pro 12) for primary outcomes was conducted. The power calculation for our study was based on results of a home-based RT+PRO intervention conducted by de Carvalho Bastone et al., (327). Based on a 6.1 kg mean difference for handgrip strength and a 5.2 kg mean standard deviation between control and experimental groups we calculated an effect size of 1.17 ((22.55-16.46)/5.2 kg). A a of 0.05 and a power of 80% determined that a sample size of 24 would be necessary. To account for a 20% attrition rate, we attempted to recruit 29 participants. Data Analyses All variables were assessed via null-hypothesis testing, and analyses were conducted using SPSS version 25.0 (SPSS, Inc., Chicago, IL). Data were presented as means ± standard deviations (SD). Dependent variables (body composition, strength, physical function, TNF-a, CRP, QoL, macronutrient intake, and activity levels) were analyzed at baseline by a one-way analysis of variance (ANOVA) to determine if there were baseline differences between groups. To test hypothesis 1, a 2 x 2 (group x time) repeated-measures ANOVA (RMANOVA) was used \n\n 72 \nto identify statistically significant main effects of group, time, or between-group interactions of group by time for body composition across two time points (baseline and 12 weeks). To test hypothesis 2, a 2 x 2 (group x time) RMANOVA was used to identify statistically significant main effects of group, time, or between-group interactions of group by time for TNF-a and CRP across two time points (baseline and 12 weeks). To test hypothesis 3, a 2 x 2 (group x time) RMANOVA was used to identify statistically significant main effects of group, time, or between-group interactions of group by time for strength, physical function and QoL across two time points (baseline and 12 weeks). To analyze dietary intake and step counts, a 2 x 3 (group x time) RMANOVA was used to identify statistically significant main effects of group, time, or between-group interactions of group by time across three time points (baseline, 6 weeks, 12 weeks). In the case that sphericity was violated, a Greenhouse-Geisser correction was performed. In the case of significance, a post hoc one-way ANOVA was used to identify significant differences. Effect sizes (ES; Partial Eta2) were calculated by standardizing mean differences to the standard deviations (SD) of the PRO condition. To remove small sample bias, the SD used in calculation of ES was divided by 1 − 3¬ (4v − 1), where v is equal to the degrees of freedom (328). Effect sizes are defined as trivial 0.0–0.2, small 0.2–0.6, moderate 0.6–1.2, large 1.2–2.0, very large 2.0–4.0, extremely large >4.0 (329). Pearson Product Moment Correlations were also completed to evaluate relations between some of the measured values at baseline. All significance was set at p<0.05. \n\n 73 \nCHAPTER 4 RESULTS Participants A total of 136 TAVR patients were presented with an opportunity to participate in the study. Of these, 107 declined to participate after receiving a detailed description of the requirements of the study. Of the 29 participants who completed informed consents, 6 were unable to be contacted and were not enrolled. Therefore, a total of 23 participants completed baseline testing and were stratified by gender and arm curl performance to one of two intervention groups: 1) RT+PRO or 2) PRO. Eleven participants were stratified to the RT+PRO group while 12 participants were stratified to the PRO group. One participant in the PRO group was excluded after ~2 weeks due to inability to consume the protein supplement. Overall, a total of 22 participants completed the study and were included in the results. An outline of the participant flow through the study is displayed in Figure 4. \n \nFigure 4: Participant Flow Through the Study \n\n 74 \nBaseline Characteristics Of the participants Caucasians comprised 95.5% of the study population (n=21) while African Americans comprised 4.5% (n=1). The average number of comorbidities for each participant was 2 ± 3 ranging from 0-3. Tables 1, 2, 3, 4, and 5 present data taken during baseline testing including anthropometrics, body composition, food intake, physical activity, blood pressure, clinical makers of inflammation, muscular strength, physical function, and QoL by group. No significant differences were found for any of the baseline measurements when comparing RT+PRO to PRO except for diastolic blood pressure (Table 2). The study population averaged 75.6±6.5 years of age ranging from 67-90 years of age. Males averaged 74.9±5.8 years of age while females averaged 77.4±7.9 years of age (Table 1). BMI averaged 31.3±6.4 kg/m2 ranging from 18.6 – 42.8 kg/m2. On average, the study population was classified as obese class I (30.0-34.9 kg/m2). Specifically, three had normal BMI (18.5-24.9 kg/m2), seven were overweight (25.0-29.9 kg/m2), six were obese class I, three were obese class II, and three were obese class III (≥40.0 kg/m2). Waist circumference measurements identified central adiposity in 15 participants (Females: >88 cm; Males: >102 cm; Females: n=5; Males: n=10). Skeletal muscle index (SMI) averaged 10.5±1.2 kg/m2 for males and 7.0±2.1 kg/m2 for females. Gender averages did not fall below their respective cut-off values for low muscle mass however low muscle mass was identified in four participants (Males: n=1; Females: n=3). Prior to starting the intervention, participants in PRO consumed below the RDA (<0.8 g of protein/kg of body weight) for protein while participants in RT+PRO consumed slightly above the RDA for protein. Activity levels classified both groups as sedentary (<5,000 steps/d) (330) \n\n 75 \nTable 1: Baseline Anthropometrics & Body Composition (N=22) RT+PRO (n=11) PRO (n=11) Female 3/11 4/11 Age (y) 74 ± 6 77 ± 7 Height (m) 1.70 ± 0.09 1.69 ± 0.13 Weight (kg) 86.4 ± 15.4 92.2 ± 21.6 BMI (kg/m2) 30.1 ± 6.3 32.4 ± 6.6 Waist Circumference (cm) 99.9± 13.1 102.3 ± 17.2 Fat Weight (kg) 29.6 ± 7.5 33.3 ± 10.0 Lean Weight (kg) 56.9 ± 10.2 58.9 ± 15.9 Body Fat (%) 32.9 ± 5.6 36.5 ± 7.5 SMM (kg) 27.5 ± 6.7 27.3 ± 9.2 SMI (kg/m2) 9.5 ± 2.3 9.3 ± 2.3 Low Muscle Mass (%) 18 (2/11) 18 (2/11) Carbohydrate (g/kg/d) 2.11 ± 1.03 2.04 ± 1.10 Protein (g/kg/d) 0.84 ± 0.29 0.68 ± 0.49 Fat (g/kg/d) 0.73 ± 0.37 0.56 ± 0.25 Caloric Intake (kcal/d) 1,573 ± 640 1,316 ± 327 Activity Level (steps/d) 4,602 ± 3,394 4,929 ± 3,456 Values are means ± SD. Reported protein consumption was before participants began taking the protein supplement RT+PRO: Resistance Training and Protein Supplementation. PRO: Protein Supplementation Only. BMI: Body Mass Index. SMM: Skeletal Muscle Mass. SMI: Skeletal Muscle Index Table 2 displays echocardiographic characteristics of participants assessed one day post-TAVR. The measurements of the aortic valve and ejection fraction data were taken from participants’ medical records prior to the start of the study. The time since receiving TAVR averaged 3.7±5.1 months and ranged from 0.25-18 months. The presence of hypertension, hyperlipidemia, and diabetes were confirmed by use of prescription medications and the medical history questionnaire (Appendix J). Three blood samples (RT+PRO: n=2, PRO: n=1) were removed from analysis of TNF-α due to insufficient serum availability for the follow-up visit. One sample was removed from CRP analysis (PRO: n=1) due to detection of fluid overflow in one sample well. Normative values for TNF-α and CRP post-TAVR patients range from 12-42 pg/mL and 2.0-3.5 mg/L, respectively (288, 331). Our TNF- α values fell well below the normative values for TAVR patients. \n\n 76 \nTable 2: Baseline Clinical & Echocardiographic Characteristics (N=22) RT+PRO (n=11) PRO (n=11) Months Removed from TAVR 4.4 ± 6.4 3.0 ± 3.6 Heart Rate (bpm) 64 ± 7 66 ± 13 Systolic Blood Pressure (mmHg) 144 ± 15 138 ± 18 Diastolic Blood Pressure (mmHg) 73 ± 7 68 ± 6€ Aortic Valve Area (cm2) 1.8 ± 0.6 2.2 ± 0.7 Mean Aortic Valve Gradient (mmHg) 10.6 ± 3.8 10.5 ± 6.0 Ejection Fraction (%) 61.5 ± 3.9 64.1 ± 5.4 TNF-α (pg/mL) (n=19) Ω 1.0 ± 0.3 1.2 ± 0.5 CRP (mg/L) (n=21) Ω Ω 3.1 ± 2.1 2.5 ± 2.1 Hypertension (%) 91 (10/11) 55 (6/11) Hyperlipidemia (%) 82 (9/11) 18 (2/11) Diabetes (%) 36 (4/11) 18 (2/11) Values are means ± SD. RT+PRO: Resistance Training and Protein Supplementation. PRO: Protein Supplementation Only. TAVR: Transcatheter Valve Replacement. TNF-α: Tumor necrosis factor alpha. CRP: C-reactive protein. Ω n=9 for RT+PRO and n=10 for PRO. Ω Ω n=11 for RT+PRO and n=10 for PRO € p<0.05, significantly different from RT+PRO. Table 3 displays all measurements of muscular strength assessed during baseline testing. Maximum handgrip strength averaged 28.1±8.3 kg for males and 14.9±5.1 kg for females. Nine participants were identified as having low handgrip strength (Males: <27 kg; Females: <16 kg; Males: n=6; Females: n=3) (56). One female participant had arthritis in both hands but completed the assessment. The maximum number of arm curls completed in 30 seconds averaged 17±5 for males and 14±3 for females. On average, both males and females completed the average number of arm curls for their age range (75-79 years of age) based on normative values from the Senior Fitness Test (Males:13-19 arm curls; Females: 11-17 arm curls) (332). Four participants were unable to complete the average number of arm curls for their respective age range (Males: n=3; Females: n=1) (332). The maximum number of chair stands completed in 30 seconds was 11±3 for males and 11±3 for females. On average, both males and females completed the average number of chair stands for their age range (75-79 years of age) based on normative values from the Senior Fitness Test (Males: 11-17 chair stands; Females: 10-15 chair \n\n 77 \nstands) (332). Seven participants completed below average on the number of chair stands for their respective age range (Males: n=6; Females: n=1) (332). One participant from PRO was removed from analysis of average and peak isometric leg strength due to sensitive skin at the site of leg dynamometer measurement and did not do the test. Table 3: Baseline Muscular Strength Measurements (N=22) RT+PRO (n=11) PRO (n=11) Handgrip Strength RA (kg) 24.6 ± 9.2 22.5 ± 11.1 Handgrip Strength LA (kg) 23.8 ± 10.1 21.9 ± 10.2 30-second Arm Curl Reps RA 15 ± 5 17 ± 5 30-second Arm Curl Reps LA 15 ± 5 17 ± 5 30-second Arm Curl RPE RA 12.5 ± 2.7 11.8 ± 2.4 30-second Arm Curl RPE LA 13.9 ± 2.8 12.0 ± 1.8 Peak Isometric Leg Strength 26.3 ± 7.6 26.0 ± 9.0 Average Isometric Leg Strength (kg) Ω 24.8 ± 8.2 23.5 ± 8.9 30-second Chair Stand Reps 11 ± 3 12 ± 2 30-second Chair Stand RPE 12.9 ± 3.6 11.3 ± 2.2 Peak Power (W) 736 ± 178 750 ± 300 Peak Velocity (m/s) 0.87 ± 0.20 0.81 ± 0.22 Values are means ± SD. Ω n=10 for PRO. RT+PRO: Resistance Training and Protein Supplementation. PRO: Protein Supplementation Only. Reps: repetitions, RA: Right arm, LA: Left arm, RPE: Rating of Perceived Exertion. Peak Power and Peak Velocity taken from 5-repetition chair stand test. Table 4 displays all measurements of physical function assessed during baseline testing. SPPB composite score averaged 10.1±1.8 points for the study population. Five participants were identified as having low physical function due to a SPPB composite score ≤8 points (Males: n=2; Females: n=3) (56). Gait speed averaged 0.90±0.19 m/s for the study population. Four participants were identified as having low gait speed (≤0.8 m/s; Males: n=2; Females: n=2) (56). Time to complete 5 chair stands averaged 11.8±3.1 seconds for the study population. Two participants were unable to complete 5 chair stands in ≤15 seconds (Males: n=1; Females: n=1). The average time to complete the 8-foot Timed Up-and-Go (TUG) was 7.1±2.1 seconds for males and 9.9±3.9 seconds for females. On average, the time to complete the 8-foot TUG test \n\n 78 \nwas greater than the normative values for females in this age range (75-79 years of age) based on normative values from the Senior Fitness Test (Females: 5.2-7.4 seconds) (332). Only one female was able to complete the 8-foot TUG in the average time for her respective age range Male participants on average were able to complete the 8-foot TUG within the average normative values for their age range (75-79 years of age; Males: 4.6-7.2 seconds). Two males were unable to complete the 8-foot TUG in the average time for their respective age range (332). Only one female was able to complete the 8-foot TUG in the average time for her respective age range (332). The average steps completed in the 2-minute step test were 82.8±30.5 for males and 80.4±26.4 for females which was representative of their age range (75-79 years of age) based on normative values from the Senior Fitness Test (Males: 73-109 steps; Females: 68-100 steps) (332). Table 4: Baseline Physical Function Measurements (N=22) RT+PRO (n=11) PRO (n=11) SPPB Score 10.1 ± 1.7 9.9 ± 2.0 Gait Speed (m/s) 0.89 ± 0.15 0.91 ± 0.22 Chair Time (seconds) 12.3 ± 3.8 11.2 ± 2.4 8-foot TUG (seconds) 8.1 ± 2.5 7.8 ± 3.6 2-minute Step Test (steps) 77.6 ± 34.2 86.5 ± 22.7 2-minute Step Test RPE 15.4 ± 3.0 14.1 ± 2.1 Values are means ± SD. RT+PRO: Resistance Training and Protein Supplementation. PRO: Protein Supplementation Only. SPPB: Short Physical Performance Battery. TUG: Timed Up and Go. RPE: Rating of Perceived Exertion. Table 5 displays all measurements of QoL assessed during baseline testing. The average SF-12 PCS score and SF-12 MCS score was 43.0±9.6 and 51.1±9.4 for the study population, respectively. The SF-12 PCS average score places the study population below the national average of 50 which indicates that our population perceived that their QoL was greatly impacted by physical health problems. Fifteen participants had a SF-12 PCS score below the national \n\n 79 \naverage (Males: n=10; Females: n=5). Eight participants had a SF-12 MCS score below the national average of 50 (Males: n=6; Females: n=2). Table 5: Baseline Quality of Life Assessment (N=22) RT+PRO (n=11) PRO (n=11) SF-12 PCS 42.4 ± 10.4 43.7 ± 9.2 SF-12 MCS 48.9 ± 10.3 53.3 ± 8.4 KCCQ 76.1 ± 23.4 83.8 ± 17.5 SarQoL 63.7 ± 12.9 69.7 ± 13.6 Values are means ± SD. RT+PRO: Resistance Training and Protein Supplementation. PRO: Protein Supplementation Only. PCS: Physical component score. MCS: Mental component score. KCCQ: Kansas City Cardiomyopathy Questionnaire. SarQoL: Sarcopenia Quality of Life Questionnaire. Pearson Product Moment correlations were completed on selected baseline measures of blood biomarkers, cardiovascular values, physical function, body composition, and protein intake. Aortic valve area (AVA) had significant positive correlations with body weight (r=0.465), waist circumference (r=0.465), lean mass (r=0.557), skeletal muscle mass (r=0.538) and right (r=0.440) and left (r=0.424) handgrip strength. CRP had a positive correlation with fat weight (r=0.494) and a negative correlation with gait speed (r=-0.513). Systolic blood pressure also had a negative correlation with gait speed (r=-0.423). Percent body fat was negatively correlated with gait speed (r=-0.499). SMI was negatively correlated with TUG (r=-0.471) and peak leg strength was also negatively correlated with TUG (r=-0.702). Peak leg strength was positively correlated with gait speed (r=0.440). Protein intake was positively correlated with repetitions completed on the 30-second chair stand test (r=0.568), composite score on the SPPB (r=0.510), and steps per day (r=0.471). Protein intake was negatively correlated with fat weight (r=-0.516) and waist circumference (r=-0.473). \n\n 80 \nPost-Intervention Measures Table 6 displays the progression of the training volume from the first week to the 6th week, to the 12th week of training and total training volume completed over the 12 weeks for participants in RT+PRO. All participants completed the 12 weeks of training twice a week for a 100% compliance rate. A significant main effect of time was found for upper body training volume (F(1,10)=53.323, p<0.001, ES=0.842) and lower body training volume (F(1,10)=58.470, p<0.001, ES=0.854), when comparing the three time periods. Post hoc analysis revealed significant increases in training volume from the first week to week 6 (p<0.001), week 6 to week 12 (p=0.003), and the first week to week 12. Protein adherence for both groups was over 90%. Protein supplement adherence is reported for 16 participants (RT+PRO: n=9; PRO: n=7) as six participants did not return their supplement adherence tracking sheet. However, all participants were asked to show their empty tubs of protein which they all did prior to receiving more protein supplement. For the participants that turned in their protein tubs and adherence sheets RT+PRO was 91% and PRO was 95%. Table 6: Training Volume of Participants Across the 12 Weeks (N=22) Week 1 (n=11) Week 6 (n=11) Week 12 (n=11) Upper Body Training Volume (kg) 465 ± 133 1,235 ± 494¥ 1,681 ± 541¥β Lower Body Training Volume (kg) 336 ± 47 769 ± 219¥ 1,075 ± 292¥β Total Training Volume (kg) 798 ± 162 2,004 ± 695¥ 2,756 ± 808¥β Total Upper Body Training Volume (kg) 28,690 ± 10,492 Total Lower Body Training Volume (kg) 18,452 ± 5,138 Total Training Volume (kg) 47,144 ± 15,364 Values are means ± SD. ¥ p<0.001, significantly different from baseline β p<0.001, significantly different from week 6 Table 7 displays the results for all measures of body composition at baseline and immediately following RT+PRO or PRO. A significant main effect of time was found for waist \n\n 81 \ncircumference indicating that both groups saw a reduction in waist circumference from baseline to week 12 (F(1,20)=5.198, p=0.034, ES=0.206). No other main effects or group x time interactions were measured. It should be noted that RT+PRO maintained SMI throughout the trial while PRO experience a 0.2 kg/m2 reduction. Table 7: Body Composition (N=22) Pre RT+PRO (n=11) Post RT+PRO (n=11) Pre PRO (n=11) Post PRO (n=11) Weight (kg) 86.4 ± 15.4 86.3 ± 15.1 92.2 ± 21.6 92.9 ± 21.6 BMI (kg/m2) 30.1 ± 6.3 29.9 ± 5.8 32.4 ± 6.6 32.3 ± 6.5 Waist Circumference (cm) 99.9± 13.1 98.1 ± 12.4† 102.3 ± 17.2 100.9 ±16.4† Fat Weight (kg) 29.6 ± 7.5 28.1 ± 7.6 33.3 ± 10.0 34.4 ± 9.0 Lean Weight (kg) 56.9 ± 10.2 57.9 ± 9.2 58.9 ± 15.9 58.7 ±16.0 Body Fat (%) 32.9 ± 5.6 32.4 ± 5.6 36.5 ± 7.5 37.1 ± 7.0 SMM (kg) 27.5 ± 6.7 27.6 ± 6.2 27.3 ± 9.2 26.9 ± 9.1 SMI (kg/m2) 9.5 ± 2.3 9.5 ± 2.0 9.3 ± 2.3 9.1 ± 2.3 Values are means ± SD. RT+PRO: Resistance Training and Protein Supplementation. PRO: Protein Supplementation Only. BMI: Body mass index, SMM: Skeletal Muscle Mass, SMI: Skeletal Muscle Index. † p<0.05, main effect of time. Table 8 displays the results for all clincial measurements taken at baseline and immediately following RT+PRO or PRO. A significant main effect of time (F(1,19)=9.166, p=0.007, ES=0.325) was found for CRP. A group x time interaction that approached significance was also found (F(1,19)=4.075, p=0.058, ES=0.177). Because this interaction approached significance a post hoc analysis was conducted. Results revealed a significant time effect for RT+PRO. These results indicate that participants in RT+PRO experienced a reduction in serum levels of CRP from baseline to week 12. While not statiscially significant, PRO experienced a reduction of 0.3 mg/L for CRP that may provide a clinical benefit. \n\n 82 \nTable 8: Clinical Measures (N=22) Pre RT+PRO (n=11) Post RT+PRO (n=11) Pre PRO (n=11) Post PRO (n=11) Heart Rate (bpm) 64 ± 7 66 ± 10 66 ± 13 69 ± 13 Systolic Blood Pressure (mmHg) 144 ± 15 147 ± 16 133± 18 131 ± 20 Diastolic Blood Pressure (mmHg) 73 ± 7 74 ± 13 68 ± 6 67 ± 10 TNF- α (pg/mL) (n=19) Ω 1.0 ± 0.3 1.0 ± 0.4 1.2 ± 0.5 1.1 ± 0.4 CRP (mg/L) (n=21) Ω Ω 3.1 ± 2.1 2.0 ± 1.5† 2.5 ± 2.1 2.2 ± 2.0† Values are means ± SD. RT+PRO: Resistance Training and Protein Supplementation. PRO: Protein Supplementation Only. TNF-α: Tumor necrosis factor alpha. CRP: C-reactive protein. Ω n=9 for RT+PRO and n=10 for PRO. Ω Ω n=11 for RT+PRO and n=10 for PRO † p<0.01, main effect of time Table 9 displays the results for all measures of muscular strength at baseline and immediately following RT+PRO or PRO. Significant main effects of time were found for the 30-second arm curl using the right arm (F(1,20)=26.449, p<0.001, ES=0.569) and 30-second arm curl using the left arm (F(1,20)=28.736, p<0.001, ES=0.590). A significant group x time interaction was found for 30-second arm curl RPE using the left arm (F(1,20)=6.006, p=0.05, ES=0.375). Post hoc analysis revealed a significant time effect for RT+PRO (F(1,10)=6.006, p=0.032, ES=0.382). These results indicate both groups significantly improved their 30-second arm curl using the right and left arms from baseline to week 12, potentially indicating a learning effect. In addition, participants in RT+PRO also experienced a significantly greater reduction in RPE on the 30-second arm curl using the left arm. While not significant, there was a group x time interaction that approached significance (p=0.082) on 30-second arm curl when using the left arm. A significant main effect of time (F(1,20)=5.625, p=0.028, ES=0.228) and a group x time interaction (F(1,20)=4.900, p=0.039, ES=0.197) were found for 30-second chair stand reps. Post hoc analysis revealed a significant time effect for RT+PRO (F(1,10)=15.749, p=0.003, ES=0.612). \n\n 83 \nA significant group x time interaction was also found for 30-second chair stand RPE (F(1,20)=6.057, p=0.023, ES=0.232). Post hoc analysis did not find any significant time or group effects indicating that both groups changed differently over time for 30-second chair stand RPE. These results indicate that participants in RT+PRO experienced a greater improvement in 30-second chair stand repetitions compared to those in PRO from baseline to week 12. In addition, participants in RT+PRO experienced a significant reduction in RPE on 30-second chair stand while participants in PRO experienced a significant increase in RPE from baseline to week 12. While not significant, there was a main effect of time that approached significance for 30-second chair stand reps (F(1,10)=4.865, p=0.052, ES=0.327). Table 9: Muscular Strength Measurements (N=22) Pre RT+PRO (n=11) Post RT+PRO (n=11) Pre PRO (n=11) Post PRO (n=11) Handgrip Strength RA (kg) 24.6 ± 9.2 26.8 ± 8.2 22.5 ± 11.1 24.1 ± 9.5 Handgrip Strength LA (kg) 23.8 ± 10.1 25.8 ± 8.6 21.9 ± 10.2 22.9 ± 10.1 30-second Arm Curl Reps RA 15 ± 5 20 ± 6†† 17 ± 5 19 ± 5†† 30-second Arm Curl Reps LA 15 ± 5 19 ± 5†† 17 ± 5 19 ± 6†† 30-second Arm Curl RPE RA 12.5 ± 2.7 10.7 ± 2.5 11.8 ± 2.4 12.2 ± 1.9 30-second Arm Curl RPE LA 13.9 ± 2.8 11.2 ± 2.5*∞ 12.0 ± 1.8 12.5 ± 2.2 Peak Isometric Leg Strength 26.3 ± 7.6 28.7 ± 5.1 26.0 ± 9.0 27.8 ± 9.0 Average Isometric Leg Strength (kg) 24.8 ± 8.2 24.8 ± 4.2 23.5 ± 8.9 25.2 ± 8.8 30-second Chair Stand Reps 11 ± 3 13 ± 3*∞ 12 ± 2 12 ± 3 30-second Chair Stand RPE 12.9 ± 3.6 11.5 ± 3.5* 11.3 ± 2.2 12.8 ± 1.7 Peak Power (W) 736 ± 178 779 ± 207 750 ± 300 782 ± 375 Peak Velocity (m/s) 0.87 ± 0.20 0.92 ± 0.23 0.81 ± 0.22 0.84 ± 0.32 Values are means ± SD. RT+PRO: Resistance Training and Protein Supplementation. PRO: Protein Supplementation Only. Reps: repetitions, RA: Right arm, LA: Left arm, RPE: Rating of perceived exertion. Peak Power and Peak Velocity taken from 5-repetition chair stand test. * p<0.05, group x time interaction ∞ p<0.001, time effect † p<0.05, main effect of time †† p<0.001, main effect of time Table 10 displays the results for all measures of physical function at baseline and immediately following RT+PRO or PRO. A significant main effect of time (F(1,20)=7.531, \n\n 84 \np=0.013, ES=0.274) and a group x time interaction (F(1,20)=5.086, p=0.035, ES=0.203) were found for time to complete 5 sit to stands in a chair. Post hoc analysis revealed a significant time effect for RT+PRO (F(1,10)=9.655, p=0.011, ES=0.491). This result indicates that participants in RT+PRO experienced a greater improvement in time to complete 5 sit to stands in a chair from baseline to week 12 compared to PRO. No other significant differences were found for all other measures of physical function. Table 10: Physical Function Measurements (N=22) Pre RT+PRO (n=11) Post RT+PRO (n=11) Pre PRO (n=11) Post PRO (n=11) SPPB Score 10.1 ± 1.7 10.1 ± 2.1 9.9 ± 2.0 10.3 ± 1.8 Gait Speed (m/s) 0.89 ± 0.15 0.89 ± 0.18 0.91 ± 0.22 0.92 ± 0.23 Chair Time (seconds) 12.3 ± 3.8 9.6 ± 2.7*∞ 11.2 ± 2.4 10.9 ± 2.9 8-foot TUG (seconds) 8.1 ± 2.5 7.3 ± 1.7 7.8 ± 3.6 7.8 ± 2.8 2-minute Step Test (steps) 78 ± 34 96 ± 22 87 ± 23 83 ± 28 2-minute Step Test RPE 15.4 ± 3.0 14.3 ± 2.5 14.1 ± 2.1 14.5 ± 1.8 Values are means ± SD. RT+PRO: Resistance Training and Protein Supplementation. PRO: Protein Supplementation Only. SPPB: Short Physical Performance Battery, Chair Time: Time to five sit to stands in a chair. TUG: Timed Up and Go. RPE: Rating of Perceived Exertion * p<0.05, group x time interaction ∞ p<0.001, time effect Table 11 displays the results from three QoL surveys completed at baseline and immediately following RT+PRO or PRO. A significant main effect of time (F(1,20)=6.926, p=0.016, ES=0.257) and group x time interaction (F(1,20)=8.476, p=0.009, ES=0.298) were found for the SarQoL survey. Post hoc analysis revealed a significant time effect for RT+PRO (F(1,10)=18.022, p=0.002, ES=0.643). This result indicates that participants in RT+PRO experienced a greater improvement in sarcopenia related QoL from baseline to week 12 compared to participants in PRO. While not statistically significant, clinically meaningful changes were found only for those in RT+PRO on the PCS and MCS components of the SF-12 \n\n 85 \nand the KCCQ. Clinically meaningful changes have been previously defined as improvement of ³2 points on either component of the SF-12 and an improvement of ³5 points on the KCCQ overall summary score (333, 334) Table 11: Quality of Life Assessment (N=22) Pre RT+PRO (n=11) Post RT+PRO (n=11) Pre PRO (n=11) Post PRO (n=11) SF-12 PCS 42.4 ± 10.4 44.6 ± 10.3C 43.7 ± 9.2 44.5 ± 12.4 SF-12 MCS 48.9 ± 10.3 53.4 ± 9.1C 53.3 ± 8.4 53.0 ± 8.4 KCCQ 76.1 ± 23.4 85.1 ± 17.0C 83.8 ± 17.5 81.2 ± 25.6 SarQoL 63.7 ± 12.9 74.0 ± 14.6*∞ 69.7 ± 13.6 69.2 ± 16.1 Values are means ± SD. RT+PRO: Resistance Training and Protein Supplementation. PRO: Protein Supplementation Only. PCS: Physical component score. MCS: Mental component score. KCCQ: Kansas City Cardiomyopathy Questionnaire. SarQoL: Sarcopenia Quality of Life Questionnaire. * p<0.05, group x time interaction ∞ p<0.001, time effect C, clinically meaningful change Table 12 displays the results from 3-day food logs and activity logs completed at baseline, week 6, and week 12 for RT+PRO and PRO in addition to protein change from baseline to week 6 and baseline to week 12. A significant main effect of time was found for protein intake (F(1,20)=215.201, p<0.001, ES=0.956). Post hoc analysis revealed that protein intake was significantly greater at week 6 and at week 12 compared to baseline for both groups (RT+PRO: Week 6: F(1,10)=51.886, p<0.001, Week 12: F(1,10) =48.613, p<0.001; PRO: Week 6: F(1,10)=126.515, p<0.001, Week 12: F(1,10)=48.613, p<0.001). No significant differences were found for protein intake between week 6 and week 12. A significant main effect of time was found for fat intake (F(1,20)=4.436, p=0.04, ES=0.303). Post hoc analysis revealed a significant reduction in fat intake for RT+PRO when comparing week 6 to baseline (F(1,10)=6.185, p<0.032) but not when comparing week 6 to week 12 or week 12 to baseline. A significant main effect of time was found for carbohydrate intake (F(1,20)=4.661, p<0.001, ES=0.552). Post hoc analysis \n\n 86 \nrevealed a significant reduction in carbohydrate intake for PRO when comparing week 12 to baseline (F(1,10)=5.476, p<0.041) but not when comparing week 6 to week 12 or week 6 to baseline. No significant main effects or group x time interactions were found for caloric intake, activity levels, or protein change. Table 12: Dietary Intake and Activity Levels (N=22) \n \n\n\n 87 \nCHAPTER 5 DISCUSSION The results of the present study demonstrate that RT+PRO significantly improved some measures of muscular strength, inflammation (CRP), and QoL, compared to PRO. No significant differences were found between groups for any measures of body composition or physical function. The lack of a true control group makes it impossible to confirm if the addition of PRO to RT contributed to our significant findings. Overall, our findings indicate that we partially accept our hypothesis of significant improvements in body composition for RT+PRO compared to maintenance of body composition for PRO. We partially accept our hypothesis of significant reductions in inflammation for RT+PRO compared to PRO. Finally, we also partially accept our hypothesis of significant improvements in physical function, strength, and QoL for RT+PRO compared to PRO. We accept that RT+PRO improved SarQoL score, 30-second chair stand repetitions, time to complete 5 sit to stands in a chair, and CRP levels compared to PRO. We also accept that body composition remained unchanged for PRO. Body Composition The lack of findings for changes in the measures of body composition in the present study, particularly muscle mass, are like other studies that have utilized a home-based resistance training program combined with protein supplementation. In a clustered randomized control trial, Van den Helder et al., (335), conducted a 6-month home-based resistance training program with or without increased dietary protein intake in older adults (72.0±6.5 years of age; N=224). Seventeen exercises focusing on improving standing, transferring objects, lifting objects, getting up from the floor, and self-care were conducted at least 2x/week at an intensity of 5-8/10 on the modified Borg scale. Participants did 1 set of each exercise for 30 seconds per exercise and \n\n 88 \nprogressed to three sets for a total of 120 seconds per exercise. Dietary protein intake was increased to 1.2-1.5 g/kg/d from 1.07±0.31 g/kg/day for participants in addition to the resistance training program in one arm of the study. Results demonstrated maintenance of skeletal muscle mass (SMM) for participants who resistance trained and increased protein intake but did not demonstrate accretion of SMM (SMM: Baseline: 20.8±0.5 vs. 6 months: 20.8±0.5 kg, p=0.154; Protein intake: Baseline: 1.1±0.0 vs. 6 months: 1.4±0.0 g/kg/d, p<0.001). Of note, participants who resistance trained and did not increase protein intake over 6 months lost muscle mass (Δ − 0.2 vs 0.0 kg, p=0.017). Perhaps if our participants had not been taking protein they too may have lost muscle mass over the 12 weeks. Similar to our study, de Carvalho Bastone et al., (327) conducted a 12-week home-based resistance training program that, unlike Van den Helder et al., (335), randomized older adults into 4 groups of either control, protein supplementation (S), resistance training (RT), and resistance training with protein supplementation (RTS) (76±7 years of age; N=80). Full body resistance training was conducted 3x/week at 80% 1-RM utilizing ankle weights, dumbbells, and elastic bands for 3 sets of 8 repetitions. Participants in the supplementation groups consumed an additional 40g of protein per day in the form of drinkable protein supplement. Results in relation to SMI were like that of our study in that RT+PRO led to maintenance of muscle mass over 12 weeks (SMI: S: 7.05±0.80 vs. 7.47±1.47 kg/m2; RTS: 7.25±0.98 vs. 7.74±1.23 kg/m2, p=0.198). In addition, the RT only group experienced a slight nonsignificant reduction as opposed to maintenance or gain of muscle mass (SMI: 8.17±1.51 vs. 7.91±1.42 kg/m2, p=0.198). Maintenance of muscle mass is crucial for TAVR patients to prevent a decrease in QoL and an increase in mortality risk (24, 336). While the present study did not observe the desired outcome of increased muscle mass, we did not have a decrease in muscle mass. Our maintenance \n\n 89 \nof muscle mass finding is not unusual when compared to the literature reviewing many home-based resistance training programs. A possible explanation may lie in the role that training volume (weight lifted x repetitions x sets) plays on muscle hypertrophy. As mentioned, Peterson et al., (278), Kumar et al., (284), and Sheffield-Moore et al., (285) demonstrated the importance of training volume in stimulating MPS in older adults and gaining muscle mass, and these studies suggest that older adults appear unable to stimulate MPS to the same degree as younger adults in the absence of adequate training volume. For example, Sheffield-Moore et al., (285) reported no difference in post-exercise MPS between older and younger adults when older adults doubled training volume at 80% 1-RM (3 sets of 8 repetitions vs. 6 sets of 8 repetitions). Peterson et al., (278) found that for every 10 additional sets of whole-body exercise performed per exercise session an average 0.5 kg increase in lean body mass was gained in older adults. Home-based exercise programs can be limited in the intensity that participants are able to do and the volume of training that participants are willing to complete. Facility based exercise programs can provide greater amounts of weight via the use of machines that could provide a greater stimulus for increases in muscle mass. As an example, in a previous 12-week trial conducted in our laboratory with resistance machines, participants attained a total training volume of 486,550±140,402 kg at a training intensity of ≥70% 1-RM using 3 sets of 10 repetitions for 10 exercises (337). This study in women significantly increased muscle mass by approximately 0.8 kg. In the present study, total training volume and intensity fell well-below that of the machine-based resistance training (47,144 ± 15,364 kg, 1-RM <50%) despite similar sets and repetitions (3 sets of 8-15 repetitions). Therefore, it is important to acknowledge that when doing home-based exercise programs training volumes may be lower than facility-based resistance training programs. Lower training volume may not result in significant improvements \n\n 90 \nin muscle mass and/or improvements may take longer to acquire. However, home-based programs are preferred by many older adults and may be beneficial in attenuating the losses in muscle mass seen with aging and disuse. To maximize the feasibility and cost effectiveness, our home-based RT protocol, participants utilized common items found around the home as weights. For example, gallon milk jugs were used as dumbbells and sand-filled socks were used as ankle weights. The capacity of each vessel limited the maximum weight that each participant could use to 3.6 kg or 7.2 kg when utilizing one or two milk jugs, respectively, or 2.3 kg or 4.6 kg when using one or two ankle weights, respectively. While training volume was progressed throughout the 12-week intervention in the form of sets and repetitions, our intervention was not able to approach the 50-60% 1-RM achieved by Pressler et al., (43), let alone the 80% 1-RM applied by Sheffield-Moore et al. (286). It is possible that our participants were not able to maximize post-exercise MPS due to this lower training volume potentially explaining the maintenance of muscle mass as opposed to an increase in muscle mass. While our initial hypothesis was incorrect, the importance of SMI maintenance by RT+PRO and PRO cannot be understated. Both QoL and morality rates worsen with reductions of SMI in TAVR patients (24, 336). Therefore, the maintenance of SMI prevented any further reductions in QoL or increases in mortality risk. In fact, RT+PRO resulted in statistically and clinically significant improvements in QoL. When comparing the results of RT+PRO to PRO, and to other studies, it appears that RT+PRO is unique in its ability to induce maintenance of muscle mass. While not statistically significant, participants in PRO experienced a 0.2 kg/m2 decline in SMI compared to complete maintenance of SMI in RT+PRO. In addition, QoL scores, while not statistically significant, declined for the SF-12 MCS score, KCCQ, and SarQoL. Thus, \n\n 91 \nit is possible that even slight reductions in muscle mass can impact QoL in TAVR patients. A previous trial from our laboratory suggests similar reductions for SMI over ~6 months post-TAVR (SMI: 47.5±10.9 vs. 46.5±10.1 cm2/m2) while protein intakes were below the RDA (0.7±0.4 g/kg/d; N=19). In addition, de Carvalho Bastone et al., (327) and Van den Helder et al., (335) demonstrated that RT alone does not allow for complete maintenance of SMM/SMI without added protein supplementation. Therefore, RT should be performed in combination with PRO to maximize both maintenance of muscle mass and QoL while potentially reducing mortality risk. Blood Biomarkers Results of the current study indicated that neither of the participant groups experienced a reduction in TNF- α, indicating that the RT program and protein supplementation utilized in this study did not influence serum levels of this inflammatory cytokine. Comparing our results to the available literature, it is interesting to note that our participants’ values fell well below the average for patients who were ~3 months post-procedure (1.0-1.2 vs 11.1-27.7 pg/mL) and below overweight and obese adults (1.0-1.2 vs 1.7-3.5 pg/mL) (288, 331, 338, 339). The exceedingly low levels of our participants bring into question the assay range and sensitivity of the Human TNF-α Quantikine ELISA’s used for analysis. Despite the literature supporting serum TNF-α within both assay’s range, our assays detected levels that were much lower. Considering the age and comorbidity profile of our population, it seems unlikely that TNF-α levels would be that low. The present study observed significantly reduced serum levels of CRP in the RT+PRO compared to PRO. The change experienced by RT+PRO (−1.1mg/L) is in line with previously reported reductions for older adults participating in RT (MD = −0.61 mg/L; 95% CI = −0.83 - \n\n 92 \n−0.31mg/L; p<0.001) (301). These results were also observed in the absence of a reduction in fat mass. This may imply that protein supplementation alone can reduce CRP with greater reductions achieved when RT is added, independent of losses in fat mass. Recalling that elevations in CRP can come in response to numerous inflammatory cytokines, it is possible that a reduction in CRP was spurred by concomitant reduction in inflammatory cytokine(s) other than TNF-α. Evidence of this is provided by Ogawa et al., (304) who found that 12 weeks of RT in older women (85±5 years of age; N=21) induced a significant reduction in CRP (Pre: 2.4±3.2 vs. Post: 1.5±2.2 ng·mL−1, p<0.05) without reduction in TNF-α (Pre: 0.9±0.7 vs. Post: 1.0±0.8 pg·mL−1, p>0.05). While fat mass was not directly measured in their study, weight (46.3±9.8 vs. 46.9±9.3 kg, p>0.05), BMI (21.2±4.0 vs.21.3±3.8 kg/m2, p>0.05), and waist circumference (80.4±11.3 vs.79.9±11.2 cm, p>0.05) did not change over 12 weeks. The significant reduction in CRP was paired with significant reductions in both heat shock protein 70 (HSP70; Pre: 3.3±2.1 vs. Post: 2.2±1.7 ng·mL−1, p<0.01) and serum amyloid A (SAA; 54.2 ±39.7 vs. 34.9±35.1 μg·mL−1, p<0.05). While not an inflammatory cytokine, HSP70 is noted as a mediator of inflammation that can induce production of interleukin 1 beta (IL1-β), IL-6, and TNF-α via NF-κB activation (340). In addition, much like CRP, SAA is an acute phase protein that is produced in response to increased inflammatory cytokine production with a reduction being indicative of reduced inflammation (341). Therefore, it is possible that a RT-induced reduction of inflammatory cytokines other than TNF-α may explain our observed reduction of CRP in RT+PRO. Had we analyzed a wider range of inflammatory cytokines it is possible that we would have identified those that caused a reduction in CRP. \n\n 93 \n Even though we did not find a statistically significant reduction in CRP for PRO it should not be discounted that protein supplementation can aid in inflammation reduction. A meta-analysis by Zhou et al., (342) reported a significant reduction in CRP (−0.42 mg/L, 95% CI: −0.96, 0.13) for middle-aged and older and adults (46-77 years of age; N=540) following ≥4 weeks of whey protein supplementation. The reduction we found in CRP for PRO (−0.3 mg/L) is not far from this finding. Therefore, it is possible that PRO alone could lead to a beneficial reduction of CRP in TAVR patients if supplementation occurred over a longer period or if participants had higher values. In a subgroup analysis, reductions in CRP were greatest among those who consumed ≥20g of whey protein per day (−0.72 mg/L, 95% CI: −0.97, −0.47) and had CRP levels ≥3.0mg/L (−0.67 mg/L, 95% CI: −1.21, −0.14). These findings are directly in line with the CRP and protein supplementation profiles of RT+PRO. At baseline, the CRP level for participants in RT+PRO was 3.1±2.1 mg/L before they began consumption of 75 g/d of supplemental whey protein. Considering the baseline CRP level for RT+PRO, it is certainly possible that a large increase in protein supplementation caused a significant reduction in CRP. This is further enforced by the reduction in CRP experienced by PRO despite having 0.6 mg/L lower CRP levels at baseline. However, the potential influence of RT on CRP reduction must also be considered. Therefore, it is possible that the combination of PRO with RT amplified the reduction of CRP in RT+PRO compared to PRO. Recalling that TAVR itself can elevate CRP by 0.5 mg/L (288), RT+PRO or PRO may provide an effective method for reducing inflammation caused by both TAVR and other comorbidities. \n\n 94 \nMuscular Strength and Physical Function In combination with maintenance of SMI, our results also showed that RT+PRO was effective at improving some measures of muscular strength compared to PRO. Consistently, other studies have shown home-based RT to improve measures of muscular strength despite having little impact on muscle mass (327, 335, 343, 344, 345, 346, 347). In a systematic review of 8 studies by Thiebaud et al., (347) (76±3 years of age; N=631) RT duration averaged 35.3±36.3 weeks with training frequency averaging 3.5±1.1 days/week. On average, 2.1±0.8 sets of 9.5±3.3 repetitions were completed per exercise utilizing bodyweight, dumbbells, elastic bands, and ankle weights for resistance. Four of the assessed studies reported intensity as repetitions (Range: 8-15 repetitions) while two reported intensities utilizing %1-RM (60-80%) and the modified Borg Scale (7-8/10). Like the findings of the present study, significant improvements in muscular strength were reported in half of the analyzed studies. For the studies that reported maximum voluntary contraction torque or force, lower body strength increased by 4.7–13.1 Nm (p=0.01), 1.15 kg (p≤0.05), 2.8–3.4 kgF (p<0.001), and 0.43 Nm/kg (p<0.05). Contrary to our findings, 5 of the 8 studies analyzed in this review reported significant improvements in physical function assessed via TUG (-0.8±0.5 seconds; p<0.05). A recent systematic review by Mañas et al., (348) of 21 studies (69-84 years of age; N=4,053) found home-based RT was conducted on average 2-7 days/week and lasted 12-52 weeks. Exercise modalities included elastic bands in two studies and bodyweight, dumbbell, ankle weight, cycle, or flexibility exercises in the other 19 studies. Of the studies that reported, exercise sets ranged from 1-3 and repetitions ranged from 8-15 with intensity at an RPE of 10-15 (on the 20-point Borg scale). Nine of the studies reviewed were included in a meta-analysis to determine the effect of home-based RT on muscular strength and physical function. Results \n\n 95 \nindicated a small significant beneficial effect of home-based RT on knee extensor strength (Hedges’ g = 0.33; 95%CI=0.11, 0.56; p=0.004; n=609) and balance as assessed by postural sway (Hedges’ g=0.32; 95 %CI=0.16, 0.49; p<0.001; n=556). The meta-analysis of these studies did not demonstrate significant improvements in handgrip strength (Hedges’ g=-0.04; 95%CI=-0.87, 0.79; p=0.932; n=555), the TUG test (Hedges’ g=0.32; 95%CI=-0.14, 0.78; p=0.178; n=996) or the SPPB (Hedges’ g=0.25; 95%CI=-0.17, 0.67; p=0.248; N=1,063). It is important to acknowledge that participants in RT+PRO experienced an improvement in muscular strength in the absence of muscle hypertrophy. Our finding illustrates the non-linear relationship between muscle mass and muscular strength. Neuromuscular adaptations such as increased rate coding and improved motor unit recruitment and synchronization can cause increased muscular strength independent of muscle hypertrophy (349). In fact, neuromuscular adaptations are noted to occur after 6 weeks of RT whereas muscle hypertrophy may take 12 or more weeks to occur (350). Therefore, the length of our trial was more conducive for producing improvement in muscular strength as opposed to muscle hypertrophy. Longer training duration may produce improvements in both muscular strength and muscle mass. Comparing the available literature to our results, home-based RT may have the ability to improve measures of muscular strength. However, it does not appear to be as effective at improving measures of physical function. Thiebaud et al., (347) concluded that “home-based resistance training can improve both strength and functional ability, but the improvements are generally small. The intensity of the exercises might not progress sufficiently enough to produce large improvements in strength because of less supervision or a lack of motivation to increase intensity further.” Supporting this conclusion, Peterson et al., (283) showed that a progressive increase in training intensity (low intensity (<60% 1-RM), low/moderate intensity (60-69% 1-\n\n 96 \nRM), moderate/high intensity (70-79% 1-RM), and high intensity (≥80% 1-RM)) resulted in a subsequent 5.5% increase in relative strength for each level of increased intensity in older adults. While our participants trained at a lower intensity for most exercises it is important to note that gains in strength were still made. Other studies showing improvements in physical function following resistance training progressed participants from low intensity (<60% 1-RM) to high intensity (≥80% 1-RM) over the course of a RT program (276, 277). Based on the literature and the results of the current study, it could be posited that improvements in physical function, despite improvements in muscular strength, may not manifest at lower training intensities. Our findings of improved strength without improvements in physical function may be explained by the limitations in a home-based RT placed on training intensity. In addition to training intensity, training type may have played a role in our lack of findings for physical function. Power training (PT) may be more effective for improving physical function in older adults compared to RT. Miszko et al., (351) conducted a 16-week intervention comparing PT to RT in older adults (73±6 years of age, N=39). RT involved 3 sets of 6-8 repetitions of seated row, chest press, triceps extension, leg press, leg extension, seated leg curl biceps curls, plantar flexion, and squat. Intensity progressed from 50-70% of the 1-RM by week 8, and then remained at 80% 1-RM for weeks 9–16. PT involved all the same exercises but substituted jump squats for squats. Intensity progression remained the same as RT for the first 8 weeks and then the program was altered to increase muscle power. Each participant performed 3 sets 6-8 repetitions at 40% 1-RM value as fast as possible. The concentric action was performed in ~1 second and the eccentric action in ~2 seconds. Results showed that participants in PT significantly improved their score on the continuous scale physical function performance test (CS-PFP) compared to RT (RT: Baseline: 56±10, Week 16: 58±10 vs. PT: Baseline: 58±13, \n\n 97 \nWeek 16: 67±13 points, p=0.03). Future trials should consider the incorporation of PT to home-based trials due to its beneficial effects of physical function and high safety profile in older adults (352). Quality of Life Pressler et al., (43) remains the only study in TAVR patients to assess the effect of RT on QoL. When compared to RT+PRO, participants in Pressler et al., (43) began at slightly lower SF-12 PCS scores (39.5±10.0 vs. 42.4±10.4 points), higher SF-12 MCS scores (54.1±10.0 vs. 48.9±10.3), and similar KCCQ scores (76.5±16.1 vs. 76.1±23.4 points). Pressler et al. (43) found significant improvements on both SF-12 PCS (39.5±10.0 vs. 45.9 ± 8.9 points, p<0.05), but not MCS (54.1±10.0 vs. 54.3±8.4 points, p=0.857), and KCCQ overall summary score (76.5±16.1 vs. 81.9±18.3, p<0.05). While our results for RT+PRO did not find a statistically significant improvement in either component of the SF-12 or the KCCQ summary score, the improvements that were observed are clinically meaningful. An improvement of ³2 points on either component of the SF-12 and an improvement of ³5 points on the KCCQ overall summary score have been noted as clinically meaningful changes (333, 353). Thus, it does appear that home-based RT has a positive impact on both health and disease specific QoL when assessed by SF-12 and KCCQ, respectively. Our findings for RT+PRO differ from that of Pressler et al., (43) in that we did find a clinically meaningful change in MCS score (+0.2 vs +4.5 points). There is evidence to suggest that RT has a positive impact on MCS score (354). Specifically, RT interventions have shown the ability to improve psychosocial measures such as coherence, perceived stress, depression, anxiety, and fatigue (354). However, it is also possible that the weekly contact with participants provided by our intervention may have also had a positive influence on MCS score. Hawton et \n\n 98 \nal., (355) demonstrated a significant impact of social isolation on MCS score for older adults (70.3±11.7 years of age; N=393). Older adults who were classified as having less than monthly direct contact with family, friends, or neighbors had significantly lower MCS scores compared to older adults who had less than weekly direct contact with family, friends, or neighbors (47.1±10.4 vs. 40.0±11.6 points, p<0.01). It is important to note that while those with less than weekly direct contact (i.e. more frequent contact) had a better MCS score, both groups were below the national average of 50 (333) indicating that isolation of any kind may be detrimental to MCS score for older adults. The COVID-19 pandemic significantly increased isolation time for many older adults due to their elevated mortality risk (356). It is conceivable that, in addition to the potential benefit from RT, our weekly digitally supervised exercise sessions may have helped improve MCS scores by providing frequent contact and reducing the feeling of isolation. It should be mentioned that isolation may have also impacted SF-12 MCS for PRO. Participants in PRO did not have the same level of weekly interaction that participants in RT+PRO did. Participants in PRO were sent reminder texts each day to consume their protein supplement however there was no weekly video conferencing and limited phone calls. Therefore, had weekly contact with PRO been equivalent to RT+PRO it is possible that a similar improvement in SF-12 MCS score would have been observed. To our knowledge, our study is the first to evaluate the effects of RT+PRO or PRO on disease specific QoL as assessed by the SarQoL. It is interesting to note that despite the small percentage of participants that presented with low muscle mass, significant improvements were found on the SarQoL following RT. It is important to note that the definition of sarcopenia incorporates more than the absence or presence of low muscle mass. The revised definition of sarcopenia by the second meeting of European Working Group on Sarcopenia in Older People \n\n 99 \n(EWGSOP2), muscle mass, strength, and physical function are all taken into account when diagnosing sarcopenia (56). The SarQoL incorporates these same factors when determining how sarcopenia may be impacting an individual’s QoL (357). Since participants in RT+PRO significantly improved strength compared to PRO, it seems possible that improvement in QoL was influenced by the gains in muscular strength made from RT despite the lack of improvement in SMI or physical function. In addition, the clinically meaningful improvement found on SF-12 MCS for those in RT+PRO compared to PRO could have also influenced the mental and physical health domain of the SarQoL contributing to a significantly higher score. Activity Levels and Dietary Intake Protein Intake Prior to daily participation in our study and subsequent consumption of a protein supplement, participants in both groups of our study were either below or barely above the RDA for protein intake. These findings are in accordance with preliminary data from our laboratory suggesting that TAVR patients consume below the RDA for protein intake at 0.7±0.4 g/kg/d (N=19). All participants achieved large increases in daily protein intake and were above 1.2 g/kg/d which has been suggested as the true RDA for the maintenance of muscle mass (309, 310). A 40% greater retention of muscle mass has been reported in older adults when consuming 1.2 g/kg/d vs. 0.8 g/kg/d over 3 years (307). Overall, monitoring TAVR patients at high vs. low protein intake for >6 months may help to detect a positive effect from increased protein consumption. Despite consuming ~1.6 g/kg/d of protein throughout our study, participants in RT+PRO did not experience an accretion of muscle mass. While established as a method for attaining a \n\n 100 \npositive net balance and lengthening the duration of anabolic sensitivity, the addition of protein supplementation to RT may not be effective in older adults for accretion of muscle mass (318, 319). Studies with higher training intensity than ours (80% 1-RM) and similar length (12-24 weeks) that combined RT and protein supplementation have failed to find improvements in muscle mass compared to control groups (321, 323, 358, 359, 360). Conversely, the recent meta-analysis by Hou et al., (320) suggests that protein supplementation can have an additive effect on muscle mass when combined with RT. Important distinctions between studies that did or did not find an additive effect of protein are the amount of protein or leucine consumed and training intensity. Studies that were unable to find significant gains in muscle mass consumed either equivalent to or less than the suggested RDA for maintenance of muscle mass (1.2 g/kg/d) or utilized an amino acid supplement with insufficient leucine content (<2 g) (321, 323, 358, 359, 361). The studies that exceeded either of these thresholds were able to find an additive effect of protein supplementation on muscle mass when combined with RT (50, 362, 363, 364, 365). In addition, to the adequate amounts of protein and/or leucine consumed, nearly all the studies (5 out of 6) also reported progressing participants to a 1-RM of at least 60-75%. Therefore, while protein intake in our study has been shown to be high enough for other studies in improving muscle mass, it appears that without adequate training intensity the additive effect of protein supplementation may not occur. In addition to training intensity, another factor that may have effected muscle mass (and the lack of changes in muscle mass) is the total caloric intake of the participants in this study. While protein accounted for a significantly higher percentage of caloric intake in both groups, there were no significant changes found for caloric intake after the addition of the protein supplement. It should also be noted that our participants did not consume >2000kcal/d despite \n\n 101 \nmany participants having BMI that classified them as obese (31.3±6.4 kg/m2). This indicates that their average caloric intake was likely underreported. Participants in RT+PRO and PRO consumed nearly the same number of calories before and during our 12-week study. Therefore, the suggested caloric surplus of 356-478 kcal/d for gaining muscle was not attained (366, 367). Basal metabolic rate (BMR) measurements taken from hand-foot BIA at baseline and 12 weeks indicated that despite a heightened protein intake our participants remained in a caloric deficit (RT+PRO BMR Baseline:1759±302 vs. RT+PRO BMR Week 12:1697±347 kcal/d; PRO BMR Baseline:1790±483 vs. PRO BMR Week 12: 1780±489 kcal/d). It appears that the additional caloric load provided by the protein supplement was consumed in place and not in addition to each participant’s habitual caloric intake. While there is evidence to suggest that RT+PRO in individuals who are naïve to training, overweight, or obese can achieve gains in muscle mass while in a caloric deficit (368, 369, 370), the studies that found significant gains in muscle mass utilized a greater training intensity (70-80% 1-RM) than the present study (368, 370). When combined with a caloric deficit it is possible that inadequate training intensity negated any gains in muscle mass to occur Overall, our finding of muscle mass retention in RT+PRO is vitally important in TAVR patients for the maintenance of QoL and prevention of increased mortality risk (24, 33, 336). Activity Levels Preliminary data from our laboratory suggest that, in addition to protein intake below the RDA, TAVR patients are sedentary (<5,000 steps/d) in the ~6 months following their procedure (Baseline: 2594±2357 vs. ~6 months: 2594±2357 steps/d). Our preliminary data are in line with our current findings in that, excluding weekly RT, both groups remained sedentary throughout our study. This finding underscores the importance of heightened protein intake and/or RT in \n\n 102 \nolder adults, specifically TAVR patients. The high frequency of multiple comorbidities in TAVR patients may cause increased susceptibility to bouts of disuse atrophy or significant reductions in step count (23). The occurrence of either may lead to significant reductions in both basal and postprandial MPS and ultimately muscle mass (142, 147, 149, 150). However, increased protein intake, RT, or a combination of both are established as reliable methods to stimulate MPS and maintain or even gain muscle mass. Our preliminary findings did not demonstrate a significant reduction of SMI when protein consumption was below the RDA for ~6 months post-TAVR but SMI was still lost. Nevertheless, it is possible that a higher daily protein intake and/or participation in RT could help to slow or prevent the loss of muscle mass that may occur >6 months post-TAVR. Correlations of Baseline Measures The participants in the present study had mean dependent values that were like healthy older adults. Perhaps if we were able to recruit TAVR patients that were frailer and/or considered higher surgical risk, improvements in our dependent values would have been achieved. Despite the lack of change in the dependent variables, the present study did find significant correlations in dependent variables that would suggest that if our intervention was continued for a longer period of time or provided a greater stimulus, significant improvements in health, body composition, strength, and physical function would have been observed. For example, aortic valve area (AVA) had significant positive correlations with lean mass (r=0.557), skeletal muscle mass (r=0.538), and right (r=0.440) and left (r=0.424) handgrip strength, suggesting that perhaps AVA can be preserved by utilizing interventions that maintain or increase lean mass and strength. Other correlations included the following: fat weight was positively correlated with CRP (r=0.494); percent body fat was negatively correlated with gait \n\n 103 \nspeed (r=-0.499); SMI was negatively correlated with TUG (r=-0.471); peak leg strength was negatively correlated with TUG (r=-0.702); and peak leg strength was positively correlated with gait speed (r=0.440). These relationships again suggest that interventions that produce positive changes in CRP, body composition and strength may be able to help TAVR patients maintain their functional ability. Baseline correlations with several of the dependent variables and protein levels also suggest that higher levels of protein consumption may be beneficial over time for TAVR patients. Protein intake was positively correlated with repetitions completed on the 30-second chair stand test (r=.568), composite score on the SPPB (r=.510), and steps per day (r=.471) and negatively correlated with fat weight (r=-0.516) and waist circumference (r=-0.473), suggesting increased protein intake can help to maintain optimal body weight and improve functionality in TAVR patients. Limitations and Future Directions There are several limitations to our study that should be discussed. Home-based exercise programs for older adults are typically limited in the ability to increase training intensity. Had our study been gym-based with access to equipment that would provide a greater training intensity, it is possible that significant changes in body composition and physical function would have been found. We fell short of our goal for sample size (N=24) which left our study underpowered and may have also impacted our ability to detect significant changes in our dependent variables. Had we met our goal it is possible that we would have found significant changes in our dependent variables. Our study took place during the Covid-19 pandemic which posed significant challenges to participant recruitment. Covid-19 may have also influenced the type of participants recruited as we found that more of the robust and healthier TAVR patients were interested in participating in the research project. These patients may not have been as \n\n 104 \nconcerned about socially isolating as compared to higher risk patients who were frailer and/or had more comorbidities. Our study did not incorporate a true control group therefore we are unable to determine if muscle mass maintenance was because of high protein intake or other factors. However, we believe the benefit of a high protein intake post-TAVR outweighed the risk of consuming a low protein diet. Our participants were asked to consume their protein supplement in addition to their habitual diet to create a caloric surplus. However, participants did not reach a caloric surplus when comparing baseline caloric intake to mid-point and post-intervention, as calculated by the BIA machine. Additionally, we did not standardize water consumption 24 hours prior to the conduction of hand-foot BIA. Participants were encouraged to consume water to attain normal hydration levels, but the amount was not specified. With standardization it is possible that differences in body composition could have been found. The error associated with our BIA machine is 4 to 5% (371). Due to the testing error of the machine perhaps small meaningful changes that occurred over the 12-week study may not have been accurately assessed. Finally, while we asked participants to document their protein consumption and show us their empty tubs of protein, we did not have a foolproof method of confirming consumption. Future research should aim to conduct a home-based RT program of larger sample size that will progress participants to >60% 1-RM in unison with protein intakes ≥1.2g/kg/d for longer periods of time. Ideally, a true control group and a group that participates in RT but does not consume a protein supplement should also be incorporated. Future research should also aim to incorporate frequent assessments of metabolic rate in accordance with dietary assessment to ensure attainment of a caloric surplus for the duration of the studies. To ensure compliance to \n\n 105 \nsupplements, future research should take advantage of video conferencing to confirm protein supplement consumption. Conclusions The present study found that a home-based RT program with protein supplementation that was digitally supervised improved measures of muscular strength, inflammation, and QoL in TAVR patients over a 12-week period. The convenience of digitally supervised home-based RT presents an opportunity to improve patient participation in cardiac rehabilitation. Without the necessity of travel or expensive exercise equipment TAVR patients were able to achieve benefits from both RT and increased protein intake. The implementation of digitally supervised home-based RT to current cardiac rehabilitation may help a larger percentage of TAVR patients to participate in exercise programs. Home-based RT of longer durations and utilizing higher training intensity may elicit greater changes in QoL and improve health, body composition, strength, and functionality. Protein supplementation consumed in unison with RT in TAVR patients may prevent further loss of muscle mass post-TAVR compared to protein supplementation alone. High protein consumption for periods of >6 months may elicit a benefit for the retention of muscle mass. \n\n 106 \nAPPENDIX A IRB APPROVAL LETTER \n\n\n 107 \n \n \n\n\n 108 \n \n\n\n 109 \nAPPENDIX B INFORMED CONSENT FORM \n \n\n\n 110 \n \n\n\n 111 \n \n\n\n 112 \n \n\n\n 113 \n \n\n\n 114 \n \n\n\n 115 \n \n\n\n 116 \n \n\n\n 117 \n \n\n\n 118 \n \n\n\n 119 \nAPPENDIX C PHYSICIAN CONSENT FORM \n \n\n\n 120 \nAPPENDIX D INFORMATIONAL PAMPHLET \n \n\n\n 121 \n \n\n\n 122 \nAPPENDIX E TMH HIPAA AUTHORIZATION \n \n\n\n 123 \n \n\n\n 124 \n \n\n\n 125 \n \n\n\n 126 \nAPPENDIX F AUTHORIZATION FORM \n \n\n\n 127 \nAPPENDIX G RECRUITMENT LETTER \n \n\n\n 128 \nAPPENDIX H QUALITY OF LIFE QUESTIONNAIRES \n \n\n\n 129 \n \n\n\n 130 \n \n\n\n 131 \n \n\n\n 132 \n \n\n\n 133 \n \n\n\n 134 \n \n\n\n 135 \n \n\n\n 136 \n \n\n\n 137 \n \n\n\n 138 \n \n\n\n 139 \nAPPENDIX I DIAGRAM OF EXERCISES \n\n\n 140 \n \n\n\n 141 \n \n\n\n 142 \n \n\n\n 143 \n \n\n\n 144 \n \n\n\n 145 \n \n\n\n 146 \n \n\n\n 147 \n \n\n\n 148 \n \n\n\n 149 \n \n\n\n 150 \n \n\n\n 151 \nAPPENDIX J MEDICAL HISTORY QUESTIONAIRRE \n \n\n\n 152 \n\n\n 153 \n\n\n 154 \n \n\n\n 155 \nREFERENCES 1. Nations U. World population prospects: The 2010 revision. UN; 2010. 2. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. The Lancet. 2006;368(9540):1005-11. 3. Lindroos M, Kupari M, Heikkilä J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. Journal of the American College of Cardiology. 1993;21(5):1220-5. 4. Kanwar A, Thaden JJ, Nkomo VT. Management of Patients With Aortic Valve Stenosis. Mayo Clin Proc. 2018;93(4):488-508. 5. Bates ER. Treatment options in severe aortic stenosis. Circulation. 2011;124(3):355-9. 6. Klabunde R. Cardiovascular physiology concepts. Lippincott Williams & Wilkins; 2011. 7. Cribier, Eltchaninoff H, Bash A et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002;106(24):3006-8. 8. Cribier, Eltchaninoff H, Tron C et al. Early experience with percutaneous transcatheter implantation of heart valve prosthesis for the treatment of end-stage inoperable patients with calcific aortic stenosis. J Am Coll Cardiol. 2004;43(4):698-703. 9. Nishimura RA, Otto CM, Bonow RO et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(22):2438-88. 10. Kodali SK, Williams MR, Smith CR et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med. 2012;366(18):1686-95. 11. Smith CR, Leon MB, Mack MJ et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364(23):2187-98. 12. Brennan JM, Thomas L, Cohen DJ et al. Transcatheter Versus Surgical Aortic Valve Replacement: Propensity-Matched Comparison. J Am Coll Cardiol. 2017;70(4):439-50. 13. Mack MJ, Leon MB, Thourani VH et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med. 2019;380(18):1695-705. 14. Baron SJ, Arnold SV, Reynolds MR et al. Durability of quality of life benefits of transcatheter aortic valve replacement: long-term results from the CoreValve US extreme risk trial. American heart journal. 2017;194:39-48. \n\n 156 \n15. Leon MB, Smith CR, Mack MJ et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2016;374(17):1609-20. 16. Leon MB, Smith CR, Mack M et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363(17):1597-607. 17. Barbanti M, Petronio AS, Ettori F et al. 5-Year Outcomes After Transcatheter Aortic Valve Implantation With CoreValve Prosthesis. JACC Cardiovasc Interv. 2015;8(8):1084-91. 18. Chakos A, Wilson-Smith A, Arora S et al. Long term outcomes of transcatheter aortic valve implantation (TAVI): a systematic review of 5-year survival and beyond. Ann Cardiothorac Surg. 2017;6(5):432-43. 19. Morley, Bauer JM. Editorial: The future of sarcopenia. Curr Opin Clin Nutr Metab Care. 2019;22(1):1-3. 20. Sayer AA, Robinson SM, Patel HP, Shavlakadze T, Cooper C, Grounds MD. New horizons in the pathogenesis, diagnosis and management of sarcopenia. Age Ageing. 2013;42(2):145-50. 21. Cao L, Morley JE. Sarcopenia Is Recognized as an Independent Condition by an International Classification of Disease, Tenth Revision, Clinical Modification (ICD-10-CM) Code. J Am Med Dir Assoc. 2016;17(8):675-7. 22. Delmonico MJ, Harris TB, Lee JS et al. Alternative definitions of sarcopenia, lower extremity performance, and functional impairment with aging in older men and women. J Am Geriatr Soc. 2007;55(5):769-74. 23. Dahya V, Xiao J, Prado CM et al. Computed tomography-derived skeletal muscle index: A novel predictor of frailty and hospital length of stay after transcatheter aortic valve replacement. Am Heart J. 2016;182:21-7. 24. Heidari B, Al-Hijji MA, Moynagh MR et al. Transcatheter Aortic Valve Replacement Outcomes in Patients with Sarcopenia. EuroIntervention. 2019. 25. Morley, Kim M, Haren M, Kevorkian R, Banks W. Frailty and the aging male. The Aging Male. 2005;8(3-4):135-40. 26. Mok M, Allende R, Leipsic J et al. Prognostic Value of Fat Mass and Skeletal Muscle Mass Determined by Computed Tomography in Patients Who Underwent Transcatheter Aortic Valve Implantation. Am J Cardiol. 2016;117(5):828-33. 27. Alvarez P, Hannawi B, Guha A. Exercise And Heart Failure: Advancing Knowledge And Improving Care. Methodist Debakey Cardiovasc J. 2016;12(2):110-5. 28. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323(4):236-41. \n\n 157 \n29. Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol. 2011;301(6):H2181-90. 30. Kapadia SR, Yakoob K, Nader S, Thomas JD, Mann DL, Griffin BP. Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload. Journal of the American College of Cardiology. 2000;36(1):208-12. 31. Rauchhaus M, Doehner W, Francis DP et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 2000;102(25):3060-7. 32. Garg L, Agrawal S, Pew T et al. Psoas muscle area as a predictor of outcomes in transcatheter aortic valve implantation. The American journal of cardiology. 2017;119(3):457-60. 33. Soud M, Alahdab F, Ho G et al. Usefulness of skeletal muscle area detected by computed tomography to predict mortality in patients undergoing transcatheter aortic valve replacement: a meta-analysis study. Int J Cardiovasc Imaging. 2019;35(6):1141-7. 34. Musalek C, Kirchengast S. Grip Strength as an Indicator of Health-Related Quality of Life in Old Age-A Pilot Study. Int J Environ Res Public Health. 2017;14(12). 35. Tzeng YH, Wei J, Tsao TP et al. Computed Tomography-Determined Muscle Quality Rather Than Muscle Quantity Is a Better Determinant of Prolonged Hospital Length of Stay in Patients Undergoing Transcatheter Aortic Valve Implantation. Acad Radiol. 2019. 36. Alfredsson J, Stebbins A, Brennan JM et al. Gait Speed Predicts 30-Day Mortality After Transcatheter Aortic Valve Replacement: Results From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Circulation. 2016;133(14):1351-9. 37. Kagase A, Yamamoto M, Shimura T et al. Sex-Specific Grip Strength After Transcatheter Aortic Valve Replacement in Elderly Patients. JACC. Cardiovascular interventions. 2018;11(1):100. 38. Vikberg S, Sorlen N, Branden L et al. Effects of Resistance Training on Functional Strength and Muscle Mass in 70-Year-Old Individuals With Pre-sarcopenia: A Randomized Controlled Trial. J Am Med Dir Assoc. 2019;20(1):28-34. 39. Marcus RL, Addison O, Kidde JP, Dibble LE, Lastayo PC. Skeletal muscle fat infiltration: impact of age, inactivity, and exercise. J Nutr Health Aging. 2010;14(5):362-6. 40. Ribeiro GS, Melo RD, Deresz LF, Dal Lago P, Pontes MR, Karsten M. Cardiac rehabilitation programme after transcatheter aortic valve implantation versus surgical aortic valve replacement: Systematic review and meta-analysis. European journal of preventive cardiology. 2017;24(7):688-97. \n\n 158 \n41. Imran HM, Baig M, Mujib M et al. Comparison of phase 2 cardiac rehabilitation outcomes between patients after transcatheter versus surgical aortic valve replacement. European journal of preventive cardiology. 2018;25(15):1577-84. 42. Voller H, Salzwedel A, Nitardy A, Buhlert H, Treszl A, Wegscheider K. Effect of cardiac rehabilitation on functional and emotional status in patients after transcatheter aortic-valve implantation. Eur J Prev Cardiol. 2015;22(5):568-74. 43. Pressler A, Christle JW, Lechner B, Grabs V. Exercise training improves exercise capacity and quality of life after transcatheter aortic valve implantation: A randomized pilot trial. Am Heart J. 2016;182:44-53. 44. Dent E, Morley JE, Cruz-Jentoft AJ et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management. J Nutr Health Aging. 2018;22(10):1148-61. 45. Campbell WW, Trappe TA, Wolfe RR, Evans WJ. The recommended dietary allowance for protein may not be adequate for older people to maintain skeletal muscle. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2001;56(6):M373-M80. 46. Moore DR, Churchward-Venne TA, Witard O et al. Protein ingestion to stimulate myofibrillar protein synthesis requires greater relative protein intakes in healthy older versus younger men. J Gerontol A Biol Sci Med Sci. 2015;70(1):57-62. 47. Deutz NE, Bauer JM, Barazzoni R et al. Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN Expert Group. Clinical nutrition. 2014;33(6):929-36. 48. Traylor DA, Gorissen SH, Phillips SM. Perspective: protein requirements and optimal intakes in aging: are we ready to recommend more than the recommended daily allowance? Advances in Nutrition. 2018;9(3):171-82. 49. Wolfe RR, Miller SL, Miller KB. Optimal protein intake in the elderly. Clin Nutr. 2008;27(5):675-84. 50. Tieland, Dirks ML, van der Zwaluw N et al. Protein supplementation increases muscle mass gain during prolonged resistance-type exercise training in frail elderly people: a randomized, double-blind, placebo-controlled trial. Journal of the American Medical Directors Association. 2012;13(8):713-9. 51. Daly RM, O’Connell SL, Mundell NL, Grimes CA, Dunstan DW, Nowson CA. Protein-enriched diet, with the use of lean red meat, combined with progressive resistance training enhances lean tissue mass and muscle strength and reduces circulating IL-6 concentrations in elderly women: a cluster randomized controlled trial. The American journal of clinical nutrition. 2014;99(4):899-910. \n\n 159 \n52. Mori H, Tokuda Y. Effect of whey protein supplementation after resistance exercise on the muscle mass and physical function of healthy older women: A randomized controlled trial. Geriatrics & gerontology international. 2018;18(9):1398-404. 53. Rennie MJ. Anabolic resistance: the effects of aging, sexual dimorphism, and immobilization on human muscle protein turnover. Appl Physiol Nutr Metab. 2009;34(3):377-81. 54. Burd NA, Wall BT, van Loon LJ. The curious case of anabolic resistance: old wives' tales or new fables? J Appl Physiol (1985). 2012;112(7):1233-5. 55. AHA. Problem: Aortic Valve Stenosis. 2019. 56. Cruz-Jentoft AJ, Bahat G, Bauer J et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019. 57. Engineering NIoB [Internet]. 58. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Applied Physiology, Nutrition, and Metabolism. 2008;33(5):997-1006. 59. Mazess RB, Barden HS, Bisek JP, Hanson J. Dual-energy x-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. The American journal of clinical nutrition. 1990;51(6):1106-12. 60. Morley JE, Vellas B, van Kan GA et al. Frailty consensus: a call to action. J Am Med Dir Assoc. 2013;14(6):392-7. 61. Laplante M, Sabatini DM. mTOR Signaling. Cold Spring Harb Perspect Biol. 2012;4(2). 62. Guralnik JM, Ferrucci L, Pieper CF et al. Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2000;55(4):M221-M31. 63. Association AH [Internet]. 64. Iung B, Vahanian A. Epidemiology of valvular heart disease in the adult. Nat Rev Cardiol. 2011;8(3):162-72. 65. Lee A, Wei S, Schwertani A. A Notch more: Molecular players in bicuspid aortic valve disease. J Mol Cell Cardiol. 2019. 66. Prasad Y, Bhalodkar NC. Aortic sclerosis--a marker of coronary atherosclerosis. Clin Cardiol. 2004;27(12):671-3. \n\n 160 \n67. Thaden JJ, Nkomo VT, Enriquez-Sarano M. The global burden of aortic stenosis. Prog Cardiovasc Dis. 2014;56(6):565-71. 68. Novaro GM, Katz R, Aviles RJ et al. Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: the Cardiovascular Health Study. J Am Coll Cardiol. 2007;50(20):1992-8. 69. Yan AT, Koh M, Chan KK et al. Association Between Cardiovascular Risk Factors and Aortic Stenosis: The CANHEART Aortic Stenosis Study. J Am Coll Cardiol. 2017;69(12):1523-32. 70. Michelena H, Desjardins V, Avierinos J. Valvulopathies| Natural history of asymptomatic patients with normally functioning or minimally dysfunctional bicuspid aortic valve in the community, in: Circulation, 117 (2008), pp. 2776-2784, et al. In: Elsevier Masson; 2008. 71. Nishimura, Otto CM, Bonow RO et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2017;70(2):252-89. 72. Otto CM, Prendergast B. Aortic-valve stenosis—from patients at risk to severe valve obstruction. New England Journal of Medicine. 2014;371(8):744-56. 73. Cribier. The development of transcatheter aortic valve replacement (TAVR). Global cardiology science & practice. 2016;2016(4). 74. Nishimura RA, Otto CM, Bonow RO et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;70(2):252-89. 75. Lieberman EB, Bashore TM, Hermiller JB et al. Balloon aortic valvuloplasty in adults: failure of procedure to improve long-term survival. J Am Coll Cardiol. 1995;26(6):1522-8. 76. Nishimura RA, Holmes DR, Jr., Reeder GS. Percutaneous balloon valvuloplasty. Mayo Clin Proc. 1990;65(2):198-220. 77. Participants NBVR. Percutaneous balloon aortic valvuloplasty. Acute and 30-day follow-up results in 674 patients from the NHLBI Balloon Valvuloplasty Registry. Circulation. 1991;84(6):2383-97. 78. Kapadia SR, Leon MB, Makkar RR et al. 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385(9986):2485-91. \n\n 161 \n79. Adams DH, Popma JJ, Reardon MJ. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;371(10):967-8. 80. Skelding KA, Yakubov SJ, Kleiman NS et al. Transcatheter Aortic Valve Replacement Versus Surgery in Women at High Risk for Surgical Aortic Valve Replacement (from the CoreValve US High Risk Pivotal Trial). Am J Cardiol. 2016;118(4):560-6. 81. Gleason TG, Reardon MJ, Popma JJ et al. 5-Year Outcomes of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement in High-Risk Patients. J Am Coll Cardiol. 2018;72(22):2687-96. 82. Thourani VH, Kodali S, Makkar RR et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet. 2016;387(10034):2218-25. 83. Tamburino C, Barbanti M, D'Errigo P et al. 1-Year Outcomes After Transfemoral Transcatheter or Surgical Aortic Valve Replacement: Results From the Italian OBSERVANT Study. J Am Coll Cardiol. 2015;66(7):804-12. 84. Reardon MJ, Van Mieghem NM, Popma JJ et al. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2017;376(14):1321-31. 85. Thyregod HG, Steinbruchel DA, Ihlemann N et al. Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Valve Stenosis: 1-Year Results From the All-Comers NOTION Randomized Clinical Trial. J Am Coll Cardiol. 2015;65(20):2184-94. 86. Popma JJ, Deeb GM, Yakubov SJ et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. 2019;380(18):1706-15. 87. Reinohl J, Kaier K, Reinecke H et al. Effect of Availability of Transcatheter Aortic-Valve Replacement on Clinical Practice. N Engl J Med. 2015;373(25):2438-47. 88. Minutello RM, Wong SC, Swaminathan RV et al. Costs and in-hospital outcomes of transcatheter aortic valve implantation versus surgical aortic valve replacement in commercial cases using a propensity score matched model. Am J Cardiol. 2015;115(10):1443-7. 89. Burrage M, Moore P, Cole C et al. Transcatheter Aortic Valve Replacement is Associated with Comparable Clinical Outcomes to Open Aortic Valve Surgery but with a Reduced Length of In-Patient Hospital Stay: A Systematic Review and Meta-Analysis of Randomised Trials. Heart Lung Circ. 2017;26(3):285-95. 90. Babaliaros V, Devireddy C, Lerakis S et al. Comparison of transfemoral transcatheter aortic valve replacement performed in the catheterization laboratory (minimalist approach) versus hybrid operating room (standard approach): outcomes and cost analysis. JACC Cardiovasc Interv. 2014;7(8):898-904. \n\n 162 \n91. Attizzani GF, Alkhalil A, Padaliya B et al. Comparison of Outcomes of Transfemoral Transcatheter Aortic Valve Implantation Using a Minimally Invasive Versus Conventional Strategy. Am J Cardiol. 2015;116(11):1731-6. 92. Tarantini G, Purita PAM, D'Onofrio A et al. Long-term outcomes and prosthesis performance after transcatheter aortic valve replacement: results of self-expandable and balloon-expandable transcatheter heart valves. Ann Cardiothorac Surg. 2017;6(5):473-83. 93. Duncan A, Ludman P, Banya W et al. Long-term outcomes after transcatheter aortic valve replacement in high-risk patients with severe aortic stenosis: the U.K. Transcatheter Aortic Valve Implantation Registry. JACC Cardiovasc Interv. 2015;8(5):645-53. 94. Baumgartner RN, Koehler KM, Gallagher D et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147(8):755-63. 95. Jang IY, Jung HW, Lee CK, Yu SS, Lee YS, Lee E. Comparisons of predictive values of sarcopenia with different muscle mass indices in Korean rural older adults: a longitudinal analysis of the Aging Study of PyeongChang Rural Area. Clin Interv Aging. 2018;13:91-9. 96. Dodds RM, Syddall HE, Cooper R et al. Grip strength across the life course: normative data from twelve British studies. PLoS One. 2014;9(12):e113637. 97. Bohannon RW, Peolsson A, Massy-Westropp N, Desrosiers J, Bear-Lehman J. Reference values for adult grip strength measured with a Jamar dynamometer: a descriptive meta-analysis. Physiotherapy. 2006;92(1):11-5. 98. Pavasini R, Guralnik J, Brown JC et al. Short Physical Performance Battery and all-cause mortality: systematic review and meta-analysis. BMC Med. 2016;14(1):215. 99. Studenski S, Perera S, Patel K et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-8. 100. Newman AB, Simonsick EM, Naydeck BL et al. Association of long-distance corridor walk performance with mortality, cardiovascular disease, mobility limitation, and disability. JAMA. 2006;295(17):2018-26. 101. Bischoff HA, Stahelin HB, Monsch AU et al. Identifying a cut-off point for normal mobility: a comparison of the timed 'up and go' test in community-dwelling and institutionalised elderly women. Age Ageing. 2003;32(3):315-20. 102. Bergland A, Jorgensen L, Emaus N, Strand BH. Mobility as a predictor of all-cause mortality in older men and women: 11.8 year follow-up in the Tromso study. BMC Health Serv Res. 2017;17(1):22. 103. Nemec U, Heidinger B, Sokas C, Chu L, Eisenberg RL. Diagnosing sarcopenia on thoracic computed tomography: quantitative assessment of skeletal muscle mass in \n\n 163 \npatients undergoing transcatheter aortic valve replacement. Academic radiology. 2017;24(9):1154-61. 104. Trommelen J [Internet]. Nutrition Tactics. 105. Schoenfeld B. Science and Development of Muscle Hypertrophy. USA: Human Kinetics 2016, 213 p. 106. Brook MS, Wilkinson DJ, Mitchell WK et al. Synchronous deficits in cumulative muscle protein synthesis and ribosomal biogenesis underlie age‐related anabolic resistance to exercise in humans. The Journal of physiology. 2016;594(24):7399-417. 107. Bodine SC, Stitt TN, Gonzalez M et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nature cell biology. 2001;3(11):1014-9. 108. Jacinto E, Hall MN. Tor signalling in bugs, brain and brawn. Nature reviews Molecular cell biology. 2003;4(2):117-26. 109. Thomas G, Hall MN. TOR signalling and control of cell growth. Current opinion in cell biology. 1997;9(6):782-7. 110. Laplante M, Sabatini DM. mTOR signaling at a glance. Journal of cell science. 2009;122(20):3589-94. 111. Menon S, Dibble CC, Talbott G et al. Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome. Cell. 2014;156(4):771-85. 112. Yoon M-S. mTOR as a key regulator in maintaining skeletal muscle mass. Frontiers in physiology. 2017;8:788. 113. Schiaffino S, Dyar KA, Ciciliot S, Blaauw B, Sandri M. Mechanisms regulating skeletal muscle growth and atrophy. The FEBS journal. 2013;280(17):4294-314. 114. Gordon BS, Kelleher AR, Kimball SR. Regulation of muscle protein synthesis and the effects of catabolic states. The international journal of biochemistry & cell biology. 2013;45(10):2147-57. 115. Zhang Y, Pan X, Sun Y, Geng Y-j, Yu X-Y, Li Y. The Molecular Mechanisms and Prevention Principles of Muscle Atrophy in Aging. In. Muscle Atrophy: Springer; 2018, pp. 347-68. 116. Goodman CA, Mayhew DL, Hornberger TA. Recent progress toward understanding the molecular mechanisms that regulate skeletal muscle mass. Cellular signalling. 2011;23(12):1896-906. 117. Nakashima K, Yakabe Y. AMPK activation stimulates myofibrillar protein degradation and expression of atrophy-related ubiquitin ligases by increasing FOXO transcription \n\n 164 \nfactors in C2C12 myotubes. Bioscience, biotechnology, and biochemistry. 2007;71(7):1650-6. 118. Miyazaki M, Esser KA. Cellular mechanisms regulating protein synthesis and skeletal muscle hypertrophy in animals. Journal of Applied Physiology. 2009;106(4):1367-73. 119. Spangenburg EE. Changes in muscle mass with mechanical load: possible cellular mechanisms. Applied Physiology, Nutrition, and Metabolism. 2009;34(3):328-35. 120. Yarasheski KE, Zachwieja JJ, Bier DM. Acute effects of resistance exercise on muscle protein synthesis rate in young and elderly men and women. American Journal of Physiology-Endocrinology And Metabolism. 1993;265(2):E210-E4. 121. Rooyackers OE, Adey DB, Ades PA, Nair KS. Effect of age on in vivo rates of mitochondrial protein synthesis in human skeletal muscle. Proceedings of the National Academy of Sciences. 1996;93(26):15364-9. 122. Welle S, Thornton C, Jozefowicz R, Statt M. Myofibrillar protein synthesis in young and old men. American Journal of Physiology-Endocrinology And Metabolism. 1993;264(5):E693-E8. 123. Trappe T, Williams R, Carrithers J et al. Influence of age and resistance exercise on human skeletal muscle proteolysis: a microdialysis approach. The Journal of physiology. 2004;554(3):803-13. 124. Volpi E, Sheffield-Moore M, Rasmussen BB, Wolfe RR. Basal muscle amino acid kinetics and protein synthesis in healthy young and older men. Jama. 2001;286(10):1206-12. 125. Volpi E, Ferrando AA, Yeckel CW, Tipton KD, Wolfe RR. Exogenous amino acids stimulate net muscle protein synthesis in the elderly. The Journal of clinical investigation. 1998;101(9):2000-7. 126. Cuthbertson D, Smith K, Babraj J et al. Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle. The FASEB Journal. 2005;19(3):422-4. 127. Rennie MJ. Anabolic resistance: the effects of aging, sexual dimorphism, and immobilization on human muscle protein turnover. Applied Physiology, Nutrition, and Metabolism. 2009;34(3):377-81. 128. Kumar V, Selby A, Rankin D et al. Age‐related differences in the dose–response relationship of muscle protein synthesis to resistance exercise in young and old men. The Journal of physiology. 2009;587(1):211-7. 129. Moore DR, Churchward-Venne TA, Witard O et al. Protein ingestion to stimulate myofibrillar protein synthesis requires greater relative protein intakes in healthy older versus younger men. Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences. 2015;70(1):57-62. \n\n 165 \n130. Crozier SJ, Kimball SR, Emmert SW, Anthony JC, Jefferson LS. Oral leucine administration stimulates protein synthesis in rat skeletal muscle. J Nutr. 2005;135(3):376-82. 131. Kim DH, Kim JY, Yu BP, Chung HY. The activation of NF-κB through Akt-induced FOXO1 phosphorylation during aging and its modulation by calorie restriction. Biogerontology. 2008;9(1):33-47. 132. Wang X, Proud CG. The mTOR pathway in the control of protein synthesis. Physiology. 2006;21(5):362-9. 133. E.Levine MHaJ. Endocrinology. 6 ed. Upper Saddle River, NJ: Pearson Education Inc.; 2006. 134. Kim J-a, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006;113(15):1888-904. 135. Jonk AM, Houben AJ, De Jongh RT, Serné EH, Schaper NC, Stehouwer CD. Microvascular dysfunction in obesity: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Physiology. 2007;22(4):252-60. 136. Rasmussen BB, Fujita S, Wolfe RR et al. Insulin resistance of muscle protein metabolism in aging. The FASEB journal. 2006;20(6):768-9. 137. Boulanger C, Lüscher T. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. The Journal of clinical investigation. 1990;85(2):587-90. 138. Fujita S, Glynn EL, Timmerman KL, Rasmussen BB, Volpi E. Supraphysiological hyperinsulinaemia is necessary to stimulate skeletal muscle protein anabolism in older adults: evidence of a true age-related insulin resistance of muscle protein metabolism. Diabetologia. 2009;52(9):1889-98. 139. Fujita S, Rasmussen BB, Cadenas JG et al. Aerobic exercise overcomes the age-related insulin resistance of muscle protein metabolism by improving endothelial function and Akt/mammalian target of rapamycin signaling. Diabetes. 2007;56(6):1615-22. 140. Guillet C, Prod’homme M, Balage M et al. Impaired anabolic response of muscle protein synthesis is associated with S6K1 dysregulation in elderly humans. The FASEB Journal. 2004;18(13):1586-7. 141. Wall BT, van Loon LJ. Nutritional strategies to attenuate muscle disuse atrophy. Nutrition reviews. 2013;71(4):195-208. 142. Kortebein P, Ferrando A, Lombeida J, Wolfe R, Evans WJ. Effect of 10 days of bed rest on skeletal muscle in healthy older adults. Jama. 2007;297(16):1769-74. \n\n 166 \n143. Ferrando AA, Paddon-Jones D, Hays NP et al. EAA supplementation to increase nitrogen intake improves muscle function during bed rest in the elderly. Clinical nutrition. 2010;29(1):18-23. 144. Smith GI, Reeds DN, Hall AM, Chambers KT, Finck BN, Mittendorfer B. Sexually dimorphic effect of aging on skeletal muscle protein synthesis. Biology of sex differences. 2012;3(1):11. 145. Drummond MJ, Dickinson JM, Fry CS et al. Bed rest impairs skeletal muscle amino acid transporter expression, mTORC1 signaling, and protein synthesis in response to essential amino acids in older adults. American Journal of Physiology-Endocrinology and Metabolism. 2012;302(9):E1113-E22. 146. Suetta C, Frandsen U, Jensen L et al. Aging affects the transcriptional regulation of human skeletal muscle disuse atrophy. PloS one. 2012;7(12). 147. Kortebein P, Symons TB, Ferrando A et al. Functional impact of 10 days of bed rest in healthy older adults. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2008;63(10):1076-81. 148. Hvid L, Aagaard P, Justesen L et al. Effects of aging on muscle mechanical function and muscle fiber morphology during short-term immobilization and subsequent retraining. Journal of applied physiology. 2010;109(6):1628-34. 149. Breen L, Stokes KA, Churchward-Venne TA et al. Two weeks of reduced activity decreases leg lean mass and induces “anabolic resistance” of myofibrillar protein synthesis in healthy elderly. The Journal of Clinical Endocrinology & Metabolism. 2013;98(6):2604-12. 150. Devries MC, Breen L, Von Allmen M et al. Low‐load resistance training during step‐reduction attenuates declines in muscle mass and strength and enhances anabolic sensitivity in older men. Physiological reports. 2015;3(8):e12493. 151. Tieland M, Borgonjen-Van den Berg KJ, van Loon LJ, de Groot LC. Dietary protein intake in community-dwelling, frail, and institutionalized elderly people: scope for improvement. European journal of nutrition. 2012;51(2):173-9. 152. Shad BJ, Thompson JL, Breen L. Does the muscle protein synthetic response to exercise and amino acid-based nutrition diminish with advancing age? A systematic review. American Journal of Physiology-Endocrinology and Metabolism. 2016;311(5):E803-E17. 153. Watson KB. Physical inactivity among adults aged 50 years and older—United States, 2014. MMWR. Morbidity and mortality weekly report. 2016;65. 154. Caspersen CJ, Pereira MA, Curran KM. Changes in physical activity patterns in the United States, by sex and cross-sectional age. Medicine & Science in Sports & Exercise. 2000;32(9):1601-9. \n\n 167 \n155. Harvey JA, Chastin SF, Skelton DA. How sedentary are older people? A systematic review of the amount of sedentary behavior. Journal of aging and physical activity. 2015;23(3):471-87. 156. Troiano RP, Berrigan D, Dodd KW, Masse LC, Tilert T, McDowell M. Physical activity in the United States measured by accelerometer. Medicine & Science in Sports & Exercise. 2008;40(1):181-8. 157. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. New England journal of medicine. 1999;340(6):448-54. 158. Franceschi C, Bonafè M, Valensin S et al. Inflamm‐aging: an evolutionary perspective on immunosenescence. Annals of the new York Academy of Sciences. 2000;908(1):244-54. 159. Ogawa S, Yakabe M, Akishita M. Age-related sarcopenia and its pathophysiological bases. Inflammation and regeneration. 2016;36(1):17. 160. Grounds MD, Radley HG, Gebski BL, Bogoyevitch MA, Shavlakadze T. Implications of cross‐talk between tumour necrosis factor and insulin‐like growth factor‐1 signalling in skeletal muscle. Clinical and Experimental Pharmacology and Physiology. 2008;35(7):846-51. 161. De Benedetti F, Meazza C, Oliveri M et al. Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology. 2001;142(11):4818-26. 162. Bouzid MA, Filaire E, McCall A, Fabre C. Radical Oxygen Species, Exercise and Aging: An Update. Sports Med. 2015;45(9):1245-61. 163. Gomes MJ, Martinez PF, Pagan LU et al. Skeletal muscle aging: influence of oxidative stress and physical exercise. Oncotarget. 2017;8(12):20428. 164. Zhang Y, Pan X, Sun Y, Geng YJ, Yu XY, Li Y. The Molecular Mechanisms and Prevention Principles of Muscle Atrophy in Aging. Adv Exp Med Biol. 2018;1088:347-68. 165. Southgate RJ, Neill B, Prelovsek O et al. FOXO1 regulates the expression of 4E-BP1 and inhibits mTOR signaling in mammalian skeletal muscle. Journal of Biological Chemistry. 2007;282(29):21176-86. 166. Gumucio JP, Mendias CL. Atrogin-1, MuRF-1, and sarcopenia. Endocrine. 2013;43(1):12-21. 167. Kim J-S, Wilson JM, Lee S-R. Dietary implications on mechanisms of sarcopenia: roles of protein, amino acids and antioxidants. The Journal of nutritional biochemistry. 2010;21(1):1-13. \n\n 168 \n168. Kalinkovich A, Livshits G. Sarcopenic obesity or obese sarcopenia: a cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis. Ageing research reviews. 2017;35:200-21. 169. Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nature Reviews Endocrinology. 2018;14(9):513-37. 170. Zamboni M, Mazzali G, Fantin F, Rossi A, Di Francesco V. Sarcopenic obesity: a new category of obesity in the elderly. Nutrition, Metabolism and Cardiovascular Diseases. 2008;18(5):388-95. 171. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nature Reviews Immunology. 2005;5(12):953-64. 172. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH et al. Macrophage-specific PPARγ controls alternative activation and improves insulin resistance. Nature. 2007;447(7148):1116-20. 173. Lumeng CN, Deyoung SM, Saltiel AR. Macrophages block insulin action in adipocytes by altering expression of signaling and glucose transport proteins. American Journal of Physiology-Endocrinology and Metabolism. 2007;292(1):E166-E74. 174. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. The Journal of clinical investigation. 2003;112(12):1796-808. 175. Mathus-Vliegen EM, Basdevant A, Finer N et al. Prevalence, pathophysiology, health consequences and treatment options of obesity in the elderly: a guideline. Obesity facts. 2012;5(3):460-83. 176. Schlecht I, Fischer B, Behrens G, Leitzmann MF. Relations of visceral and abdominal subcutaneous adipose tissue, body mass index, and waist circumference to serum concentrations of parameters of chronic inflammation. Obesity facts. 2016;9(3):144-57. 177. Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-α and IL-6. Diabetes research and clinical practice. 2005;69(1):29-35. 178. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. The Journal of Clinical Endocrinology & Metabolism. 1998;83(3):847-50. 179. Cuthbertson DJ, Steele T, Wilding JP et al. What have human experimental overfeeding studies taught us about adipose tissue expansion and susceptibility to obesity and metabolic complications? International journal of obesity. 2017;41(6):853-65. 180. Rutkowski JM, Stern JH, Scherer PE. The cell biology of fat expansion. Journal of cell biology. 2015;208(5):501-12. \n\n 169 \n181. Gray SL, Vidal-Puig AJ. Adipose tissue expandability in the maintenance of metabolic homeostasis. Nutrition reviews. 2007;65(suppl_1):S7-S12. 182. Crane JD, Devries MC, Safdar A, Hamadeh MJ, Tarnopolsky MA. The effect of aging on human skeletal muscle mitochondrial and intramyocellular lipid ultrastructure. Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences. 2010;65(2):119-28. 183. Petersen KF, Morino K, Alves TC et al. Effect of aging on muscle mitochondrial substrate utilization in humans. Proceedings of the National Academy of Sciences. 2015;112(36):11330-4. 184. Waters DL. Intermuscular adipose tissue: a brief review of etiology, association with physical function and weight loss in older adults. Annals of Geriatric Medicine and Research. 2019;23(1):3-8. 185. Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IκB-α. Diabetes. 2002;51(7):2005-11. 186. Boura-Halfon S, Zick Y. Phosphorylation of IRS proteins, insulin action, and insulin resistance. American Journal of Physiology-Endocrinology and Metabolism. 2009;296(4):E581-E91. 187. Mathias S, PEÑA LA, KOLESNICK RN. Signal transduction of stress via ceramide. Biochemical Journal. 1998;335(3):465-80. 188. Capurso C, Capurso A. From excess adiposity to insulin resistance: the role of free fatty acids. Vascular pharmacology. 2012;57(2-4):91-7. 189. Li H, Junk P, Huwiler A et al. Dual effect of ceramide on human endothelial cells: induction of oxidative stress and transcriptional upregulation of endothelial nitric oxide synthase. Circulation. 2002;106(17):2250-6. 190. De Larichaudy J, Zufferli A, Serra F et al. TNF-α-and tumor-induced skeletal muscle atrophy involves sphingolipid metabolism. Skeletal muscle. 2012;2(1):2. 191. Rivas DA, McDonald DJ, Rice NP, Haran PH, Dolnikowski GG, Fielding RA. Diminished anabolic signaling response to insulin induced by intramuscular lipid accumulation is associated with inflammation in aging but not obesity. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2016;310(7):R561-R9. 192. Bosma M. Lipid droplet dynamics in skeletal muscle. Experimental cell research. 2016;340(2):180-6. 193. Goodpaster BH, Carlson CL, Visser M et al. Attenuation of skeletal muscle and strength in the elderly: The Health ABC Study. Journal of applied physiology. 2001;90(6):2157-65. \n\n 170 \n194. Goodpaster BH, Thaete FL, Simoneau J-A, Kelley DE. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes. 1997;46(10):1579-85. 195. Kelley DE, Slasky BS, Janosky J. Skeletal muscle density: effects of obesity and non-insulin-dependent diabetes mellitus. The American journal of clinical nutrition. 1991;54(3):509-15. 196. Choi SJ, Files DC, Zhang T et al. Intramyocellular lipid and impaired myofiber contraction in normal weight and obese older adults. Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences. 2016;71(4):557-64. 197. Porter MM, Vandervoort AA, Lexell J. Aging of human muscle: structure, function and adaptability. Scandinavian journal of medicine & science in sports. 1995;5(3):129-42. 198. Roos MR, Rice CL, Vandervoort AA. Age‐related changes in motor unit function. Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine. 1997;20(6):679-90. 199. Lang T, Streeper T, Cawthon P, Baldwin K, Taaffe DR, Harris T. Sarcopenia: etiology, clinical consequences, intervention, and assessment. Osteoporosis international. 2010;21(4):543-59. 200. Vandervoort AA. Aging of the human neuromuscular system. Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine. 2002;25(1):17-25. 201. Deschenes MR. Effects of aging on muscle fibre type and size. Sports medicine. 2004;34(12):809-24. 202. Delbono O. Neural control of aging skeletal muscle. Aging cell. 2003;2(1):21-9. 203. Larsson L, Ansved T. Effects of ageing on the motor unit. Progress in neurobiology. 1995;45(5):397-458. 204. Andersen JL. Muscle fibre type adaptation in the elderly human muscle. Scandinavian journal of medicine & science in sports. 2003;13(1):40-7. 205. Larsson L, Sjödin B, Karlsson J. Histochemical and biochemical changes in human skeletal muscle with age in sedentary males, age 22–65 years. Acta Physiologica Scandinavica. 1978;103(1):31-9. 206. Harridge SD, Kryger A, Stensgaard A. Knee extensor strength, activation, and size in very elderly people following strength training. Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine. 1999;22(7):831-9. 207. Connelly DM, Rice CL, Roos MR, Vandervoort AA. Motor unit firing rates and contractile properties in tibialis anterior of young and old men. Journal of applied Physiology. 1999;87(2):843-52. \n\n 171 \n208. Klass M, Baudry S, Duchateau J. Age-related decline in rate of torque development is accompanied by lower maximal motor unit discharge frequency during fast contractions. Journal of applied physiology. 2008;104(3):739-46. 209. Christie A, Kamen G. Doublet discharges in motoneurons of young and older adults. Journal of neurophysiology. 2006;95(5):2787-95. 210. Landi F, Calvani R, Tosato M et al. Anorexia of Aging: Risk Factors, Consequences, and Potential Treatments. Nutrients. 2016;8(2):69. 211. Ford ES, Dietz WH. Trends in energy intake among adults in the United States: findings from NHANES. The American journal of clinical nutrition. 2013;97(4):848. 212. Morley JE. Anorexia of aging: physiologic and pathologic. The American journal of clinical nutrition. 1997;66(4):760-73. 213. Hays NP, Roberts SB. The anorexia of aging in humans. Physiology & behavior. 2006;88(3):257-66. 214. Briefel RR, McDowell MA, Alaimo K et al. Total energy intake of the US population: the third National Health and Nutrition Examination Survey, 1988-1991. The American journal of clinical nutrition. 1995;62(5):1072S-80S. 215. Calvani R, Martone AM, Marzetti E et al. Pre-hospital dietary intake correlates with muscle mass at the time of fracture in older hip-fractured patients. Frontiers in aging neuroscience. 2014;6:269. 216. Landi F, Liperoti R, Russo A et al. Association of anorexia with sarcopenia in a community-dwelling elderly population: results from the ilSIRENTE study. European journal of nutrition. 2013;52(3):1261-8. 217. Di Francesco V, Fantin F, Omizzolo F et al. The anorexia of aging. Digestive Diseases. 2007;25(2):129-37. 218. Fukunaga A, Uematsu H, Sugimoto K. Influences of aging on taste perception and oral somatic sensation. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2005;60(1):109-13. 219. Di Francesco V, Zamboni M, Dioli A et al. Delayed postprandial gastric emptying and impaired gallbladder contraction together with elevated cholecystokinin and peptide YY serum levels sustain satiety and inhibit hunger in healthy elderly persons. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2005;60(12):1581-5. 220. Zumbach MS, Boehme MWJ, Wahl P, Stremmel W, Ziegler R, Nawroth PP. Tumor necrosis factor increases serum leptin levels in humans. The Journal of Clinical Endocrinology & Metabolism. 1997;82(12):4080-2. \n\n 172 \n221. Francis J, MohanKumar P, MohanKumar SM, Quadri S. Systemic administration of lipopolysaccharide increases plasma leptin levels. Endocrine. 1999;10(3):291-5. 222. Arunkumar S, Kalappanavar AN, Annigeri RG, Shakunthala G. Adverse oral manifestations of cardiovascular Drugs. J Dent Med Sci. 2013;7:64-71. 223. Rhodus NL, Brown J. The association of xerostomia and inadequate intake in older adults. J Am Diet Assoc. 1990;90(12):1688-92. 224. Syed Q, Hendler KT, Koncilja K. The Impact of Aging and Medical Status on Dysgeusia. Am J Med. 2016;129(7):753 e1-6. 225. Romeiro FG, Okoshi K, Zornoff LA, Okoshi MP. Gastrointestinal changes associated to heart failure. Arq Bras Cardiol. 2012;98(3):273-7. 226. Beaudart C, McCloskey E, Bruyere O et al. Sarcopenia in daily practice: assessment and management. BMC Geriatr. 2016;16(1):170. 227. Shen W, Punyanitya M, Wang Z et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. Journal of applied physiology. 2004;97(6):2333-8. 228. Aukrust P, Ueland T, Lien E et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. The American journal of cardiology. 1999;83(3):376-82. 229. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). Journal of the American College of Cardiology. 1996;27(5):1201-6. 230. Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. The Lancet. 2000;356(9233):930-3. 231. Collamati A, Marzetti E, Calvani R et al. Sarcopenia in heart failure: mechanisms and therapeutic strategies. Journal of geriatric cardiology: JGC. 2016;13(7):615. 232. Genth-Zotz S, Von Haehling S, Bolger AP et al. Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure. The American journal of cardiology. 2002;90(11):1226-30. 233. Castillero E, Yerebakan H, Sorabella R et al. DIFFERING PATTERNS OF MYOSTATIN SIGNALING REGULATE HYPERTROPHY IN SEVERE AORTIC STENOSIS AND HYPERTROPHIC CARDIOMYOPATHY. Journal of the American College of Cardiology. 2014;63(12 Supplement):A954. 234. Gielen S, Sandri M, Kozarez I et al. Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the \n\n 173 \nrandomized Leipzig Exercise Intervention in Chronic Heart Failure and Aging catabolism study. Circulation. 2012;125(22):2716-27. 235. Gruson D, Ahn SA, Ketelslegers JM, Rousseau MF. Increased plasma myostatin in heart failure. European journal of heart failure. 2011;13(7):734-6. 236. George I, Bish LT, Kamalakkannan G et al. Myostatin activation in patients with advanced heart failure and after mechanical unloading. European journal of heart failure. 2010;12(5):444-53. 237. Heineke J, Auger-Messier M, Xu J et al. Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation. 2010;121(3):419. 238. Drexler H, Riede U, Munzel T, Konig H, Funke E, Just H. Alterations of skeletal muscle in chronic heart failure. Circulation. 1992;85(5):1751-9. 239. Bekfani T, Pellicori P, Morris DA et al. Sarcopenia in patients with heart failure with preserved ejection fraction: Impact on muscle strength, exercise capacity and quality of life. Int J Cardiol. 2016;222:41-6. 240. Trombetti A, Reid KF, Hars M et al. Age-associated declines in muscle mass, strength, power, and physical performance: impact on fear of falling and quality of life. Osteoporos Int. 2016;27(2):463-71. 241. Bye A, Sjøblom B, Wentzel‐Larsen T et al. Muscle mass and association to quality of life in non‐small cell lung cancer patients. Journal of cachexia, sarcopenia and muscle. 2017;8(5):759-67. 242. Afilalo J, Lauck S, Kim DH et al. Frailty in Older Adults Undergoing Aortic Valve Replacement: The FRAILTY-AVR Study. J Am Coll Cardiol. 2017;70(6):689-700. 243. Forcillo J, Condado JF, Ko Y-A et al. Assessment of commonly used frailty markers for high-and extreme-risk patients undergoing transcatheter aortic valve replacement. The Annals of thoracic surgery. 2017;104(6):1939-46. 244. Kaymaz D, Candemir IC, Ergun P, Demir N, Tasdemir F, Demir P. Relation between upper-limb muscle strength with exercise capacity, quality of life and dyspnea in patients with severe chronic obstructive pulmonary disease. Clin Respir J. 2018;12(3):1257-63. 245. Kang SY, Lim J, Park HS. Relationship between low handgrip strength and quality of life in Korean men and women. Quality of Life Research. 2018;27(10):2571-80. 246. Kano S, Yamamoto M, Shimura T et al. Gait Speed Can Predict Advanced Clinical Outcomes in Patients Who Undergo Transcatheter Aortic Valve Replacement: Insights From a Japanese Multicenter Registry. Circ Cardiovasc Interv. 2017;10(9). \n\n 174 \n247. Bjerk M, Brovold T, Skelton DA, Bergland A. Associations between health-related quality of life, physical function and fear of falling in older fallers receiving home care. BMC geriatrics. 2018;18(1):253. 248. Ilgin D, Ozalevli S, Kilinc O, Sevinc C, Cimrin AH, Ucan ES. Gait speed as a functional capacity indicator in patients with chronic obstructive pulmonary disease. Annals of thoracic medicine. 2011;6(3):141. 249. Kon SS, Patel MS, Canavan JL et al. Reliability and validity of 4-metre gait speed in COPD. European Respiratory Journal. 2013;42(2):333-40. 250. Guadalupe S, Teruya S, Helmke S, De Los Santos J, Maurer M, Castano A. FUNCTIONAL CAPACITY MEASURED BY THE SHORT PHYSICAL PERFORMANCE BATTERY (SPPB) AND NOT CARDIAC PARAMETERS ARE INDEPENDENTLY ASSOCIATED WITH QUALITY OF LIFE IN PATIENTS WITH TRANSTHYRETIN CARDIOMYOPATHY. Journal of the American College of Cardiology. 2019;73(9 Supplement 1):763. 251. Hamaguchi Y, Kaido T, Okumura S et al. Impact of quality as well as quantity of skeletal muscle on outcomes after liver transplantation. Liver Transpl. 2014;20(11):1413-9. 252. Okumura S, Kaido T, Hamaguchi Y et al. Impact of preoperative quality as well as quantity of skeletal muscle on survival after resection of pancreatic cancer. Surgery. 2015;157(6):1088-98. 253. Assosciation AH. Cardiac rehabilitation: putting more patients on the road to recovery. In: 2013. 254. Holmes DR, Brennan JM, Rumsfeld JS et al. Clinical outcomes at 1 year following transcatheter aortic valve replacement. Jama. 2015;313(10):1019-28. 255. Aragam KG, Moscucci M, Smith DE et al. Trends and disparities in referral to cardiac rehabilitation after percutaneous coronary intervention. American heart journal. 2011;161(3):544-51. e2. 256. Aragam KG, Dai D, Neely ML et al. Gaps in referral to cardiac rehabilitation of patients undergoing percutaneous coronary intervention in the United States. Journal of the American College of Cardiology. 2015;65(19):2079-88. 257. Mead H, Andres E, Ramos C, Siegel B, Regenstein M. Barriers to effective self-management in cardiac patients: the patient's experience. Patient education and counseling. 2010;79(1):69-76. 258. Butchart EG, Gohlke-Bärwolf C, Antunes MJ et al. Recommendations for the management of patients after heart valve surgery. European Heart Journal. 2005;26(22):2463-71. \n\n 175 \n259. Del Buono MG, Arena R, Borlaug BA et al. Exercise intolerance in patients with heart failure: JACC state-of-the-art review. Journal of the American College of Cardiology. 2019;73(17):2209-25. 260. Piepoli MF, Corra U, Benzer W et al. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. European Journal of Cardiovascular Prevention & Rehabilitation. 2010;17(1):1-17. 261. Genta, Tidu M, Bouslenko Z et al. Cardiac rehabilitation after transcatheter aortic valve implantation compared to patients after valve replacement. J Cardiovasc Med (Hagerstown). 2017;18(2):114-20. 262. Russo N, Compostella L, Tarantini G et al. Cardiac rehabilitation after transcatheter versus surgical prosthetic valve implantation for aortic stenosis in the elderly. Eur J Prev Cardiol. 2014;21(11):1341-8. 263. Fauchere I, Weber D, Maier W et al. Rehabilitation after TAVI compared to surgical aortic valve replacement. Int J Cardiol. 2014;173(3):564-6. 264. Zanettini R, Gatto G, Mori I et al. Cardiac rehabilitation and mid-term follow-up after transcatheter aortic valve implantation. Journal of geriatric cardiology: JGC. 2014;11(4):279. 265. Genta, Tidu M, Corbo P et al. Predictors of survival in patients undergoing cardiac rehabilitation after transcatheter aortic valve implantation. Journal of Cardiovascular Medicine. 2019;20(9):606-15. 266. Schulte JN, Yarasheski KE. Effects of resistance training on the rate of muscle protein synthesis in frail elderly people. International journal of sport nutrition and exercise metabolism. 2001;11(s1):S111-S8. 267. Atherton PJ, Babraj J, Smith K, Singh J, Rennie MJ, Wackerhage H. Selective activation of AMPK-PGC-1α or PKB-TSC2-mTOR signaling can explain specific adaptive responses to endurance or resistance training-like electrical muscle stimulation. The FASEB journal. 2005;19(7):786-8. 268. Cornish SM, Chilibeck PD. Alpha-linolenic acid supplementation and resistance training in older adults. Applied Physiology, Nutrition, and Metabolism. 2009;34(1):49-59. 269. Greiwe JS, Cheng B, RUBIN DC, Yarasheski KE, SEMENKOVICH CF. Resistance exercise decreases skeletal muscle tumor necrosis factor α in frail elderly humans. The FASEB Journal. 2001;15(2):475-82. 270. Kamen G, Knight CA. Training-related adaptations in motor unit discharge rate in young and older adults. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2004;59(12):1334-8. \n\n 176 \n271. Häkkinen K, Alen M, Kallinen M, Newton R, Kraemer W. Neuromuscular adaptation during prolonged strength training, detraining and re-strength-training in middle-aged and elderly people. European journal of applied physiology. 2000;83(1):51-62. 272. Yasuda T, Fukumura K, Nakajima T. Short physical performance battery for middle-aged and older adult cardiovascular disease patients: implication for strength tests and lower extremity morphological evaluation. J Phys Ther Sci. 2017;29(4):748-53. 273. Chiles Shaffer N, Fabbri E, Ferrucci L, Shardell M, Simonsick EM, Studenski S. Muscle Quality, Strength, and Lower Extremity Physical Performance in the Baltimore Longitudinal Study of Aging. J Frailty Aging. 2017;6(4):183-7. 274. Jung H, Yamasaki M. Association of lower extremity range of motion and muscle strength with physical performance of community-dwelling older women. J Physiol Anthropol. 2016;35(1):30. 275. Frontera WR, Meredith CN, O'Reilly KP, Knuttgen HG, Evans WJ. Strength conditioning in older men: skeletal muscle hypertrophy and improved function. Journal of applied physiology. 1988;64(3):1038-44. 276. Fiatarone MA, Marks EC, Ryan ND, Meredith CN, Lipsitz LA, Evans WJ. High-intensity strength training in nonagenarians. Effects on skeletal muscle. JAMA. 1990;263(22):3029-34. 277. Liu CJ, Latham NK. Progressive resistance strength training for improving physical function in older adults. Cochrane Database Syst Rev. 2009;(3):CD002759. 278. Peterson MD, Sen A, Gordon PM. Influence of resistance exercise on lean body mass in aging adults: a meta-analysis. Med Sci Sports Exerc. 2011;43(2):249-58. 279. Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412-23. 280. Nicklas BJ, Chmelo E, Delbono O, Carr JJ, Lyles MF, Marsh AP. Effects of resistance training with and without caloric restriction on physical function and mobility in overweight and obese older adults: a randomized controlled trial. Am J Clin Nutr. 2015;101(5):991-9. 281. Mueller M, Breil FA, Vogt M et al. Different response to eccentric and concentric training in older men and women. Eur J Appl Physiol. 2009;107(2):145-53. 282. Taaffe DR, Henwood TR, Nalls MA, Walker DG, Lang TF, Harris TB. Alterations in muscle attenuation following detraining and retraining in resistance-trained older adults. Gerontology. 2009;55(2):217-23. 283. Peterson MD, Rhea MR, Sen A, Gordon PM. Resistance exercise for muscular strength in older adults: a meta-analysis. Ageing Res Rev. 2010;9(3):226-37. \n\n 177 \n284. Kumar V, Atherton PJ, Selby A et al. Muscle protein synthetic responses to exercise: effects of age, volume, and intensity. Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences. 2012;67(11):1170-7. 285. Sheffield-Moore M, Paddon-Jones D, Sanford A et al. Mixed muscle and hepatic derived plasma protein metabolism is differentially regulated in older and younger men following resistance exercise. American Journal of Physiology-Endocrinology and Metabolism. 2005;288(5):E922-E9. 286. Fry CS, Drummond MJ, Glynn EL et al. Aging impairs contraction-induced human skeletal muscle mTORC1 signaling and protein synthesis. Skeletal muscle. 2011;1(1):1-11. 287. Bagur R, Rodes-Cabau J, Dumont E et al. Exercise capacity in patients with severe symptomatic aortic stenosis before and six months after transcatheter aortic valve implantation. Am J Cardiol. 2011;108(2):258-64. 288. Hewing B, Ellerbroek R, Au SC-D et al. Levels of Circulating Intermediate Monocytes Decrease after Aortic Valve Replacement in Patients with Severe Aortic Stenosis. Thrombosis and haemostasis. 2017;117(12):2346-55. 289. Alves JP, Nunes RB, Stefani GP, Dal Lago P. Resistance training improves hemodynamic function, collagen deposition and inflammatory profiles: experimental model of heart failure. PloS one. 2014;9(10). 290. Donnelly RP, Freeman SL, Hayes MP. Inhibition of IL-10 expression by IFN-gamma up-regulates transcription of TNF-alpha in human monocytes. The Journal of Immunology. 1995;155(3):1420-7. 291. Macêdo Santiago LÂ, Neto LGL, Borges Pereira G et al. Effects of resistance training on immunoinflammatory response, TNF-alpha gene expression, and body composition in elderly women. Journal of aging research. 2018;2018. 292. Phillips MD, Patrizi RM, Cheek DJ, Wooten JS, Barbee JJ, Mitchell JB. Resistance training reduces subclinical inflammation in obese, postmenopausal women. Medicine & Science in Sports & Exercise. 2012;44(11):2099-110. 293. Gerber IL, Stewart RA, Hammett CJ et al. Effect of aortic valve replacement on c-reactive protein in nonrheumatic aortic stenosis. The American journal of cardiology. 2003;92(9):1129-32. 294. Galante A, Pietroiusti A, Vellini M et al. C-reactive protein is increased in patients with degenerative aortic valvular stenosis. Journal of the American College of Cardiology. 2001;38(4):1078-82. 295. Imai K, Okura H, Kume T et al. C-reactive protein predicts severity, progression, and prognosis of asymptomatic aortic valve stenosis. American heart journal. 2008;156(4):713-8. \n\n 178 \n296. Sánchez PL, Santos JL, Kaski JC et al. Relation of circulating C-reactive protein to progression of aortic valve stenosis. The American journal of cardiology. 2006;97(1):90-3. 297. Do U, Ahn J-M, Kang D-Y et al. Association and Prognostic Implication of C-Reactive Protein with Risk of 1-Year Death or Disabling Stroke After Transcatheter Aortic Valve Replacement. Structural Heart. 2019;3(4):312-20. 298. Hioki H, Watanabe Y, Kozuma K et al. Effect of serum C-reactive protein level on admission to predict mortality after transcatheter aortic valve implantation. The American journal of cardiology. 2018;122(2):294-301. 299. Schaap LA, Pluijm SM, Deeg DJ, Visser M. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. The American journal of medicine. 2006;119(6):526. e9-. e17. 300. Lapice E, Maione S, Patti L et al. Abdominal adiposity is associated with elevated C-reactive protein independent of BMI in healthy nonobese people. Diabetes care. 2009;32(9):1734-6. 301. Sardeli AV, Tomeleri CM, Cyrino ES, Fernhall B, Cavaglieri CR, Chacon-Mikahil MPT. Effect of resistance training on inflammatory markers of older adults: a meta-analysis. Experimental gerontology. 2018;111:188-96. 302. Mavros Y, Kay S, Simpson KA et al. Reductions in C-reactive protein in older adults with type 2 diabetes are related to improvements in body composition following a randomized controlled trial of resistance training. Journal of cachexia, sarcopenia and muscle. 2014;5(2):111-20. 303. Ribeiro AS, Tomeleri CM, Souza MF et al. Effect of resistance training on C-reactive protein, blood glucose and lipid profile in older women with differing levels of RT experience. Age. 2015;37(6):109. 304. Ogawa K, Sanada K, Machida S, Okutsu M, Suzuki K. Resistance exercise training-induced muscle hypertrophy was associated with reduction of inflammatory markers in elderly women. Mediators of inflammation. 2010;2010. 305. Brooks N, Layne JE, Gordon PL, Roubenoff R, Nelson ME, Castaneda-Sceppa C. Strength training improves muscle quality and insulin sensitivity in Hispanic older adults with type 2 diabetes. International journal of medical sciences. 2007;4(1):19. 306. Bowman S, Clemens J, Thoerig R, Friday J, Shimizu M, Moshfegh A. Food Surveys Research Group, Beltsville Human Nutrition Research Center, Agricultural Research Service. 2013. 307. Houston DK, Nicklas BJ, Ding J et al. Dietary protein intake is associated with lean mass change in older, community-dwelling adults: the Health, Aging, and Body Composition (Health ABC) Study. Am J Clin Nutr. 2008;87(1):150-5. \n\n 179 \n308. Mitchell CJ, Milan AM, Mitchell SM et al. The effects of dietary protein intake on appendicular lean mass and muscle function in elderly men: a 10-wk randomized controlled trial. Am J Clin Nutr. 2017;106(6):1375-83. 309. Humayun MA, Elango R, Ball RO, Pencharz PB. Reevaluation of the protein requirement in young men with the indicator amino acid oxidation technique. The American journal of clinical nutrition. 2007;86(4):995-1002. 310. Rafii M, Chapman K, Owens J et al. Dietary protein requirement of female adults> 65 years determined by the indicator amino acid oxidation technique is higher than current recommendations. The Journal of nutrition. 2014;145(1):18-24. 311. Tessier AJ, Chevalier S. An Update on Protein, Leucine, Omega-3 Fatty Acids, and Vitamin D in the Prevention and Treatment of Sarcopenia and Functional Decline. Nutrients. 2018;10(8). 312. Long X, Ortiz-Vega S, Lin Y, Avruch J. Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency. Journal of Biological Chemistry. 2005;280(25):23433-6. 313. Katsanos CS, Kobayashi H, Sheffield-Moore M, Aarsland A, Wolfe RR. A high proportion of leucine is required for optimal stimulation of the rate of muscle protein synthesis by essential amino acids in the elderly. American Journal of Physiology-Endocrinology And Metabolism. 2006;291(2):E381-E7. 314. Gorissen SH, Burd NA, Hamer HM, Gijsen AP, Groen BB, Van Loon LJ. Carbohydrate coingestion delays dietary protein digestion and absorption but does not modulate postprandial muscle protein accretion. The Journal of Clinical Endocrinology & Metabolism. 2014;99(6):2250-8. 315. Drummond MJ, Dreyer HC, Pennings B et al. Skeletal muscle protein anabolic response to resistance exercise and essential amino acids is delayed with aging. Journal of applied physiology. 2008;104(5):1452-61. 316. Flück M. Regulation of protein synthesis in skeletal muscle. Deutsche Zeitschrift fur Sportmedizin. 2012;63(3):75. 317. Kumar V, Atherton P, Smith K, Rennie MJ. Human muscle protein synthesis and breakdown during and after exercise. Journal of Applied Physiology. 2009;106(6):2026-39. 318. Burd NA, West DW, Moore DR et al. Enhanced amino acid sensitivity of myofibrillar protein synthesis persists for up to 24 h after resistance exercise in young men. The Journal of nutrition. 2011;141(4):568-73. 319. Pennings B, Koopman R, Beelen M, Senden JM, Saris WH, Van Loon LJ. Exercising before protein intake allows for greater use of dietary protein–derived amino acids for de \n\n 180 \nnovo muscle protein synthesis in both young and elderly men. The American journal of clinical nutrition. 2011;93(2):322-31. 320. Hou L, Lei Y, Li X et al. Effect of Protein Supplementation Combined With Resistance Training on Muscle Mass, Strength and Function in the Elderly: A Systematic Review and Meta-Analysis. The journal of nutrition, health & aging. 2019;23(5):451-8. 321. Maltais ML, Ladouceur JP, Dionne IJ. The effect of resistance training and different sources of postexercise protein supplementation on muscle mass and physical capacity in sarcopenic elderly men. Journal of strength and conditioning research. 2016;30(6):1680-7. 322. Cermak NM, Res PT, de Groot LC, Saris WH, Van Loon LJ. Protein supplementation augments the adaptive response of skeletal muscle to resistance-type exercise training: a meta-analysis. The American journal of clinical nutrition. 2012;96(6):1454-64. 323. Chalé A, Cloutier GJ, Hau C, Phillips EM, Dallal GE, Fielding RA. Efficacy of whey protein supplementation on resistance exercise–induced changes in lean mass, muscle strength, and physical function in mobility-limited older adults. Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences. 2012;68(6):682-90. 324. Janssen I, Heymsfield SB, Baumgartner RN, Ross R. Estimation of skeletal muscle mass by bioelectrical impedance analysis. Journal of applied physiology. 2000;89(2):465-71. 325. Chien MY, Huang TY, Wu YT. Prevalence of sarcopenia estimated using a bioelectrical impedance analysis prediction equation in community‐dwelling elderly people in Taiwan. Journal of the American Geriatrics Society. 2008;56(9):1710-5. 326. Bosse JD, Dixon BM. Dietary protein in weight management: a review proposing protein spread and change theories. Nutrition & metabolism. 2012;9(1):81. 327. de Carvalho Bastone A, Nobre LN, de Souza Moreira B et al. Independent and combined effect of home-based progressive resistance training and nutritional supplementation on muscle strength, muscle mass and physical function in dynapenic older adults with low protein intake: A randomized controlled trial. Archives of Gerontology and Geriatrics. 2020;89:104098. 328. Hopkins WG, Marshall SW, Batterham AM, Hanin J. Progressive statistics for studies in sports medicine and exercise science. In: LWW; 2009. 329. Cohen J. Statistical power analysis for the behavioral sciences. Academic press; 2013. 330. Tudor-Locke C, Bassett DR. How many steps/day are enough? Sports medicine. 2004;34(1):1-8. 331. Mirna M, Paar V, Kellermair J et al. Tumor necrosis factor alpha-an underestimated risk predictor in patients undergoing transcatheter aortic valve replacement (TAVR)? In: Proceedings of the WIENER KLINISCHE WOCHENSCHRIFT. 2021. p. S117-S. \n\n 181 \n332. Jones CJ, Rikli RE. Measuring functional. The Journal on active aging. 2002;1(24-30). 333. Ware JE, Snow KK, Kosinski M, Gandek B. New England Medical Center Hospital. Health Institute. SF-36 health survey: Manual and interpretation guide. Boston (MA): The Health Institute, New England Medical Center. 1993. 334. Arnold SV, Spertus JA, Lei Y et al. Use of the Kansas City Cardiomyopathy Questionnaire for monitoring health status in patients with aortic stenosis. Circulation: Heart Failure. 2013;6(1):61-7. 335. Van den Helder J, Mehra S, van Dronkelaar C et al. Blended home‐based exercise and dietary protein in community‐dwelling older adults: a cluster randomized controlled trial. Journal of cachexia, sarcopenia and muscle. 2020;11(6):1590-602. 336. Damluji AA, Rodriguez G, Noel T et al. Sarcopenia and health-related quality of life in older adults after transcatheter aortic valve replacement. American heart journal. 2020;224:171-81. 337. Madzima TA, Ormsbee MJ, Schleicher EA, Moffatt RJ, Panton LB. Effects of resistance training and protein supplementation in breast cancer survivors. Medicine and science in sports and exercise. 2017;49(7):1283-92. 338. Rodríguez‐Morán M, Guerrero‐Romero F. Elevated concentrations of TNF‐alpha are related to low serum magnesium levels in obese subjects. Magnesium Research. 2004;17(3):189-96. 339. Tsigos C, Kyrou I, Chala E et al. Circulating tumor necrosis factor alpha concentrations are higher in abdominal versus peripheral obesity. Metabolism. 1999;48(10):1332-5. 340. Asea A, Kraeft S-K, Kurt-Jones EA et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nature medicine. 2000;6(4):435-42. 341. De Buck M, Gouwy M, Wang JM et al. The cytokine-serum amyloid A-chemokine network. Cytokine & growth factor reviews. 2016;30:55-69. 342. Zhou L-M, Xu J-Y, Rao C-P, Han S, Wan Z, Qin L-Q. Effect of whey supplementation on circulating C-reactive protein: A meta-analysis of randomized controlled trials. Nutrients. 2015;7(2):1131-43. 343. Tsekoura M, Billis E, Tsepis E et al. The effects of group and home-based exercise programs in elderly with sarcopenia: a randomized controlled trial. Journal of clinical medicine. 2018;7(12):480. 344. Hong J, Kim J, Kim SW, Kong H-J. Effects of home-based tele-exercise on sarcopenia among community-dwelling elderly adults: Body composition and functional fitness. Experimental gerontology. 2017;87:33-9. \n\n 182 \n345. Capodaglio P, Facioli M, Burroni E, Giordano A, Ferri A, Scaglioni G. Effectiveness of a home-based strengthening program for elderly males in Italy. A preliminary study. Aging clinical and experimental research. 2002;14(1):28-34. 346. Boshuizen HC, Stemmerik L, Westhoff MH, Hopman-Rock M. The effects of physical therapists’ guidance on improvement in a strength-training program for the frail elderly. Journal of aging and physical activity. 2005;13(1):5-22. 347. Thiebaud RS, Funk MD, Abe T. Home‐based resistance training for older adults: a systematic review. Geriatrics & gerontology international. 2014;14(4):750-7. 348. Mañas A, Gómez-Redondo P, Valenzuela PL, Morales JS, Lucía A, Ara I. Unsupervised home-based resistance training for community-dwelling older adults: A systematic review and meta-analysis of randomized controlled trials. Ageing Research Reviews. 2021:101368. 349. Bompa TO, Carrera M. Periodization training for sports. Human Kinetics Champaign; 2005. 350. Baechle TR, Earle RW. Essentials of strength training and conditioning. Human kinetics; 2008. 351. Miszko TA, Cress ME, Slade JM, Covey CJ, Agrawal SK, Doerr CE. Effect of strength and power training on physical function in community-dwelling older adults. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2003;58(2):M171-M5. 352. Sayers SP, Gibson K. High-speed power training in older adults: A shift of the external resistance at which peak power is produced. Journal of strength and conditioning research/National Strength & Conditioning Association. 2014;28(3):616. 353. Arnold SV, Spertus JA, Vemulapalli S et al. Quality-of-life outcomes after transcatheter aortic valve replacement in an unselected population: a report from the STS/ACC Transcatheter Valve Therapy Registry. JAMA cardiology. 2017;2(4):409-16. 354. Hart PD, Buck DJ. The effect of resistance training on health-related quality of life in older adults: Systematic review and meta-analysis. Health promotion perspectives. 2019;9(1):1. 355. Hawton A, Green C, Dickens AP et al. The impact of social isolation on the health status and health-related quality of life of older people. Quality of Life Research. 2011;20(1):57-67. 356. Caramelo F, Ferreira N, Oliveiros B. Estimation of risk factors for COVID-19 mortality-preliminary results. MedRxiv. 2020. \n\n 183 \n357. Beaudart, Biver E, Reginster JY et al. Validation of the SarQoL®, a specific health‐related quality of life questionnaire for Sarcopenia. Journal of cachexia, sarcopenia and muscle. 2017;8(2):238-44. 358. Kim HK, Suzuki T, Saito K et al. Effects of exercise and amino acid supplementation on body composition and physical function in community‐dwelling elderly Japanese sarcopenic women: a randomized controlled trial. Journal of the American Geriatrics Society. 2012;60(1):16-23. 359. Kim H, Kim M, Kojima N et al. Exercise and nutritional supplementation on community-dwelling elderly Japanese women with sarcopenic obesity: a randomized controlled trial. Journal of the American Medical Directors Association. 2016;17(11):1011-9. 360. Finger D, Goltz FR, Umpierre D, Meyer E, Rosa LHT, Schneider CD. Effects of protein supplementation in older adults undergoing resistance training: a systematic review and meta-analysis. Sports medicine. 2015;45(2):245-55. 361. Arnarson A, Geirsdottir OG, Ramel A, Briem K, Jonsson P, Thorsdottir I. Effects of whey proteins and carbohydrates on the efficacy of resistance training in elderly people: double blind, randomised controlled trial. European journal of clinical nutrition. 2013;67(8):821-6. 362. Verreijen AM, Verlaan S, Engberink MF, Swinkels S, de Vogel-van den Bosch J, Weijs PJ. A high whey protein–, leucine-, and vitamin D–enriched supplement preserves muscle mass during intentional weight loss in obese older adults: a double-blind randomized controlled trial. The American journal of clinical nutrition. 2015;101(2):279-86. 363. Nabuco HC, Tomeleri CM, Sugihara Junior P et al. Effects of whey protein supplementation pre-or post-resistance training on muscle mass, muscular strength, and functional capacity in pre-conditioned older women: a randomized clinical trial. Nutrients. 2018;10(5):563. 364. Junior PS, Ribeiro AS, Nabuco HC et al. Effects of whey protein supplementation associated with resistance training on muscular strength, hypertrophy, and muscle quality in preconditioned older women. International journal of sport nutrition and exercise metabolism. 2018;28(5):528-35. 365. Candow DG, Chilibeck PD, Facci M, Abeysekara S, Zello GA. Protein supplementation before and after resistance training in older men. European journal of applied physiology. 2006;97(5):548-56. 366. Dunford M, Macedonio M. Weight management. Sports Nutrition. A Handbook for Professionals. Chicago, IL: Academy of Nutrition and Dietetics. 2018:218-37. 367. Burke L, Deakin V, Deakin V. Clinical sports nutrition. McGraw-Hill Beijing, Boston; 2000. \n\n 184 \n368. Longland TM, Oikawa SY, Mitchell CJ, Devries MC, Phillips SM. Higher compared with lower dietary protein during an energy deficit combined with intense exercise promotes greater lean mass gain and fat mass loss: a randomized trial. The American journal of clinical nutrition. 2016;103(3):738-46. 369. Nindl BC, Harman EA, Marx JO et al. Regional body composition changes in women after 6 months of periodized physical training. Journal of Applied Physiology. 2000;88(6):2251-9. 370. Donnelly J, Sharp T, Houmard J et al. Muscle hypertrophy with large-scale weight loss and resistance training. The American journal of clinical nutrition. 1993;58(4):561-5. 371. Biodynamics. Quick Start Guide for the BIA 310e. In: Biodynamics Corporation; 2004-2017, p 15. \n\n 185 \nBIOGRAPHICAL SKETCH CURRICULUM VITA Christopher M. Schattinger, M.S., CSCS, CISSN Florida State University Department of Nutrition, Food, and Exercise Sciences College of Human Sciences Telephone: (330) 360-0228 E-mail: cms15j@my.fsu.edu EDUCATION and TRAINING 2017-Present Ph.D., Exercise Physiology Florida State University Department of Nutrition, Food and Exercise Sciences Mentor: Lynn B. Panton, Ph.D. 2015-2017 M.S., Exercise Physiology Emphasis: Sports Nutrition Florida State University Department of Nutrition, Food and Exercise Sciences Mentor: Lynn B. Panton, Ph.D. 2011-2015 B.S., Exercise Science Emphasis: Scientific Foundations University of South Carolina Department of Exercise Science Mentor: Ray W. Thompson, Ph.D. PROFESSIONAL EXPERIENCE 2016-Present Graduate Teaching Assistant Florida State University Department of Nutrition, Food and Exercise Sciences 2016-2017 Personal Trainer and Staff Supervisor Florida State University Bobby E. Leach Center 2013-2015 Assistant House Manager University of South Carolina Koger Center for the Arts \n\n 186 \nREFEREED ABSTRACTS C.M. Schattinger, J.L. Leonard, A.E. Artese, C.L. Pappas, M.J. Ormsbee and L.B. Panton. “The Effect of Pre-Sleep Consumption of Casein Protein on Resting Metabolic Rate and Appetite in Sedentary Postmenopausal Women.” Medicine and Science in Sports and Exercise, (2018) May; 50:5 Supplement. C.M. Schattinger, J.L. Leonard, A.E. Artese, C.L. Pappas, M.J. Ormsbee and L.B. Panton. “The Effect of Pre-Sleep Consumption of Casein Protein on Resting Metabolic Rate and Appetite in Sedentary Premenopausal Women.” Medicine and Science in Sports and Exercise, (2019) May; 51:5 Supplement. REFEREED PUBLICATIONS Schattinger, C. M., Leonard, J. T., Pappas, C. L., Ormsbee, M. J., & Panton, L. B. (2020). The Effects of Pre-Sleep Consumption of Casein Protein on Next-Morning Measures of Resting Metabolic Rate and Appetite Compared Between Sedentary Pre- and Postmenopausal Women. British Journal of Nutrition, 1-29. LOCAL and REGIONAL REFEREED PROFESSIONAL CONFERENCES R.I. Doiron, C.M. Schattinger and RW. Thompson. “The Effect of Cadence on Metabolic and Respiratory Measures During Incremental Cycle Ergometry to Max.” Southeast Chapter of the American College of Sports Medicine, Jacksonville, FL, February 2015. C.M. Schattinger, J.L. Leonard, A.E. Artese, C.L. Pappas, M.J. Ormsbee and L.B. Panton. “The Effect of Pre-Sleep Consumption of Casein Protein on Resting Metabolic Rate and Appetite in Sedentary Postmenopausal Women.” Southeast Chapter of the American College of Sports Medicine, Chattanooga, TN, February 2018. C.M. Schattinger, J.L. Leonard, A.E. Artese, C.L. Pappas, M.J. Ormsbee and L.B. Panton. “The Effect of Pre-Sleep Consumption of Casein Protein on Resting Metabolic Rate and Appetite in Sedentary Postmenopausal Women.” Annual Meeting of the American College of Sports Medicine, Minneapolis, MN, May 2018. C.M. Schattinger, J.L. Leonard, A.E. Artese, C.L. Pappas, M.J. Ormsbee and L.B. Panton. “The Effect of Pre-Sleep Consumption of Casein Protein on Resting Metabolic Rate and Appetite in Sedentary Premenopausal Women.” Southeast Chapter of the American College of Sports Medicine, Greenville, SC, February 2019. C.M. Schattinger, J.L. Leonard, A.E. Artese, C.L. Pappas, M.J. Ormsbee and L.B. Panton. “The Effect of Pre-Sleep Consumption of Casein Protein on Resting Metabolic Rate and Appetite in Sedentary Premenopausal Women.” Annual Meeting of the American College of Sports Medicine, Orlando, FL, May 2019. \n\n 187 \nC. Schattinger, G. Rodriguez, T. Gonzalez, E. Hill, T. Noel, W. Batchelor, and L. Panton, FACSM. “Relationship Between Body Composition, Strength, Physical Activity and Dietary Intake in Aortic Valve Replacement Patients.” Southeast Chapter of the American College of Sports Medicine, Jacksonville, FL, February 2020. C. Schattinger, G. Rodriguez, T. Gonzalez, E. Hill, M. Pleasants, C. Huber, T. Noel, W. Batchelor, and L. Panton, FACSM. “Assessment of Muscle Mass in Transcatheter Aortic Valve Replacement Patients Over ~6 Months Post-Procedure.” Southeast Chapter of the American College of Sports Medicine (Virtual), February 2021. TEACHING EXPERIENCE Undergraduate FLORIDA STATE UNIVERISITY Summer 2021 Science of Nutrition HUN 1201 2016-2021 Functional Anatomy and Physiology II Laboratory PET 3323C 2017-2018 Applied Exercise Physiology Laboratory APK 3110C Fall 2019 Exercise Testing and Prescription Laboratory PET 4551 LABORATORY SKILLS Human Measures • VO2 Max Testing • Wingate-30 Test • Blood Pressure • BIA • Hydrostatic Weighing • Skinfold • Waist/Hip Circumference • Polar Heart Rate Monitors • Ultrasound • Biodex"
  },
  "outcomes": {
    "primary": [
      "body-composition",
      "hypertrophy",
      "strength",
      "vo2"
    ],
    "intervention_weeks": 97,
    "primary_human": "body_comp; muscle_mass; strength; function"
  },
  "bucket": "C",
  "notes": "Thesis examining combined sprint interval training and RT vs single-mode or control in obese older adults."
}